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A b s t r a c t
Lipoprotein Lipase (LPL) plays a key role in the control of lipid metabolism and 
transport. It is responsible for the hydrolysis of the triacylglycerol component of 
circulating chylomicrons and very low density lipoproteins into free fatty acids and 2- 
monoacylglycerol that can be used by the cells. LPL has also been implicated in the 
initiation and the progression of atherosclerosis, a major contributor of coronary heart 
disease. LPL, expressed by macrophages in the atherosclerotic plaque, contributes to 
the initiation and the progression of foam cells, which represent a critical stage in the 
onset of the disease. Macrophage LPL therefore represents an excellent target against 
atherosclerosis and it is important that the processes that regulate its expression are 
understood.
Macrophage LPL can be regulated by several factors present in the 
atherosclerotic plaque including cytokines. It has been shown that cytokines exert 
their effects via transcriptional mechanisms and, previous work within the laboratory 
has identified some of the signal transduction pathways and transcription factors that 
are involved in the cytokine-mediated regulation of LPL.
Of particular interest in the laboratory is the effect of interferon-y (IFN-y) on 
LPL. IFN-y has been shown to decrease the transcription of macrophage LPL via 
decreased binding of the transcription factors Spl and Sp3 to regulatory sequences 
present in the LPL promoter region. Preliminary studies had identified a role for 
casein kinase 2 (CK2) in this response. Due to the potential significance of these 
findings, the aim of the studies presented in this thesis was to investigate the 
molecular mechanisms underlying the IFN-y-mediated inhibition of macrophage LPL 
gene transcription in detail. Specifically, it was decided to confirm the role of CK2 
and to identify other signalling pathways that were involved in this response.
Through the use of pharmacological inhibitors and dominant negative 
constructs, we confirmed a role of CK2 and identified a role for phosphatidylmositol- 
3-kinase (PI3K) and janus kinase 2 (JAK2) activation in the IFN-y-mediated 
suppression of LPL mRNA expression and promoter activity through decreased 
binding of the transcription factors Spl and Sp3.
We also identified a novel mechanism for the action of CK2 on macrophage 
LPL gene transcription. It was shown that IFN-y causes an increase in the activity of 
the catalytic subunits of CK2, and this leads to an increase in the interaction of CK2 
and Spl/Sp3. This leads to the phosphorylation of at least Spl, which then triggers a 
decrease in its binding to the LPL promoter.
In addition it was shown that IFN-y phosphorylates PKB, a key downstream 
target of PI3K, and increases its activity. Indeed, phosphorylation of extracts from 
untreated cells with recombinant PKB could decrease thd binding of Spl/Sp3 to the 
LPL promoter to levels seen in IFN-y treated cells.
The potential of other key components of the PI3K pathway in the response 
was also investigated. It was found that glycogen synthase kinase 3-p (GSK3-p) and 
the forkhead transcription factor, FRDH were not required. In contrast, a role for 
mammalian target of rapamycin (mTOR) pathway was identified.
These studies provide novel insights into the signalling pathways and 
molecular mechanisms underlying the IFN-y-mediated inhibition of LPL gene 
transcription in macrophages. The studies suggest potentially new avenues for further 
research and therapeutic approaches against atherosclerosis.
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Ch a p t e r  o n e : In t r o d u c t io n .
Chapter 1: Introduction
1.0 INTRODUCTION
1.1 Heart Disease and Atherosclerosis
In ancient times there were many theories about the function of the heart, for example 
the Chinese thought that happiness dwelt in the heart.
The first diagnosis of a heart attack was made by an American, James B. 
Herrick, in 1912. Less than sixty years later, doctors had already performed many 
heart transplants. Over the past decades, our knowledge of the heart and its associated 
diseases has increased expansively. Today it is known that diseases of the heart and 
blood vessels are the leading causes of death in the Western world (Lusis, 2000). To 
put heart disease into perspective, in the Western world more than twice as many 
people die from cardiovascular disease as from all forms of cancer. Even though we 
know of environmental risk factors that contribute significantly to the disease, its 
sustained high prevalence highlights its intricacy, and the fact that Coronary Artery 
Disease (CAD) has a complex multi-factorial aetiology.
The primary contributor to CAD is atherosclerosis, which is a chronic and 
progressive disease characterised by the accumulation of lipids and fibrous elements 
and inflammation within large arteries. The knowledge of the biochemical pathways 
involved in atherosclerosis has led to the identification of novel targets and points of 
intervention for the disease.
Over thirty years ago, it became apparent that the metabolic enzyme 
Lipoprotein Lipase (LPL) could contribute to atherosclerosis. Since then many 
laboratories have contributed to understanding how the activity of this enzyme is 
controlled. However, much remains to be achieved. The regulation of LPL with 
respect to atherosclerosis forms the focus of this thesis.
1.2 Lipoproteins
It is now well documented that endothelial cell associated-LPL is a key enzyme in 
overall lipid metabolism. Its physiological function is to hydrolyse the triacylglycerol 
components of lipoproteins in the luminal side of the capillary endothelium (Figure 
1.1) to yield free fatty acids and 2-monoacylglycerol (2MG) that can be stored as 
triglyceride (adipose tissue) or are oxidised to produce energy (muscle).
2
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Lipoproteins are responsible for carrying serum lipids. There are several types 
of lipoproteins: chylomicrons; very low density lipoproteins (VLDL); intermediate 
density lipoproteins (IDL); low density lipoproteins (LDL); and high density 
lipoproteins (HDL). The lipoproteins differ in size, electrophoretic mobility, 
composition and function. Chylomicrons are responsible for the transport of dietary 
lipids. VLDL, IDL and LDL transport endogenous triacylglycerols and cholesterol 
from the liver to peripheral tissues, and HDL transport endogenous lipids from tissues 
to the liver.
1.2.1 Chylomicrons
Chylomicrons are assembled in the intestinal mucosa. They are responsible for the 
transport of exogenous triacylglycerols and cholesterol from the intestines to skeletal 
muscle and adipose tissue, where they associate with the capillary endothelium. The 
triacylglycerol component of the chylomicron is hydrolysed by LPL to produce 2MG 
and non-esterified fatty acids that can be taken up by the tissue (Figure 1.1). The 
chylomicrons are steadily hydrolysed until they are reduced to chylomicron remnants, 
which dissociate from the capillary endothelium and re-enter circulation to be 
subsequently taken up by the liver.
1.2.2 VLDL. IDL and LDL
VLDL is synthesised in the liver from cholesterol and triglycerides derived from 
either de novo synthesis or lipoprotein uptake (Gibbons, 1990). It contains 
apolipoprotein B-100 (apoB-100), apo-Cl, -2, -3 and -E. VLDL is responsible for the 
transport of fatty acids to adipocytes for storage and to cardiac and skeletal muscle for 
energy consumption. Energy is released by the hydrolysis of VLDL by LPL (Glass 
and Witztum, 2001), which is bound to the capillary endothelium (Figure 1.1). After 
hydrolysis, the majority of the VLDL remnants (approximately 70%) are removed 
from circulation by uptake through the hepatic LDL receptor (LDL-R) (Glass and 
Witztum, 2001). The remaining particles are metabolised to IDL and then LDL by 
further removal of core triglycerides and dissociation of apolipoproteins other than 
apo-B. Remaining cholesterol ester-rich LDL delivers cholesterol to peripheral tissues 
for steroidogenesis and maintaining cell membrane integrity (Glass and Witztum, 
2001).
3
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Figure 1.1: Metabolism o f  circulating triacylglycerol-rich lipoproteins by 
endothelial lipoprotein lipase
Hydrolysis by LPL results in the formation o f Non-Esterified Fatty Acids (NEFA), 2- 
monoacylglycerol (MG) and remnants. The remnants are taken up by the hepatic LDL 
receptor (LDL-R) either directly or after modification. Abbreviations: LPL, Low 
Density Lipoprotein; VLDL, Very Low Density Lipoprotein; IDL, Intermediate 
Density Lipoprotein; RR, Remnant receptor; [Adapted from Brown and Goldstein, 
1984; Voet and Voet, 1994].
1.2.3 HDL
Essentially HDL has the opposite function of LDL, that is, it removes excess 
cholesterol from extra-hepatic cells, such as macrophages, at the vessel wall and 
delivers it to the liver, where it can be recycled or converted into bile acid and 
excreted from the body (Johnson et al., 1991). The disposal of cholesterol from cells 
is called ‘reverse cholesterol transport’ and is critical for the anti-atherogenic property 
, of this lipoprotein (Section 1.4). Nascent prep-HDL, which is secreted by the intestine 
or the liver, is a potent acceptor of excess cholesterol from peripheral tissues. Once 
HDL has taken up cholesterol, the cholesterol becomes esterified by lecithin 
cholesterol acetyltransferase (LCAT) and nascent HDL is converted to small spherical 
HDL3. Subsequently HDL3 acquires phospholipids and apolipoproteins and this 
causes its conversion into HDL2 (Johnson et al., 1991).
4
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The return of peripheral cholesterol to the liver can occur through two mechanisms. 
These are:
Simple diffusion: Simple diffusion is the spontaneous release of cholesterol from the 
membrane driven by the net concentration gradients of cholesterol. 
Apolipoprotein-mediated efflux pathway: The second mechanism, apolipoprotein- 
mediated efflux is poorly understood except that it involves the direct uptake of 
cholesterol ester from HDL. This process is facilitated by apo-E. Apo-E, which is 
present within HDL, mediates the binding of HDL to heparin sulphate proteoglycans 
(HSPG). These interactions enhance the ability of scavenger receptor binding protein- 
I  (SR-B1) to take up cholesterol esters (Arai et al., 1999).
Disturbances in the balance of lipoproteins can lead to life threatening diseases. For 
example the metabolic syndrome/syndrome X refers to people who are insulin 
resistant and dyslipidemic (elevated levels of triacylglycerol and decreased HDL). 
Likewise, homozygous familial hypercholesterolemia is characterised by the lack of 
functional LDL receptors resulting in a massive accumulation of LDL. Both diseases 
cause the patients to be at a higher risk of developing CAD (Goldstein and Brown, 
1977).
1.3 Lipoprotein Lipase
1.3.1 Background and function
Lipaemia is an increase in blood lipid levels associated with the absorption of a fatty 
meal. In 1943, Paul Hahn noticed that lipaemia could be abolished when heparin was 
injected intravenously into dogs. Subsequently Heparin Releasable Lipase was 
identified as the primary enzyme that could metabolise chylomicrons to reduce 
lipaemia (Anderson and Fawcett, 1950; Anfinsen et al., 1952). It was later found that 
a component of HDL and VLDL, called apo-C2, was essential for the activation of 
this enzyme and it then became known as LPL (Breckenridge et al., 1978).
LPL belongs to the mammalian triacylglycerol lipase gene family, of which 
Hepatic Lipase (HL), Pancreatic Lipase (PL), Endothelial Lipase (EL) and 
Phosphotidylserine phospholipase AJ_ (PPA1) are members (Wong et al, 1997). 
Lipases are water soluble enzymes that hydrolyse ester bonds of water soluble 
substrates such as triglyceride and cholesterol esters (Otarod and Goldberg, 2004).
5
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LPL, HL, PL and EL show several similarities as well as differences in properties and 
physiological functions (Table 1.1).
Table 1.1: Properties o f  mammalian triacylglycerol lipase genes
LPL HL PL EL
Major site of Parenchymal Hepatocytes Exocrine Endothelial
synthesis cells (iadipocytes 
and muscles)
pancreas cells
Substrates TAG lipids, TAG lipids, TAG lipids, Phospholipids
Phospholipids Phospholipids Phospholipids
Major site of action Capillary 
endothelial cells 
(,several tissues)
Liver sinusoids Duodenum Liver, Lung
Subunits Homodimer Monomer Monomer Monomer
Glycosylated Yes Yes Yes Yes
Binding to cell HSPG HSPG Free HSPG
surface
Agents causing Heparin Heparin None Heparin
release into
circulation
Activators Apo-C2 Possibly Apo-E Colipase None
Inhibitors Apo-C3
(possibly Apo-E)
None Bile Salt Salt
Substrates for Chylomicrons/ Chylomicron Alimentary TGs HDL
lipolysis VLDL remnants/ IDL/ 
HDL
Abbreviations: TAG, triacylglycerol (Adaptedfrom Murthy et al., 1996).
LPL is synthesised in the parenchymal cells of several tissues including skeletal 
muscle, heart, adipose tissue and the lactating mammary gland (Borensztajn, 1987). 
Subsequent to synthesis, LPL must be transported to the luminal surface of 
endothelial cells where, in its dimer form it can associate with HSPG. Administration 
of heparin can release LPL into circulation by competing with binding to HSPG 
(Saxena et a l, 1991; Hamosh and Hamosh, 1983; Bengsston-Olivecrona and 
Olivecrona, 1994; Bengsston and Olivercrona, 1981).
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1.3.2 LPL Gene Structure
The LPL gene has been mapped to human chromosome 8p22, it is 35kb in length, and 
contains ten exons and nine introns (Deeb and Peng, 1989). There is a correspondence 
between the functional domains of LPL and the exon units (Deeb and Peng, 1989; 
Yang et al., 1989). For example, exon 1 specifies the 5’ untranslated region and the 
signal peptide, exon 5 encodes the active site and exon 6 encodes the putative heparin- 
binding domain (Kirchgessner et al., 1989).
1.3.3 Synthesis, Processing and translocation of LPL
The LPL gene is expressed in the parenchymal cells of adipose tissue, the lungs, the 
adrenals and heart and skeletal muscle. Following transcription, the mRNA is 
translated into its nascent polypeptide in the endoplasmic reticulum (ER) prior to a 
series of post-translational processing events in the rough ER and the Golgi apparatus 
(Fuhramann et al., 1985; Elbein, 1991; Braun and Severson, 1992).
The initial glycosylation step is co-translational, that is, as the nascent 
polypeptide chain emerges into the lumen of the ER, there is an en bloc transfer of a 
lipid-linked oligosaccharide [Glc3 -Man9 (GlcNAc)2 ] to specific arginine residues. This 
N-terminus-linked carbohydrate moiety then undergoes a series of processing events 
when passing through the ER and the various compartments in the Golgi, each of 
which contain distinct sets of glycoprotein processing enzymes (Fuhramann et al., 
1985; Elbein, 1991). In the rough ER, three terminal glucose residues are removed by 
glucosidase I and II, followed by the removal of one mannose residue by a- 
mannosidase resulting in a molecule which is denoted as ‘high-mannose structure’ 
[Mang-(GlcNAc)2 -protein]. Although the ‘high-mannose’ form of LPL is catalytically 
active (Semb and Olivecrona, 1989), modification into a more complex form is 
required to enable the secretion of LPL from parenchymal cells (Braun and Severson, 
1992). This modification occurs in the Golgi apparatus. The ‘high-mannose structure’ 
complex is transferred to the Golgi apparatus by vesicular transport (Braun and 
Severson, 1992). The Golgi apparatus consists of at least three disk like bodies; the 
cis, medial and tram  networks, which act as a receiving, a processing and a sorting 
centre respectively (Mellman and Simons, 1992). The glycoproteins migrate through 
the Golgi apparatus in a cis to trans direction (Rothman and Orci, 1990), where they 
become modified by the resident processing enzymes. Within the c/.v-compartment,
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three mannose residues are removed by the action of mannosidase I. In the medial 
compartment, a GlcNAc residue is added to the LPL protein, followed by removal of 
two more mannose residues by the mannosidase II. Finally, in the trans compartment, 
GlcNAc, galactose and sialic acid residues may be added through a number of 
transferase reactions (Braun and Severson, 1992). The final glycoprotein secreted by 
the parenchymal cells contains approximately 8-12% carbohydrate (Iverius and 
Ostund-Lindqvist, 1976; Vannier and Ailhaud, 1989).
1.3.4 Functional anatomy of LPL
The human LPL protein consists of 448 amino acids and is organised into two 
structurally distinct regions consisting of an amino-terminal domain and a carboxy- 
terminal domain, connected by a flexible peptide. The N-terminal domain region 
consists of residues Serine (Ser132), Asparginine (Asp156) and Histidine (His241), also 
known as the catalytic triad that is covered by a polypeptide lid which regulates 
interactions with substrates (Dugi et al., 1992). It has been proposed that the 
interaction of the C-terminal domain with lipoprotein substrates results in a 
conformational change of LPL allowing the enzyme to open its lid and carry out its 
catalytic function (Santamarina-Fojo and Dugi, 1994). There is a binding site for the 
co-factor apo-C2 in the N-terminal domain (Murthy et al., 1996) and a binding site for 
LDL receptor-related protein in the C-terminal domain (Nielsen et al., 1997; 
Pentikainen et al., 2002). The C-terminal and N-terminal domains both contain 
binding sites for heparin (Nielsen et al., 1997; Sendak et al., 1998). LPL is 
physiologically active as a non-covalent homodimer which is likely to be arranged in 
a head to tail configuration (Otarod and Goldberg, 2004; Wong et al., 1997). 
However, under specific physiological conditions for example, ionic strengths and 
temperature it can dissociate into irreversible inactive monomers (Osborne et al, 
1985).
LPL is mainly localised in the capillary endothelium. However, LPL is also 
found in endothelial, macrophage and smooth muscle cells, which line the blood 
vessels and LPL present here has been suggested to play a role in atherosclerosis 
(Section 1.6). A brief introduction to atherosclerosis is presented below and the 
involvement of LPL is then discussed in more detail.
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1.4 Atherosclerosis
In essence, atherosclerosis results from a combination of interactions between the 
endothelial cells that line the blood vessels, inflammatory cells and cholesterol 
transporting proteins. The disease is further complicated by numerous cardiovascular 
risk factors such as hypertension, smoking, diabetes and age (Steinberg, 2002). The 
aetiology of atherosclerosis is extremely complex and can therefore only be discussed 
briefly in this thesis; the reader is referred to Atherosclerosis (2002) for more in depth 
information.
1.4.1 Initiation and progression of the disease
Hypercholesterolemia, particularly high plasma LDL levels, is the best documented 
initiating factor of atherosclerosis (Steinberg, 2002). Although LDL can pass freely in 
and out of the intima, hypercholesterolemia can result in the trapping of LDL in the 
subendothelial space by binding to proteoglycans. LDL is then prone to oxidation due 
to limiting levels of antioxidants. As a response to oxidised LDL, endothelial cells 
express cell adhesion molecules such as Vascular Cell-Adhesion Molecule 1 (VCAM- 
1) which attract monocytes, T-lymphocytes and leukocytes to the site of damage (Li 
etal., 1993).
High cholesterol levels also lead to an increased expression of chemoattractant 
proteins in the artery wall, including Monocyte Chemoattractant Protein-1 (MCP-1). 
MCP-1 is a key chemotactic protein which directs the entry of monocytes and T- 
lymphocytes into the artery (Cushing et al., 1990).
The circulating monocytes adhere to endothelial cells at the site of the lesion. 
Initially this binding is only weak (through selectins); firmer attachments are then 
made by integrins (Li and Glass, 2002). Monocytes then migrate through the 
endothelial cells into the intima where they become activated and differentiate into 
macrophages. These processes result in the secretion of a plethora of pro-and anti­
inflammatory products, listed in Table 1.2.
Marker proteins induced upon differentiation of monocytes into macrophages 
include the class A scavenger receptor (SR-A) (responsible for the uptake of 
acetylated LDL) and the class B scavenger receptor (CD36) (primarily responsible for 
the uptake of oxidised LDL). Unlike the LDL-R, the expression of scavenger 
receptors is not controlled by increases in the concentration of intracellular 
cholesterol. Macrophages therefore take up modified forms of LDL in an unregulated
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manner through their scavenger receptors, and this results in the formation of ‘lipid 
loaded’ foam cells, which represent early lesion formation and are important for the 
progression of the disease (Farqui and DiCorleto, 1993).
Table 1.2: Biological products from monocytes and macrophages in the
atherosclerotic lesion
B io l o g ic a l  p r o d u c t s  o f  m o n o c y t e s
AND MACROPHAGES
R e f e r e n c e s
Cytokines/Chemokines (e.g. TNF-a, IFN-y, IL- Cavaillon, 1994; Baggiolini, 2001
4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-18,
MCP-1,-2,-3, RANTES, ELC)
Complement factors (e.g. C3b) Colten et al, 1985
Coagualtion factors (e.g. prothrombin, Osterud et al, 1981; Osterud et al, 1980
fibrinogen)
Prostaglandins Narumiya et al, 1999; Wahl et al, 1990
Growth factors Heldin and Westermark, 1999
Reactive oxygen intermediates Baliavite, 1988; Conner and Grisham,
1996
Proteolytic enzymes (e.g. elastase, Shapiro et al, 1991
metalloproteinases)
Abbreviations: TNF-a, Tumour Necrosis Factor; IL-1 to IL-18, Interleukin-1 to 18; 
INF-y Interferon-y, MCP-1-3, Monocyte Chemoattractant Protein -1 to -3 (MCP-1 to 
3); RANTES, Regulated upon Activation Normal T- Cell Expressed and Secreted 
(Adapted from Osterud and Bjorklid, 2003).
The importance of macrophages in the development of atherosclerosis has 
been illustrated by the osteopetrotic mouse, which carries a naturally occurring 
mutation in the gene encoding macrophage colony stimulating factor (M-CSF), an 
important factor involved in the proliferation of monocytes. These mice exhibit an 
almost complete absence of macrophages, and when bred to apoE-deficient mice 
(which have increased levels of circulating cholesterol) they are extremely resistant to 
the development of the disease, (Smith et al, 1995; Qiao et al, 1997).
Several molecules are released by monocytes and macrophages and these have 
been shown to act as agonists or antagonists of the disease (Table 1.3).
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Table 1.3: Molecules which regulate atherosclerosis
AGONIST A n t a g o n is t C h e m o -A t t r a c t a n t
GM-CSF IFN-y M-CSF
IGF-1 IL-1 MCP-1
TNF-a TGF-p GM-CSF
TGF-a VEGF
PDGF BFGF
Abbreviations: GM-CSF, Granulocyte-Macrophage Colony
Stimulating Factor; IGF-1, Insulin-like Growth Factor; TNF-a,
Tumour Necrosis Factor a; TGF-J3, Transforming Growth Factor J3;
PDGF, Platelet Derived Growth Factor; IFN-y, Interferon-y; IL-1, 
Interleukin 1; M-CSF, Macrophage Colony Stimulating Factor; MCP- 
1, Monocyte Chemoattractant Protein 1; VEGF, Vascular Endothelial 
Growth Factor; BFGF, Basic Fibroblast Growth Factor (Adapted 
from Ross, 1993).
The early lesions of atherosclerosis are called ‘fatty streaks’ and, although not 
clinically significant, they may evolve into more complex lesions. This progression 
involves the recruitment and migration of smooth muscle cells into the intima. The 
combined influence of cytokines and oxidised LDL causes the smooth muscle cells to 
alter so that they acquire a secretary function, releasing more chemoattractants, 
cytokines and extracellular matrix proteins. Smooth muscle cells then accumulate 
cholesterol and become smooth muscle cell-derived foam cells (Figure 1.2).
The foam cells may eventually die, producing a necrotic core that becomes 
covered by a fibrous cap of extracellular matrix proteins. As the lesions progress, the 
arterial wall is remodelled; if the lesion extends inwards the vessel lumen is narrowed, 
causing angina pains. The rupture of an advanced lesion can result in the formation of 
a thrombus, which occludes the vessel lumen and results in myocardial infarction 
(Figure 1.2) (Li and Glass, 2002).
It is therefore the metabolism of lipoproteins and subsequent foam cell 
formation that triggers the onset of atherosclerosis and this is discussed further in 
Section 1.5. Several proteins contribute either directly or indirectly to this process and 
these can be pro- or anti-atherogenic. The expression of these proteins can be 
regulated by growth factors, cytokines and chemotactic factors present within the 
atherosclerotic lesion (Section 1.3). One important protein implicated in 
atherosclerosis is LPL; its role in the disease is considered further in Section 1.6.
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1.5 Lipoproteins and Atherosclerosis
Whilst LDL has an essential physiological role in transporting cholesterol to 
peripheral tissues, increased LDL cholesterol levels are also associated with an 
elevated risk of CAD (Glass and Witzum, 2001). The circulating levels of LDL are 
determined by its rate of uptake through the LDL receptors that recognise the N- 
terminal domain of apoB-100. Because cellular cholesterol levels negatively regulate 
the expression of LDL receptors, exposure of macrophages to even high levels of 
LDL does not normally lead to significant LDL uptake or foam cell formation 
(Goldstein and Brown, 1977). However, it has been shown that LDL undergoes 
modification, including oxidation, lipolysis, proteolysis and aggregation, and such 
modifications can contribute to their recognition by so called scavenger receptors on 
macrophages. The conversion of macrophages into foam-cells in the intima, which is 
important in the pathogenesis of atherosclerosis (Section 1.4), is thought to result 
from the unregulated uptake of this circulating LDL derived cholesterol (Jessup et al.,
2002). Of the different modifications of LDL, oxidation is arguably the most 
important (Lusis, 2000). Although the precise mechanisms responsible for LDL 
oxidation are not known, lipoxygenases, inducible nitric oxide synthase (iNOS) and 
several reactive oxygen species, such as hydroxyl radicals, have been proposed as 
possible contributing factors because they can stimulate LDL oxidation in vitro and 
are present within human atherosclerotic lesions (Li and Glass, 2002).
Initial oxidation of LDL results in minimally modified LDL (mmLDL), which 
has some pro-inflammatory activities. For example, mmLDL appears directly 
chemotactic for monocytes and T-cells, thereby recruiting these cells to the arterial 
wall. In addition, mmLDL induces the expression of M-CSF, which is known to 
stimulate the conversion of monocytes to macrophages (Rajavashisth et al., 1990). 
However, mmLDL is not likely to be sufficiently modified to be recognised by 
macrophage scavenger receptors; this requires further oxidation to fully oxidised LDL 
(Lusis, 2000).
Unlike LDL receptors, the expression of scavenger receptors is not controlled 
by cell cholesterol status and they can therefore mediate massive cholesterol uptake 
(Brown and Goldstein, 1983). Oxidised LDL may also increase the inflammatory 
response by recruiting more monocytes into the lesions resulting in more foam cells 
and increasing the expression of inflammatory cytokines (Osterud and Bjorklid,
2003). The arterial wall does have a variety of mechanisms to prevent such oxidation,
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for example antioxidants such as vitamin E, carotenoids and nitric oxide can suppress 
the oxidation of LDL. It is likely that a balance between pro-oxidant and anti-oxidant 
properties that determines the extent of oxidation of LDL particles and hence lesion 
formation.
Cholesterol efflux is important in maintaining cholesterol homeostasis in cells. 
Macrophages can dispose excess cholesterol in two ways. The first is by enzymatic 
modification, where cholesterol is converted into a more soluble form by 27- 
hydroxylase which can be accepted by circulating albumin (Babiker et al., 1997). The 
second is by ‘reverse cholesterol transport’ which relies upon HDL (Section 1.2.3). 
Therefore, in contrast to high LDL levels, low levels of HDL-cholesterol are an 
important cardiovascular risk factor. This is highlighted by genetic disorders such as 
Tangiers disease, which is caused by a mutation in the ATP binding cassette 
transporter (ABCA1) which is involved in cholesterol efflux, and characterised by a 
severe deficiency in HDL. This results in premature CAD (Oram, 2000; Oram and 
Vaughan, 2000). On the other hand, the genetic syndrome, familial 
hyperalphalipoproteinemia, characterised by high HDL levels, is associated with 
reduced atherosclerosis (Gordon and Rifkind, 1989; Tall, 1990).
HDL also protects from atherosclerosis by inhibiting lipoprotein oxidation. It 
has been suggested that the antioxidant properties of HDL are due in part to the ability 
of enzymes associated with HDL to protect against oxidised LDL, by destroying the 
biologically active lipids that are formed as a result of the oxidative process. Such 
enzymes include serum paraoxonase (Lusis, 2000). Therefore, HDL metabolism is 
viewed as an attractive target for the development of new therapeutic approaches to 
atherosclerosis.
It is therefore clear that the dys-regulation of lipoprotein concentrations can 
contribute to the onset of atherosclerosis. Given that LPL is expressed in the 
atherosclerotic lesion and that it can mediate the production of lipoproteins, it seems 
likely that it can also contribute to atherosclerosis. This is discussed below.
1.6 LPL and Atherosclerosis
Although it has long been widely accepted that the central function of LPL expressed 
in adipose and muscle tissue is to catalyse the hydrolysis of triacylglycerol-rich 
lipoproteins to provide metabolites for either lipid storage or utilisation, the function
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of LPL expressed in macrophages is more ambiguous. Whilst the effects of LPL on 
atherosclerosis have provoked much debate, the general consensus at the present time 
is that the role of LPL is cell-type specific. When expressed by muscle and adipose 
tissue, the enzyme plays a protective role against the disease by hydrolysing 
potentially harmful lipoproteins so that the remnants can be utilised or cleared by the 
body. On the other hand, LPL expressed by macrophages in the arterial wall 
contributes to the progression of the disease. Both the pro- and anti-atherogenic roles 
of the enzyme are considered below.
1.6.1 Pro-Atherogenic role of LPL
As mentioned above, in addition to the muscle and adipose tissue LPL, the enzyme is 
also expressed by macrophages and smooth muscle cells in atherosclerotic lesions 
(O’Brien et al., 1992). LPL secreted by these cells is likely to play a pro-atherogenic 
role. The first theory implicating LPL in atherosclerosis was proposed by Zilversmit 
in 1973; he postulated that the atherogenic remnants produced by the action of LPL 
on the triacylglycerol-rich lipoproteins in the endothelial lining of arteries might be 
taken up by arterial wall cells and could lead to the deposition of cholesterol 
(Zilversmit, 1973). He consequently demonstrated the presence of LPL activity in the 
intima of bovine aorta (DiCorletto and Zilversmit, 1975). Subsequently, several lines 
of evidence linking macrophage LPL with atherosclerosis have emerged. For 
example, the synthesis of LPL by monocyte-derived macrophages and smooth muscle 
cells present in the atherosclerotic lesion, as well as macrophage-derived foam cells in 
human coronary atherosclerotic plaques, has been demonstrated (Chiat et al., 1982; 
Herttuala et al., 1991; O’Brien et al., 1992). In addition, LPL synthesis is increased in 
patients with diabetes and familial hypercholesterolemia, and this may contribute to 
the high incidence of atherosclerosis in these individuals (Sartippour and Reiner 2000 
[a]; Beauchamp and Reiner, 2002). Furthermore, macrophages isolated from 
atherosclerotic-susceptible mice showed two to three-fold higher basal LPL mass, 
activity and mRNA levels than those from atherosclerosis-resistant mice (Reiner et 
al., 1993). In addition, Semenkovich et al., (1998) have shown that when an 
atherogenic diet is fed to heterozygous LPL deficient mice, no major differences are 
observed in terms of the onset of atherogenesis.
The most compelling evidence corroborating macrophage LPL and 
atherosclerosis has come from LPL ‘knockout studies’. The homozygous negative
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LPL genotype (LPL-/-) in mice is fatal as the animals die soon after birth because the 
capillaries become loaded with chylomicrons (Weinstock et al., 1995). As global LPL 
‘knockout’ studies are not specific for macrophages, chimeric mice that are deficient 
for macrophage LPL expression have been created by bone marrow transplantation 
techniques and have independently highlighted the importance of macrophage LPL in 
the promotion of foam cell formation. In 1999, Babaev et al., produced chimeric mice 
for the expression of macrophage LPL by the transplantation of LPL-/-, LPL +/- or 
LPL +/+ foetal liver cells, the predominant site of haematopoiesis in mammalian 
embryogenesis, into the irradiated female mice model of diet-induced atherosclerosis. 
This approach was feasible as macrophages are the only haematopoietic cells that 
express LPL. The mice were fed an identical atherosclerotic diet for 19 weeks. The 
mean lesion area was reduced by 55% in LPL-deficient mice compared to mice 
homozygous for macrophage LPL expression and by 45% when compared to the 
heterozygous genotype. Van Eck et al., (2000) used bone marrow transplantation 
from LPL-/- and LPL+/+ mice and found similar results. Overall, the studies 
demonstrate that macrophage LPL expression directly contributes to atherosclerosis 
with a pro-atherogenic diet.
Although a plethora of evidence has accumulated supporting a pro-atherogenic 
role for macrophage LPL, research has not been able to fully verify experimentally 
the mechanism responsible for such an action. There are, however, two main theories 
about the mechanisms involved. These are discussed below.
1.6.1.1 Mechanisms fo r the involvement o f  LPL in atherosclerosis:
1.6.1.1.1 Catalytic Action
As described previously, LPL-mediated lipolysis of VLDL and chylomicron particles 
leads to a decrease in their size and enrichment in their cholesteryl ester content. 
Studies have shown that these remnants are more readily taken up by macrophages 
(Lindqvist et al., 1983). Also, the hydrolysis of VLDL by LPL gives rise to LDL, one 
of the major contributors to atherosclerotic lesions (Section 1.5) because 
modifications of the molecule, particularly oxidation by free radicals, increases its 
affinity for binding to scavenger receptors (SR-A, CD36, CD38) on the surface of 
macrophages. LDL is then taken up by the macrophages, which in turn leads to foam 
cell formation (Steinberg et al., 1989). Also, the catalytic action of LPL provides free
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fatty acids which may be taken up by macrophages and re-esterified into 
triacylglycerol (Avirum et al., 1988).
1.6.1.1.2 Atherogenic ligand
In addition to its catalytic functions, LPL also appears to act as a ligand. It has the 
ability to associate with lipoproteins whilst also being able to bind HSPG, LDL-R, 
LPL-R-related protein and the VLDL receptor. This allows a bridging action that 
brings the lipoproteins within close proximity to their receptors, and this has been 
proposed to promote the accumulation of lipoproteins in vascular tissue (Rumsey et 
al., 1992). Indeed, this bridging action has been confirmed in vivo; transgenic mice 
expressing catalytically inactive LPL can still bind proteoglycans and induce the 
uptake of VLDL (Merkel et al., 1998).
It should be mentioned that the interaction of LDL with LPL is increased 
markedly by modifications of the lipoprotein, the best known of which is oxidation 
(Mead and Ramji, 1999). It has also been shown that LPL enhances the binding, 
uptake and degradation of another modified form of lipoprotein, glycated LDL 
(Zimmermann et al, 2001). Glycated LDL results from a chemical alteration of its 
apo-B residues by glucose and is, therefore more prevalent in diabetic patients 
(Zimmermann et al., 2001). It has therefore been proposed that higher levels of this 
altered lipoprotein may contribute to the increased incidence of atherosclerosis in 
diabetic patients (Mead and Ramji, 1999).
1.6.2 Anti-Atherogenic role of LPL
In contrast to the pro-atherogenic properties described above, the expression of LPL in 
tissues other than those found in the arterial wall appears to be beneficial (Kitaj ima et 
al, 2004). After all, the main catalytic function of the enzyme is to hydrolyse 
circulating lipoproteins. This allows the remnants to be taken up by lipoprotein 
receptors, thus lowering the plasma cholesterol levels. This anti-atherogenic role of 
LPL has been supported by several lines of evidence. For example, transgenic mice 
overexpressing LPL, primarily in adipose tissue, heart and skeletal muscle, have a 
markedly improved lipid profile, including elevations in HDL levels as well as a 
reduction in the concentration of plasma triglyceride and cholesterol-rich LDL 
(Shimada et al., 1993; Hayden et al., 1993). Moreover, patients who are deficient in 
LPL or have heterozygous LPL mutations that lead to a reduction in enzymatic
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activity have been reported to show signs of premature atherosclerosis (Reymer et al., 
1995; Jukema et al., 1996; Wirttrup et al., 1997; Nordestgaard et al., 1997; Henderson 
et al., 1999). Additionally, an LPL mutation responsible for an increase in the activity 
of LPL has been shown to have a protective effect on coronary heart disease (Gagne 
et al., 1999). Furthermore, the atheroprotective compound N O-1886 has been shown 
to raise LPL activity and decrease atherosclerosis in cholesterol-fed animals (Chiba et 
al., 1997; Yin and Tsutsumi, 2003).
The evidence described in sections 1.6.1 and 1.6.2 emphasise the dual role for 
LPL in atherosclerosis. Thus, the LPL-mediated breakdown of lipoproteins (allowing 
free fatty acids and 2-MG to be taken up by adipose tissue) contributes to the 
catabolism of atherogenic particles and reduced atherosclerosis, whereas synthesis of 
LPL by cells present in the arterial wall contributes to foam cell formation and 
promotes the atherosclerotic process. It is therefore the site of LPL expression that 
dictates the ultimate role of LPL in the development of- or protection against- 
atherosclerosis (Santamarina-Fojo and Dugi, 1994).
Due to its important role in atherosclerosis, the regulation of macrophage LPL 
by factors present in the atherosclerotic lesions may make a major contribution to the 
pathogenesis of the disease. Therefore the regulation of macrophage LPL gene 
expression is discussed below.
1.7 Regulation of LPL Expression
LPL expression and/or activity can change rapidly in response to physiological and 
pathophysiological conditions (Mead and Ramji, 1999). Reciprocal tissue-specific 
regulation of LPL is relatively common and helps to direct fatty acid utilisation 
according to specific metabolic demands. For example, there is a dramatic increase in 
mammary gland LPL activity with a corresponding decrease in the activity in adipose 
tissue during lactation (Mead and Ramji, 1999). Also, there is a reduction in adipose 
tissue LPL activity and an increase in cardiac tissue LPL activity in response to 
fasting; this allows fats to be diverted from storage in adipose tissue to meet the 
metabolic demands of the heart at times of calorie deprivation (Borensztajn and 
Robinson, 1970; Semb and Olivecrona, 1987, 1989; Doolittle et al., 1990). Several 
factors have been found to regulate the expression of LPL, including endocrine 
hormones, growth factors and cytokines (Table 1.4; Mead and Ramji, 2002). Some
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factors have been shown to act synergistically, for example, IFN-y and TNF-a 
(Tengku-Muhammad et al, 1998 [a]).
Table 1.4: Effects o f various mediators on LPL in different cell lines
M e d ia t o r E f f e c t C e l l  T y p e R e f e r e n c e
IFN-y 4- mRNA; i  activity 3T3-F442A Doerrler et al., 1994
i  activity 3T3-L1 Gregoire et al., 1992
4 mRNA; 4 activity J774.2 Tengku-Muhammad et 
al., 1996
4 activity NR8383 Tengku-Muhammad et 
al., 1998(b)
4 activity Human primary 
macrophages
Jonasson et al., 1990
TNF-a 4 mRNA; 4 activity 3T3-F442A Doerrler et al., 1994
4 mRNA; 4 activity 3T3-L1 Cornelius et al., 1988
4 mRNA; 4 protein 
synthetic rate;
4 activity
Human primary 
adipocytes
Fried etal., 1989
4 activity Murine peritoneal 
macrophages
Friedman et al., 1998
4 activity 4 mRNA J774.2 Tengku-Muhammad et 
al., 1996
4 activity; 4 protein 
synthetic rate
OST Sakayama et al,  1996
IL-1 4 activity; mRNA 
unchanged
3T3-F442A Doerller etal., 1994
4 mRNA; 4 protein 
synthetic rate;
4 activity
3T3-L1 Price etal., 1986 
Zechner et al., 1988 
Gimble etal., 1989
4 activity Human primary 
macrophages
Querfeld et al., 1990
4 activity; mRNA 
unchanged
Rat primary
mesenchymal heart cells
Friedman et al., 1991
4 mRNA; 4 activity J774.2 Tengku-Muhammad et 
al., 1996
IL-6 4 activity 3T3-L1 Greenberg et al., 1992
4 activity Murine adipose tissue (in
vivo)
Greenberg et al., 1992
mRNA unchanged; J774.2 Tengku-Muhammad et
activity unchanged al., 1996
IL-11 4 activity 3T3-L1 Kawashima et al., 1991
-I mRNA; -I activity J774.2 Tengku-Muhammad et 
al., 1996
LIF -I mRNA; 'I activity 3T3-L1 Mori etal., 1989
i  activity 3T3-F442A Kawakami etal., 1991
mRNA unchanged; 
activity unchanged
J774.2 Tengku-Muhammad et 
al., 1996
Catecholamines T activity Rat brown adipose tissue 
(in vivo)
Radomski, 1971
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Catecholamines T activity Rat cardiac monocytes (in Obregon, 1989
(Cont.) vivo) Carneheim et al., 1988
I  activity Rat white adipose tissue 
(in vivo)
Shima etal., 1994
Fatty acids T mRNA; T protein; 
t  activity
J774.2 Michaud and Renier, 
2001
Glucocorticoids T mRNA; T activity Human primary pre­
adipocytes
Green and Meuth, 1974
t  mRNA; T activity 3T3-L1 Ottosson et al., 1994
i  mRNA; -I protein 
synthetic rate
Rat primary pre­
adipocytes
Ong etal., 1992
Glucose T mRNA J774.2 Sartippour and Renier, 
2000 (b)
Homocysteine T mRNA J774.2 Beauchamp and Renier, 
2002
Insulin t  activity Human primary pre­
adipocytes
K.Qvnetal., 1985
t  activity; T protein 
synthetic rate; 
mRNA unchanged
3T3-L1 Eckel etal., 1978; 
Spooner et al., 1979; 
Semenkovich et al., 1989
mRNA unchanged Mouse peritoneal 
macrophages
Semenkovich et al., 1989
LPS i  mRNA; I  activity Human peritoneal 
macrophages
White et al., 1988
i  activity J774.1 Sopher and Goldman, 
1987
I  activity BMM Sopher and Goldman, 
1987
activity unchanged 3T3-L1 Kawakami et al., 1991
i  mRNA; I  protein; 
■I activity
J774.2 Tengku-Muhammad et 
al., 1996
Oestrogen i  mRNA 3T3-L1 Homma et al., 2000
Prolactin T activity 3T3-L1 Spooner et al., 1979
t  activity Murine mammary tissue Robinson, 1963 
Hamosh etal., 1970
Prostaglandin -I mRNA; i  activity Murine peritoneal 
macrophages
DeSanctis et al., 1994
■I mRNA; -I activity Rat primary adipocytes Serrero etal., 1992
i  activity 3T3-L1 Williams and Polakis, 
1977
Retinoic Acid mRNA unchanged; 
i  protein synthetic 
rate; -I activity
3T3-L1 Kamei etal., 1992
mRNA unchanged; 
■I protein synthetic 
rate; i  activity
BMM Goldman, 1990
Thyroxine T activity Rat brown adipose tissue 
(in vivo)
Hemon et al., 1975
T activity; mRNA 
unchanged
Rat white adipose tissue 
(in vivo)
Saffari et al., 1992
t  activity; mRNA 
unchanged
Rat heart (in vivo) Ong etal., 1992
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Abbreviations: BMM, Bone-marrow-derived Macrophages; 3T3-L1 and 3T3-F442A 
are murine pre-adipocyte cell lines, OST is a human osteosarcoma cell line, NR8383 is 
a rat macrophage cell line and J774.2 is a murine monocyte-derived macrophage cell 
line; LPS, Lipopolysaccharide (Table adapted from Tengku-Muhammad 1998 [c]).
The mechanisms involved in the regulation of LPL gene expression can be divided 
broadly into two levels: transcriptional and post-transcriptional.
1.7.1 Transcriptional Control
Several studies have shown that the expression of LPL during cellular differentiation, 
development and in response to cytokines and growth factors is principally regulated 
at the level of gene transcription (Hua et al, 1991; Previato et al., 1991; Currie and 
Eckel, 1992; Enerback et al., 1992). Transcriptional control is primarily achieved via 
transcription factors, which interact with czs-elements in the promoter and enhancer 
regions of the target genes. A plethora of potential cw-elements, some of which 
represent binding sites for known transcription factors, have been identified in the 
promoter of human, mouse and rat LPL genes (Table 1.5). The proximal 730-base pair 
LPL promoter region upstream of the transcriptional start site contains a number of 
potential regulatory sequences (Enerback and Gimble, 1993; Yang and Deeb, 1998). 
These include a putative TATA box at position -27; three sites for octamer binding 
proteins at positions -580, -186, and -46 (Singh et al., 1986); two CCAAT boxes at - 
65 and -506; sequences with partial homology to the glucocorticoid response element 
at -644 and -776; a cyclic AMP responsive element at -306; and HNF-3/fork head 
family transcription factor binding sites at positions -702 and -468 (Nakshatri et al., 
1995; Deeb and Peng, 1989; Enerback et al., 1992; Previato et al., 1991). The 
functional importance of some of these sites has been established. For example, it has 
been shown that NF-Y binds to the CCAAT box located at position -65 and that this is 
necessary for promoter activity (Enerback et al., 1992; Previato et al., 1991). In 
addition the CT element that interacts with the sterol regulatory element binding 
protein-1 (and Spl/Sp3) mediates the induction of LPL gene transcription in response 
to decreased cellular cholesterol levels (Schoonjans et al., 2000).
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Table 1.5: Some o f the cis-regulatory sequences within the LPL 5 - 
flanking regions o f human, mouse and rat genes_________________
CM-REGULATORY
SEQUENCES
5 ’ R e g io n  e x a m in e d
(bp RELATIVE TO TRANSCRIPTIONAL START SITE)
H u m a n M o u s e Ra t
AP-1 site -1946 -1947 -
AP-2 site -790 -444 -478
-234
CCAAT box -65 -72 -65
-506
CRE -372 - -
CT element -91 +44 +44
+62 +62
+65 +65
FSE2-like element -362 -698 -1402
-206 -529
-403
-219
-209
GRE -776 -337 -910
-644 -700 -534
-464 -457
+58 +47
HNF-3 -702 -171 -207
-468
POU -580 -893 -803
-186 -588 -576
-46 -46 -46
PPRE -169 -169 -169
TRE +23 +28 -258
+17
Abbreviations: AP, Activator protein; CRE, aAMP-responsive element; CT  
element, 5 ’-CCTCCCCC-3 ’ m otif interacts with Spl/Sp3; FSE2, Fat 
specific element 2; GRE, Glucocorticoid responsive element; HNF3, 
Forkhead family o f  transcription factors; POU, POU binding domains; 
PPRE, Peroxisome Proliferator-activated receptor element; TRE, Thyroid 
hormone Responsive Element (Table adaptedfrom Bey et al., 1998).
Some transcription factor binding sites in the LPL promoter play key roles in its 
regulation during pathophysiological conditions such as atherosclerosis and for this 
reason are discussed below in more detail.
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1.1.7.1 Activating protein-]_ (AP-1)
AP-1 is a collective term given to dimeric transcription factors of Jun, Fos or 
activating transcription factor (ATF) subunits. The transcription factors bind to the 
tumour promoter activator responsive elements (TPARE) (consensus TGA[C/G]TCA) 
in the promoter regions of the target genes. AP-1 activity is regulated through 
interactions with specific protein kinases and a variety of transcriptional co-activators 
(Karin et al., 1997). An AP-1 like binding sequence has been shown to regulate the 
transcriptional control of LPL by estrogen (Homma et al., 2000).
1.7.1.2 Oct-1
The POU family of transcription factors bind to their target sequences through their 
bipartite POU DNA-binding domains. The common cw-acting element is 5’- 
ATTTGCAT-3’. It is found in the regulatory regions of many genes and is generally 
located in close proximity of the TATA element (Falkner and Zachau, 1984). Oct-1 
and Oct-2 are the most well characterised members of the family and the expression 
of the family members differ depending upon cell type. Oct-1 contains distinct 
transcription activation domains, both located upstream and downstream to the POU 
domain. These are responsible for promoter specific activity (Tanaka et al., 1992;
1994).
Although at least one of the human octamer motifs in the LPL gene promoter 
is completely conserved in mouse and rat (Table 1.5), it has been shown that Oct-1 
and Oct-2 bind only weakly to this sequence. However, this binding is stimulated by 
TFIIB, suggesting that Oct-1 and Oct-2 may play an important role in the positioning 
of the transcription initiation site (Nakshatri et al., 1995). There is also evidence that 
the binding of Oct-1 can be regulated by protein kinase A (PKA) and protein kinase C 
(PKC) (Roberts et al., 1991).
1.7.1.3 Peroxisome Proliferator-Activated Receptor (PPAR)
PPARs belong to a nuclear hormone receptor super-family. They contain a signature 
type II zinc finger DNA binding motif and a hydrophobic ligand binding pocket 
(Chawla et al., 2001). So far, three types of PPARs have been described: -a , -y and -P 
(also referred to as -5). Each has a distinct tissue distribution (Sher et al., 1993). 
PPAR-a is predominantly expressed in brown adipose tissue, liver, kidney and 
vascular endothelial cells and is involved in the control of lipoprotein metabolism,
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fatty acid oxidation, and the cellular uptake of fatty acids (Lee et al, 2003; Elangbam 
et al., 2001). PPAR-y is highly expressed in brown and white adipose tissues and 
plays a critical role in adipocyte differentiation and fat deposition (Elangbam et al., 
2001; Lee et al., 2003). PPAR-p however, shows a widespread tissue distribution, its 
regulation and functions are not yet known (Elangbam et al., 2001).
PPARs interact with retinoid X receptor (RXR) to form heterodimers. These 
heterodimers interact with their regulatory sequences to modulate transcription 
(Temple et al., 2005). PPAR-/RXR binds to a repeat of consensus sequence elements 
(AGGTCA) separated by a single nucleotide (Temple et al., 2005). This PPAR 
recognition element has been shown to play an important role in cholesterol 
homeostasis (Auwrex et al., 1996; Table 1.5). For example, it mediates the effects of 
fatty acids, thiazolidinediones and PPAR ligands, all of which enhance LPL gene 
expression (Michaud and Reiner, 2001; Lefebvre et al., 1997; Li et al., 2002). On the 
other hand, it has been shown that the binding of the silencing mediator of retinoic 
acid and thyroid hormone receptor (SMRT) to the PPRE consensus sequence is 
associated with decreased LPL gene expression (Robinson et al., 1999; Tanuma et al.,
1995).
1.7.1.4 Specificity Proteins (Sp)
The Specificity proteins (Sp) include at least four family members, Spl to 4. They 
bind DNA with varying affinities at Sp sites which include GC-boxes 
(GGGGCGGGG) and the related GT-box (GGTGTGGGG). The transcription factors 
play important roles in a wide variety of physiological processes including cell cycle 
regulation, apoptosis and cellular changes in response to hormones (Chu and Ferro, 
2005).
Another subgroup of proteins called the Kruppel-like factors also recognise 
GT-boxes and so the Sp-family members and the kruppel-like factors have an 
overlapping binding specificity (Matsumoto et al., 1998).
The Sp family members display substantial homology. Each contains an 81 
amino acid domain with three C2 H2 -type zinc fingers responsible for the specificity of 
DNA binding (Philipsen and Suske, 1999). The members also contain glutamine-rich 
transcriptional activation domains adjacent to serine/threonine-rich stretches in their 
N-terminus (Courey and Tjian, 1988). In contrast, the N-termini of KLF proteins are
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not conserved and can contain several different domains, for example glutamine, 
proline or serine-rich regions (Matsumoto et al., 1998; Black et al., 2001).
Different members o f the family have different preferences for DNA 
sequences. For example Spl and Sp3 bind with higher affinity to GC-boxes than to 
GT-boxes (Thiesen and Bach, 1990; Kingsley and Winoto, 1992). Due to such 
differences, the families effects on transcriptional activity vary, some are repressors 
whereas others are activators (Table 1.6; Black et al., 2001).
Table 1.6: Function and properties o f  Sp transcription factors
H u m a n D is t r ib u t io n T r a n s c r i p t i o n a l  P r o p e r t ie s
C h r o m o s o m a l
l o c a t io n
Spl 12ql3 Ubiquitous •  Activator (Courey and Tjian, 1988)
(Gaynor et al., (Saffer et al., 1991) •  Synergistic activation (through
1993; Materaand multiple GC boxes in promoter
Ward, 1993) (Courey and Tjian, 1988; Courey et al., 
1989);
•  Superactivation (bound Sp 1 can be 
transcriptionally enhanced by other 
molecules) (Pascal and Tjian, 1991)
Sp2 17q21.3-q22 
(Schoy et al., 1998)
Various Cell 
(Tissues Unknown) 
(Kingsley and Winto, 
1992)
•  Unknown (potentially Activator)
Sp3 2q31 Ubiquitous •  Activator (Denning et al., 1996);
(Kalff-Suske et al., (Hagen etal., 1992) •  Repressor of Spl-mediated
1996) transcription (Hagen et al., 1994)
Sp4 7pl5.3-p21 
(Kalff-Suske et al., 
1995)
Predominantly Brain 
(also epithelia) 
(Hagen etal., 1992)
•  Activator (Hagen et al., 1994; 1995)
Sp sites are found in the promoters of many housekeeping genes and they are also 
involved in tissue-specific gene expression (Philipsen and Suske, 1999). Moreover, it 
has been shown that these sites are involved in the regulation of gene transcription in 
response to certain stimuli (Black et al., 1999; Fandos et al., 1999), thus
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demonstrating that the binding to Sp sites can be regulated in cells (Black et al., 
2001). In fact the role of Sp consensus sites has been found to be critical for the 
regulation of various genes through the action of cytokines such as tumour necrosis 
factor-a (TNF-a) (Ryuto et al., 1996), transforming growth factor-g (TGF-0) (Black 
et al., 2001) and interferon-y (IFN-y) (Ulgiati et al., 2000; Hughes et al., 2002). 
Furthermore it has been shown that Spl and Sp3 specifically interact with a CT- 
element from -91 to -83 in the LPL promoter (Yang and Deeb, 1998). In addition, it 
has been shown in our laboratory that IFN-y represses LPL gene expression via three 
binding sites within the -31/+187 region (Hughes et al., 2002). Spl and Sp3 are 
particularly important with regards to this project and so their functional properties 
are discussed in further detail.
Spl knockout mice do not survive beyond 11 days (Marin et al., 1997), 
likewise Sp3 knockout mice die prior to or at birth (Bouwman et al., 2000). However, 
due to the fact that Spl and Sp3 are indistinguishable in their DNA binding 
specificity, it is hypothesised that the transcription factors can compensate for each 
other during early development (Suske, 1999).
The activation domains of Spl appear to be essential for transcriptional 
activation whereas it is the structure and arrangement of the Sp3 recognition site that 
appears to determine its function (Gill et al., 1994). Sp3 can act as a strong activator; 
alternatively it can be transcriptionally inactive and because of its seemingly identical 
DNA binding specificity, can compete with Spl for the binding site, hence repressing 
transcription (Suske, 1999). Generally, promoters containing a single binding site are 
activated by Sp3 (Bimbaum et al., 1995).
The family are subject to regulation through a multitude of post-translational 
modifications including phosphorylation, glycosylation and acetylation (Chu and 
Ferro, 2005; Jackson et al., 1990; Jackson and Tjian, 1988). Whilst the majority of 
studies have concentrated on Spl, it is likely that these modes of regulation are 
important in the regulation of the whole family.
Spl can be phosphorylated by a number of kinases within the cell such as 
Casein kinase 2 (CK2), PKA and PKC-£ (Chu and Ferro, 2005; Black et al., 2001). 
PKA phosphorylates Spl on its N-terminus and this increases its trans-activating 
potential (Rohlff et al., 1997). Likewise, phosphorylation by other kinases can affect 
the DNA binding of Spl. For example, it has been shown that in differentiated liver
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cells CK2 phosphorylates a threonine residue in the second zinc finger of Spl and this 
inhibits its DNA binding activity (Armstrong et al., 1997). Phosphorylation can also 
lead to altered protein-protein interactions. For example, it has been suggested that the 
ability of Spl to interact with AP-2 is affected by phosphorylation (Pena et al., 1999).
1.7.2 Post-transcriptional control
Post-transcriptional control is the most common mechanism for the regulation of LPL 
gene expression in response to changes in nutritional status and stimulation by various 
hormones (Enerback and Gimble, 1993; Ranganathan et al., 1997). One of the earliest 
possible post-transcriptional modifications can occur at the level of LPL mRNA 
stability. Relatively little is known regarding this potential mechanism in the 
regulation of LPL expression. However it is apparent that insulin increases LPL 
mRNA levels in adipocytes without any changes in the rate of gene transcription, 
suggesting control at the level of mRNA stability (Semenkovich et al., 1989). Other 
methods of post-transcriptional control can occur at the protein level and include the 
synthesis, degradation, processing, secretion and translocation of the protein to the 
site of action (Mead and Ramji, 1999). Indeed, the cDNA sequences of LPL contain 
three putative sites for A-linked glycosylation (Asn-X-Ser/Thr) (Semb and 
Olivecrona, 1989) and it has been shown that the absence of glycosylation results in 
the loss of activity and secretion of the enzyme (Olivecrona et al., 1987). Also, the 3’ 
un-translated region (UTR) of LPL mRNA has been shown to bind to repressors of 
translation, which have been crucial in mediating the responses of hormones such as 
epinephrine and thyroid hormone (Ranganathan et al., 1997). The fact that 
interactions with HSPG can control the secretion of the enzyme provides an additional 
mechanism of control (Enerback and Gimble, 1993). Furthermore, the maximal 
activity of the enzyme requires the activating protein apo-C2; hence the association 
with this protein can affect the activity of LPL (Cisar et al., 1989).
1.8 C ytok ines as regu lators o f  LPL  gene expression
In summary, LPL expression is subject to regulation at multiple levels during 
physiological and pathophysiological conditions through the actions of several factors 
including cytokines (Table 1.4; Enerback and Gimble, 1993; Braun and Steverson, 
1992). The regulation of LPL produced by adipose tissue is better documented than
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that of macrophage LPL. For example, LPL expressed by adipose and muscle tissue is 
regulated in response to nutritional status and a large number of regulatory factors, 
including hormones and lipid metabolite products (Table 1.4; Enerback and Gimble, 
1993; Schoonjans et al., 1996). The regulation of macrophage LPL, which is of course 
more directly relevant to the pathogenesis of atherosclerosis, is less well understood. 
However, there is increasing evidence to support the role of several factors in the 
regulation of macrophage LPL gene expression. For instance, hydrogen peroxide, (a 
source of oxidant stress/reactive oxygen intermediates), has not only been implicated 
in the oxidation of LDL but has also been shown to increase macrophage LPL 
expression (Reiner et al, 1996). Likewise, PDGF, M-CSF and glucose have all been 
shown to increase macrophage LPL expression and all are also known to be pro- 
atherogenic (Sartippour and Reiner 2000 [b]; Reiner et al, 1996; Michaud and Reiner, 
2001; Beauchamp et al, 2000). In addition, recent studies have revealed that several 
cytokines, which have also been shown to regulate adipose LPL, can regulate the 
enzyme expressed by macrophages (Mead and Ramji, 2002). Indeed many cytokines 
are known to act in a pro-atherogenic manner whilst others have been shown to exert 
an anti-atherogenic effect; this is not surprising given their abundance in the vascular 
wall. The action of cytokines on LPL expression is likely to make a major 
contribution to the initiation and the development of the disease.
1.8.1 Cytokines
Cytokines constitute a large family of secreted proteins that form an integrated 
network of paracrine and endocrine communication between cells. The term cytokine 
encompasses Tymphokines’, ‘chemokines’, ‘colony-stimulating factors’, ‘growth 
factors’ and monokines (Oppenhein, 1998). Cytokines can be grouped further into 
families, for example, interferons, interleukins and tumour necrosis factors.
Cytokines are responsible for the regulation of fundamental biological 
processes including immunity, wound healing and haematopoiesis. Cytokines convey 
information about the status of the body to target cells by interacting with receptors on 
the surface of cells and initiating signal transduction mechanisms (Section 1.8.2.1). 
Cellular responses to cytokine stimulation depend on the type of cytokine and the 
nature of the target cell, and include proliferation, differentiation and survival (Nicola,
1994). If the regular balance of cytokine production and its control is disturbed then 
this contributes to pathological conditions. Indeed, multiple cell types produce and
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secrete inflammatory cytokines within the atherosclerotic lesion and this is now 
thought to contribute to the onset of the disease. One such cytokine is IFN-y.
The effect of IFN-y in the atherosclerotic lesion is, as with many other factors, 
complex. Several genes are either induced or repressed in response to the cytokine 
and thus can have pro- or anti-atherogenic effects (Harvey and Ramji, 2005). For 
example, IFN-y is responsible for the induction of a number of chemokines and their 
receptors which can contribute to the growth of the atherosclerotic plaque. IFN-y has 
also been shown to contribute to the destabilisation of the plaque (van der Wal et al.,
1994). On the other hand treatment of IFN-y has been shown to reduce the expression 
of scavenger receptors, SR-A and CD36, specifically in macrophages. This leads to 
the decreased uptake of oxidised LDL and hence a reduction in macrophage foam cell 
formation (Fong et al, 1990; Christin et al, 1994). IFN-y also decreases the 
expression of LDL-receptor related protein and VLDL receptor which have also been 
implicated in atherosclerosis because they have a high binding affinity for atherogenic 
remnant particles (Kosaka et al., 2001; LaMarre et al., 1993).
In addition, to the genes/cellular changes detailed above an understanding of 
the regulation of macrophage LPL expression by IFN-y has been established. IFN-y 
has been shown to reduce the expression of LPL mRNA, protein and enzymatic 
activity in several macrophage cell lines and primary cultures (Tengku-Muhammad et 
al, 1999 [a], [b]; Jonasson et al, 1990). Furthermore, it has been shown that the 
cytokine exerts its effects at the transcriptional level by decreasing the expression of 
Sp3 and reducing the Spl DNA binding (Hughes et al, 2002). It is therefore essential 
that the signalling pathways and the mechanisms through which IFN-y decreases Spl 
and Sp3 action and therefore LPL transcription are investigated in detail. Additional 
information of IFN-y and the potential signalling pathways through which it regulates 
LPL is given below.
1.8.2 Interferons
Interferons (IFNs) are pleiotrophic cytokines that play key roles in mediating antiviral 
and antigrowth responses and in modulating the immune response (Huang et al, 
1993; Muller et al, 1994; Hwang et al, 1995). IFNs can be divided into two major 
classes; Type I and Type II. The Type I family of IFNs consist of IFN-a, IFN-P, IFN- 
co and IFN-0. These proteins are acid stable and have similar structures and biological
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activities (Petska et al, 1987; Stark et al, 1998). IFN-y represents the Type II IFN. 
This protein contains a much higher content of basic residues, is acid-labile and is 
molecularly distinct from the other groups. Each class is also characterised by distinct 
intracellular signalling mechanisms (Petska et al., 1987; Stark et al, 1998). Despite 
the differences in amino acid sequences and signalling mechanisms, both types of 
IFNs exhibit common biological effects, the most prominent of which are their growth 
inhibitory activities (Platanias et al, 1999). Type I IFNs can be synthesised in any 
cell, whereas IFN-y production is limited to activated mammalian T-lymphocytes, 
macrophages and natural killer (NK) cells.
All IFNs exert their signalling effects by interacting with their cognate 
receptors; all Type I IFNs bind to the same Type I receptor, whilst IFN-y exerts its 
effects via a receptor complex consisting of IFN-y-receptor-1 (IFNGR1) and IFN-y- 
receptor-2 (IFNGR2) (Petska et al, 1987). The full spectrum of IFN responses 
following Type I IFN receptor engagement is not known, whereas that of Type II is 
better defined (Kalvakolanu, 2003).
As the expression of IFN-y is up-regulated in the atherosclerotic lesion, it is 
important to consider it in greater detail in the context of this thesis. IFN-y exists as a 
single copy in the genome and is located on human chromosome 12 in the pl2.05qter 
region. The protein exists as a homodimer (Mire-Sluis and Thorpe, 1998). As a result 
of binding to its cognate receptor, the transcription of many genes can be activated. 
This can occur immediately through the activation of signal transduction proteins 
already present in the cell, or can occur later, which requires the synthesis of proteins 
that are then responsible for gene activation (Mire-Sluis and Thorpe, 1998). Genes 
that are directly stimulated by IFN-y can contain a variety o f response elements 
including IFN-y activated sites (GAS) (Decker et al, 1997) and IFN-y activated 
transcriptional elements (GATE) (Weihua et al, 1997). The majority of early IFN-y- 
stimulated genes contain the GAS element (Decker et a l, 1997).
The IFN-y receptors are expressed on nearly all cell surfaces (with the possible 
exception of mature erythrocytes) and display strict species-specificity in their ability 
to bind to IFN-y (Stark et al, 1998). The receptor is a tetramer composed of two 
transmembrane components, IFNGR1 (90kDa) and IFNGR2 (62kDa). IFGR1 is 
necessary for IFN-y binding, whereas IFGR2 is required for signalling (Kotenko et 
al, 1995, 1996, 1997, 1999; Stark et al, 1998). It is understood that within minutes of
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binding to its receptor, IFN-y activates the Janus kinase (JAK) family of protein 
kinases, initiating the signal transduction mechanisms (see Section 1.8.3.1 and Figure
1.3).
1.8.2.1 Signal transduction Pathways
Signal transduction pathways are initiated when an extracellular signal binds to its 
cognate receptor on the cell surface, activating the receptor to relay information to the 
inside o f the cell. The receptor acts either as an ion channel, by catalysing the 
synthesis of ‘second messengers’, or by activating signal transducers such as GTP- 
binding proteins. These effects may induce transcriptional, post-transcriptional and 
post-translational responses mediated by extracellular stimuli such as IFN-y and other 
cytokines.
Table 1.7 highlights various cytokines that have been shown to be involved in 
the regulation of macrophage LPL expression and indicates the signalling pathways 
and the mechanisms which are involved in these responses.
Table 1.7: Cytokines involved in the regulation o f  LPL expression in
M e d ia t o r S ig n a l M e c h a n is m R e f e r e n c e s
IL-l TK Translational/Post- 
translational
Tengku-Muhammad et 
al., 1999 (b)
IL-11 TK T ranslational/Post- 
translational
Tengku-Muhammad et 
al., 1999 (b)
LPS TK/PI3K Translational/Post- 
translational
Tengku-Muhammad et 
al., 1996; 1998 (b); 
1999 (b)
IFN-y TK/PI3K/CK2 Transcriptional Tengku-Muhammad et 
al., 1999 (b)
TNF-a TK/PI3K T ranslational/Post- 
translational
Tengku-Muhammad et 
al., 1999 (b)
Abbreviations: IL-1-11, jnterleukin-l-l I; TK, Tyrosine Kinase; LPS, 
Lipopolysaccharide; PI3K, Phosphatidylinositol-3-kinase; IFN-y, 
Interferon-y; CK2, Casein Kinase 2 (derived from Mead and Ramji, 1999)
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1.8.3 Control of LPL expression by IFN-y
As mentioned previously, the binding of an extracellular mediator such as IFN-y 
initiates the activation of signal transducers, which can then trigger a series of signal 
transduction cascades. These cascades involve protein kinases that phosphorylate 
target cellular proteins. The importance of the protein kinases can be highlighted by 
the sequence of the human genome, which revealed the presence of almost six 
hundred genes specifying for protein kinases (The human genome project, 2001). 
Furthermore, it is apparent that a third of all cellular proteins can be phosphorylated, 
many of which can be phosphorylated at several different sites (Ahn and Resing, 
2001; Cohen, 2002). Phosphorylation can alter protein function in almost every 
conceivable way; for example, by altering the biological activity of molecules, 
altering movement between subcellular compartments or by altering protein-protein 
interactions, the end result leading to the regulation of responsive genes (Cohen, 
2002).
To gain a clear understanding of the mechanisms by which IFN-y exerts its 
effects on macrophage LPL gene expression, it is important to study the activation of 
the protein kinases and signalling cascades which respond to IFN-y. This will 
contribute to our understanding of the mode of action of this cytokine in 
atherosclerosis and may eventually assist in the development of therapeutic 
interventions. The signalling pathways which have so far been associated in IFN-y 
regulation of LPL expression are displayed in Table 1.7, some of which are described 
below in detail.
1.8.3.1 JAK-STAT pathway
A central role for Janus Kinase- Signal Transducer and Activator of Transcription 
(JAK-STAT) signalling pathways in promoting the diverse cellular responses induced 
by cytokines such as IFN-y has been established.
JAK kinases are a family of protein tyrosine kinases (PTK) (Rane and Readdy, 
2000) made up of tyrosine kinase 2 (TYK 2), JAK1, JAK2 and JAK3. They differ 
from other classes of PTK by the presence of an extra kinase domain and the lack of 
any Src Homology 2 (SH2) domains (Kalvakolanu, 2003). SH2 domains are 
conserved in many proteins involved in signal transduction and are responsible for 
receptor binding as they recognise phosphotyrosine residues on activated receptors
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(Pawson and Schlessinger, 1993). It was originally thought that this family of kinases 
was mainly responsible for signal transduction by IFNs and specific cytokines. 
However, evidence now suggests that they act as mediators of multiple signalling 
pathways and are essential for the normal function of the mammalian organism (Rane 
and Reddy, 2000). For example, over-activation of JAK has been implicated in 
tumorigenesis whereas loss of JAK function has been found to result in disease states 
such as severe-combined immunodeficiency (Rane and Reddy, 2000).
As mentioned previously, an understanding of early responses to IFN-y has 
been gained and is illustrated in Figure 1.3. The IFNGR consists of two chains, 
IFNGR1, which is constitutively bound to JAK1, and IFNGR2, which is bound to 
JAK2 (Platanias and Fish, 1999). IFN-y, a homodimer, binds to two IFNGR1 chains 
(Kotenko et al., 1995). Subsequently two IFNGR2 chains are recruited to the complex 
(Greenlund et al., 1994). Ligand-induced oligomerization of the receptor components 
brings the JAKs closer together leading to the mutual phosphorylation and activation 
of JAK, either via auto-phosphorylation or cross phosphorylation by other JAK 
kinases or TYK members. Activation of JAK leads to the phosphorylation of IFNGR1 
at tyrosine 440 by JAK1. This phosphotyrosine creates a docking site for STAT1 
(Ramana et al., 2002). This STAT1 binds to the receptor complexes through a SH2 
domain resulting in the phosphorylation of STAT1 at tyrosine 701 by JAK2. STAT1 
then dissociates from the complex, dimerises through reciprocal SH2-phosphotyrosine 
interactions, and translocates to the nucleus where it binds to its recognition sequences 
in IFN-y inducible promoters (Kotenko et al., 2000).
Phosphorylation of receptors by JAK kinases also creates a potential docking 
site for adaptor molecules such as the regulatory subunit of PI3K, which can associate 
with the receptors through their SH2 domains, thereby linking the two pathways. The 
PI3K pathway will therefore be considered in more detail.
It should be mentioned that although the emerging idea of a central role for 
JAK-STAT in IFN-y signalling has received experimental support, there is increasing 
evidence that suggests that pathways independent of JAK-STAT can also be initiated 
in response to IFN-y. For example, it has been shown that IFN-y induces major 
intracellular adhesion molecule-l (ICAM-1) gene expression in human comeal 
epithelial cells and this is not prevented by a global protein tyrosine kinase inhibitor 
(which inhibits JAK signalling) (Iwata et al., 2001). In addition, mircoarray analysis
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has revealed a number of genes that are suppressed by IFN-y in STAT null 
macrophages (Ramana et al., 2002).
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Figure 1.3: Signalling via the JAK-STAT pathways
IFN-y binds to two IFNGRJ subunits. This generates binding sites fo r  two IFNGR2 
subunits. JAK1 and JAK2 become phosphorylated and active and promote a docking 
site fo r  STAT 1 proteins. These form homodimers that can translocate to the nucleus 
and bind to regulatory regions o f  IFN-y modulated genes (Adapted from Stark et al., 
1998).
1.8.3.2 Phosphoinositide-3-Kinase
Phosphoinositide-3-kinases (PI3K) are a subfamily of lipid kinases that catalyse the 
addition of a phosphate molecule specifically to the 3-position of the inositol ring of 
phosphatidylmositol (Ptlns) (Figure 1.4).
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Figure 1.4: Sim plified representation o f  phoshatidylinositol
Ptdlns consists o f  a phosphatidic acid attached to an inositol ring via its 1 ’-OH group 
which does not carry any additional phosphates. All free  - OH groups (apart from  
those at the 2- and 6- positions can be phosphorylated in different combinations. 
(Adaptedfrom Vanhaesebroeck and Alessi, 2000).
Most of the cellular Ptdlns are phosphorylated at the 4-OH, 5-OH or both positions of 
the inositol ring and their basal levels alter only slightly during agonist stimulation 
(Toker, 2000). Conversely the basal levels of Ptdlns phosphorylated at the 3-OH 
position are low and can rise dramatically upon stimulation with certain mediators. 
This is consistent with the idea that it is the lipids phosphorylated at 3-OH that 
perform specific regulatory functions (Toker, 2000).
PI3K are a large and complex family, consisting of three classes with multiple 
subunits and isoforms. Their classification is based upon primary structure and the 
lipid signals which they generate (Toker, 2000).
Only class I PI3Ks are activated by cytokines and growth factors, 
consequently, this group is the most important with respect to this thesis and will be 
described in more detail than the other groups. Class I PI3Ks catalyse the 
phosphorylation of PtdIns-(4,5)-P2 to form PtdIns-(3,4,5)-P3 (Figure 1.5) which 
triggers downstream signalling cascades.
Class II PI3Ks are large molecules (greater than 170kDa) that generate Ptdlns- 
(3)-P and PtdIns-(3,4)-P2. The function of this class has not yet been established 
(MacDougall et al., 2004).
Class III PI3Ks are responsible for the agonist-insensitive phosphorylation of 
Ptdlns to PtdIns-(3)-P in cells (Hawkins et al., 1999). Evidence suggests that this class 
are involved in vesicular membrane trafficking (Vanhaesebroeck and Waterfield, 
1999).
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Figure 1.5: The pathways fo r  Ptdlns synthesis
The coloured boxes indicate the products from PI3K. The classes o f PI3K enzymes 
that catalyse the phosphorylation o f the different PI3K substrates are shown in the 
horizontal arrows; dashed arrows indicate the conversion o f  Ptdlns through 
unidentified PI3Ks (From Rameh and Cantley, 1999).
Class I PI3K are further sub-divided into class IA and Ib, which signal downstream of 
tyrosine kinases and heterotrimeric G-protein-coupled receptors respectively 
(Vanhaesebroeck and Waterfield, 1999). Class IA PI3K proteins are very diverse in 
mammals; they have three catalytic p i 10 iso forms (pi 108, p lio p  and pi 10a) 
(Wymann et al., 2003). The catalytic subunits can associate with any of the regulatory 
subunits of which there are five, p85a, p85p and p55y are encoded by distinct genes; 
p55a or p50a are produced from alternate transcripts of the p85a gene (Fruman and 
Cantley, 2002). The only class Ib PI3K protein identified to date consists of a pllOy 
catalytic subunit complexed with a p i01 regulatory subunit together referred to as 
PI3Ky (Vanhaesebroeck and Alessi, 2000).
The regulatory domains of class IA PI3K have no catalytic activity but possess 
two SH2 domains and a SH3 domain. As described previously, SH2 domains 
recognise phosphotyrosine residues on activated receptors. The SH3 domains are also 
conserved in many signalling proteins and mediate protein-protein interactions 
through the recognition of proline-rich sequences (Pawson and Schlessinger, 1993). It 
is the region between the two SH2 domains of the regulatory subunit that mediates the 
association with its catalytic domains by binding to its amino terminus (Kapeller and 
Cantley, 1994).
PtdIns-(3,4,5)-P3 acts as a second messenger. It is specifically recognised by 
two, structurally distinct binding domains; the pleckstrin homology (PH) domain and 
the FYVE domain, named after the proteins in which it was originally identified,
PtdIns-4-P
PtdIns-4,5-P2
PtdIns-5-P
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Fablp, YOTB, Vaclp and EEA1 (Stenmark et al., 1996). The PH domain appears to 
be more widespread (Vanhaesebroeck and Waterfield, 1999). PH domains are 
globular regions that consist of about 100 amino acids that bind to the inositol lipids 
and their head groups (Lemmon and Ferguson, 2000). PH domains are found in a 
diverse array of proteins including protein kinases (e.g. protein kinase B [PKB]), 
nucleotide exchange factors and GTP-ase activating factors. FYVE domains are 70 
amino acid long residues. The FYVE domain is a special type of RING zinc finger; it 
has eight conserved cysteines which coordinate the two zinc ions. The first zinc ion is 
coordinated by the first and third pairs of cysteines, and the second ion is coordinated 
by the second and fourth pairs (Rameh and Cantley, 1999). The PtdIns-(3)-P bind 
with greatest affinity to the FYVE domains, whereas other Ptdlns bind only weakly 
(Rameh and Cantley, 1999).
One of the best characterised PI3K effectors is the serine-threonine kinase, 
PKB, so called due to similarities to both PKA and PKC. It is also referred to as AKT 
because it is the cellular homolog of the viral oncopreotin v-AKT (Toker, 2000). PKB 
consists of an N-terminal PH domain and a C-terminal regulatory domain (Figure 
1.6). The activation of PKB subsequent to cytokine stimulation of the cells is 
dependent on the phosphorylated Ptdlns derived from PI3K (Nguyen et al., 2001). 
PtdIns-(3,4)-P2 and PtdIns-(3,4,5)-P3 bind with high affinity to the PKB PH domains 
in vivo and vitro (Franke et al., 1997). This results in the recruitment of PKB to the 
plasma membrane and the phosphorylation of key residues which are necessary for its 
activation.
1 / j O
Phosphorylation of Thr (in the activation loop of the kinase domain) occurs 
via 3’-phosphoinositide-dependent kinase I  (PDK1) activity at the membrane. 
Maximal activation requires phosphorylation of Ser473 (in the carboxy-terminal of the 
kinase domain). This is catalysed by a so far unidentified kinase, often referred to as 
PDK2 (Vanhaesebroeck and Alessi, 2000; Alessi et al., 1998). The phosphorylation of 
Thr450 is also necessary for activation. However, as this residue seems to be 
constitutively phosphorylated in the resting cell it is only the phosphorylation of 
Thr308 and Ser473 which appear to be PI3K dependant (Toker, 2000). The activation of 
PKB is illustrated in Figure 1.6. PKB mediates the downstream effects of activated 
PI3K. Indeed a plethora of PKB substrates have been identified including, cyclic 
AMP response element binding factor (CREB), caspase-9 and Glycogen Synthase 
Kinase-3a/(3 (GSK-3-a/p) (Nicholson and Anderson, 2002).
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Figure 1.6: Schematic representation o f  the likely activation o f  
PKB. Abbreviations: PIP3, Phosphatidylinositol-(3,4,3)-Pi 
(derived and modified from Downard, 1998).
Several PtdIns-(3,4,5)-P3 phosphatases have now been identified, including phosphate 
and tensin homology deleted on chromosome ten (PTEN). PTEN is a tumour 
suppressor protein that can dephosphorylate PtdIns-(3,4,5)-P3 at the 3- position. 
Another PtdIns-(3,4,5)-P3 phosphatase is SH2-domain-containing inositol 
phosphatase (SHIP) which can dephosphorylate it at the 5- position. These 
phosphatases may have a great significance in signalling (Vanhaesebroeck and Alessi, 
2000).
1.8.3.3 Casein Kinase 2
Whilst some kinases, such as PI3K, are very specific and only phosphorylate a 
handful of related proteins, others exhibit a much broader activity and can 
phosphorylate up to hundreds of proteins. One such protein kinase is casein kinase 2 
(CK2).
CK2 was first identified in liver extracts in 1954 by Burnett and Kennedy. 
Since then it has been found to be distributed ubiquitously in eukaryotic cells, where it
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can be found in the nucleus and the cytoplasm. It has also been discovered in many 
organisms, ranging from yeast to man (Faust and Montenarh, 2000). CK2 is known as 
a serine/threonine protein kinase due to its ability to phosphorylate these residues 
proximal to acidic amino acids (Bondenbach et al., 1994; Allande and Allande, 1995; 
Faust and Montenarh, 2000). A distinct minimal consensus sequence for 
phosphorylation of CK2 has also been defined, that is Ser-Xaa-Xaa-Acidic, where the 
acidic residue may be glutamic acid, aspartic acid, phospho-serine or phospho- 
tyrosine (Litchfield, 2003; Pinna, 1990). It should be noted however that not all 
substrates of CK2 conform to such consensus sequences (Litchfield, 2003).
CK2 most often exists as a tetrameric complex, consisting of two catalytic and 
two regulatory subunits. In humans two catalytic isoforms, designated CK-a and CK- 
a ’, have been well characterised, whilst a third isoform, CK 2-a” , has recently been 
identified. Although information regarding this subunit is lacking, it is known that 
CK2-a” is more closely related to CK2-a than CK 2-a’, based on its amino acid 
sequence (Shi et al., 2001; Litchfield et al., 2001). In contrast to the catalytic subunits, 
only one regulatory subunit has been identified, designated CK2-p. Tetrameric CK2 
complexes may contain identical (two CK2-a or two CK 2-a’) or non-identical (one 
CK2-a and one CK 2-a’) catalytic subunits and two regulatory subunits (Gietz et al.,
1995). The regulatory P subunits confer stability to the holoenzyme, and can modulate 
the substrate selectivity of the catalytic subunits (Allende and Allende, 1995). The 
regulatory subunit thus plays a dual role by stimulating or inhibiting CK2 activity 
depending on the nature of the substrate and the cellular status (Allende and Allende,
1995).
CK2-a and CK 2-a’ are very closely related with respect to their enzymatic 
activity in vitro (including turn over rate and substrate specificity) (Bodenbach et al., 
1994). It is not surprising therefore that the sequence of their catalytic domains exhibit 
approximately 90% identity (Litchfield and Luscher, 1993). In contrast, the C- 
terminal regions of the proteins are completely unrelated: nevertheless, these unique 
termini are conserved between species, thereby suggesting that there may be 
important functional features contained within these domains (Litchfield, 2003).
As mentioned above, CK2 is now known to have a vast array of candidate 
physiological targets that total 307 proteins, 243 of which have been shown to be 
phosphorylated in vivo (Meggio and Pinna, 2003). The known substrates make up a
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substantial majority of those implicated in the cellular signalling network. In addition 
studies have reported the activation of CK2 in response to a diverse array of stimuli 
(Litchfield et al, 1994).
Generally, signalling molecules only become active and/or phosphorylated 
upon stimulation, allowing efficient transduction of signals. The fact that CK2 is 
constitutively active and also such an important signalling molecule may therefore 
appear puzzling. The mechanisms of regulation of CK2 are speculative, but may 
include covalent modification of the kinase and interaction with protein and/or non­
protein molecules (Pinna, 2002).
Quaternary structure of kinases is generally associated with tight regulation. 
For example the heterotetrameric structure of the PKA holoenzyme is similar to that 
of CK2 but in this case it is catalytically inactive. Activation occurs when the PKA 
holoenzyme is dissociated as a result of stimulation (Pinna, 2002). However, this is 
not the case with CK2. It appears that a number of redundant mechanisms may be 
involved in the activation of CK2. For example, the unique interactions between the 
activation loop and its N-terminal segment confer the constitutive activity of the 
isolated catalytic subunit (Pinna, 2002).
1.9 A im s o f  the p roject
There is substantial data supporting the role of macrophage LPL expressed in the 
vessel wall both in the initiation and in the progression of atherosclerosis. The 
majority of this evidence has been discussed in detail. From the evidence presented 
there is little doubt that macrophage LPL expressed in the vessel wall can contribute 
to the formation of foam cells, which represents a critical stage in the onset of 
atherogenesis (Section 1.6). Likewise, it is clear that LPL expressed in adipose and 
muscle tissue acts in an anti-atherogenic manner by hydrolysing triglycerides so that 
they can be utilised by the body (Section 1.5). Therefore mechanisms that lead to a 
decrease in vessel wall LPL gene whilst not affecting or possibly raising adipose and 
muscle tissue LPL gene expression would, without doubt be of great significance in 
the development of therapeutic interventions against atherosclerosis.
Previous studies have examined the effects of a range of cytokines present in 
the atherosclerotic lesion on macrophage LPL enzymatic activity, mRNA expression 
and protein levels (Tengku-Muhammad et al., 1998 [b, c]). Of particular interest to
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our laboratory is the effect of IFN-y on macrophage LPL mRNA expression and 
enzyme activity; the cytokine induces a vast reduction of both (Tengku-Muhammad et 
al., 1998 [c]).
The importance of the signal transduction mechanisms that relay the 
information of extracellular mediators such as cytokines has been discussed. Two 
signalling pathways, CK2 and PI3K, have already been implicated in the IFN-y 
mediated suppression of LPL expression (Hughes et al., 2002; Tengku-Muhammad et 
al., 1999 [b]). As described previously, an important mechanism for the regulation of 
macrophage LPL gene transcription by IFN-y has been identified and a role for the 
transcription factors Spl and Sp3 has been established (Hughes et al., 2002). It was 
found that IFN-y decreases the binding of these transcription factors to particular 
recognition regions of the LPL promoter and that the CK2 signal transduction 
pathway is involved in this response. Due to the potential significance of these 
findings, it was decided to investigate these preliminary results further. Confirmation 
and investigation of the involvement of CK2 in the IFN-y mediated suppression of 
Spl and Sp3 binding was examined by:
analysing the binding patterns of the proteins in response to a CK2 inhibitor 
using electrophoretic mobility shift analysis (EMSA) (Chapter 3); 
assessing the effect of a dominant negative form of the enzyme on LPL 
promoter activity (Chapter 4).
These results revealed a key role for the enzyme in the response and so it was decided 
to take the analysis further through investigation of the mechanisms responsible for 
the IFN-y-mediated reduction of Spl and Sp3 DNA binding to the LPL promoter. This 
led to the unequivocal confirmation for a role of the CK2 pathway in the reduction of 
Spl binding.
In addition to the CK2 pathway, the PI3K signalling pathway has been 
implicated in the IFN-y mediated-reduction of macrophage LPL mRNA expression 
and enzymatic activity (Tengku-Muhammad et al., 1999 [b]). However, this 
investigation was restricted to the use of a single pharmacological inhibitor 
wortmannin. Also, the mechanisms by which PI3K regulated LPL expression had not 
been investigated. Therefore, it was decided to analyse the role of the PI3K signalling
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pathway in detail and to identify targets of the pathway involved in the IFN-y- 
mediated suppression of macrophage LPL gene expression. This was done by:
using dose response experiments using another inhibitor of PI3K by 
investigating its action on mRNA levels and Spl/Sp3 DNA binding (Chapter 
3; 5);
determining downstream effectors of the pathway (Chapter 5);
analysing the action of dominant negative forms of downstream effectors
(Chapter 5);
assessing the phosphorylation and activation of effectors (Chapter 5)
Furthermore, given the importance of signal transduction pathways in mediating the 
cellular responses of external mediators (Section 1.8.2.1), other aims of the project 
were to identify additional signalling cascades involved in the IFN-y mediated 
reduction of macrophage LPL mRNA expression and those that act through the 
reduction of Spl and Sp3 binding to the LPL promoter. This was achieved by 
investigating the effects of other inhibitors of specific signalling pathways on LPL 
mRNA expression and Spl/Sp3 DNA binding.
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Chapter 2: Materials and Methods
2.1 Materials
Table 2.1: Chemical reagents and materials used in this study were purchased from  
the suppliers shown below 
MATERIALS SUPPLIER
[a-32P] dCTP, [y-32P] dATP, Nick columns, 
rainbow protein size markers, KODAK X-ray 
film, ECL western blotting detection reagents, 
Mcgaprime DNA labelling kit.
Acrylamide: Bisacrylamide (29:1),
Acrylamide: Bisacrylamide (37.5:1).
DMEM and RPMI 1640 tissue culture medium. 
Kwills.
PCR grade magnesium chloride, 1 Ox NH* Buffer, 
Agarose.
AG490, LY294002. 
pH buffer solutions.
J774.2, U937, THP-1 cell lines.
2-p-mercaptoethanol, EDTA, ethanol, glycerol, 
hydrochloric acid, isopropanol, magnesium 
chloride, SDS, sodium chloride, sodium 
hydrogen phosphate, sodium dihydrogen 
phosphate, sodium hydroxide, tri-sodium citrate, 
Tris-buffer, glycine, butanol, potassium chloride. 
Saran Wrap.
Ammonium persulphate, foetal calf serum, 
penicillin/streptomycin, L-glutamine, trypsin- 
EDTA, cell scrapers, 25mm2, 75mm2 and 
125mm2 tissue culture flasks, 
lml Cryo-vials, 96-well micro-titer plates.
6-well plates, cell scrapers.
0.2pM Sterile filters, Immobilon 1500 PVDF
membrane.
lOx TBE.
DNA molecular weight markers, restriction
Amersham-Pharmacia Biotech, Bucks, UK
Anachem, Luton, UK
Autogen Bioclear, Wiltshire, UK 
Avon, Sims Portex Ltd, UK 
Bioline, London, UK
Calbiochem, Nottingham, UK 
Ciba, Loughborough, UK 
European Collection of Animal Cell 
Cultures (ECACC), Salisbury, UK 
Fisher Scientific UK, Loughborough, UK
Genetic Research Instrumentation, Essex, 
UK
Groco BRL, Paisley, UK
Greiner, Austria
Helena Biosciences, Sunderland, UK 
Millipore, Bedford, USA
National Diagnostics, Atlanta, USA 
New England Biolabs, Herts, UK
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endonucleases, total PKB antibody, Phospho- 
PKB (Ser473) antibody, Phospho-PKB (Thr308) 
antibody, PKB kinase assay kit, Phospho-FKHR 
(Ser256) antibody, Phospho-GSK-3(3 (Ser9) 
antibody, Phospho-PTEN (Ser380) antibody, 
Phospho-PDKl (Ser241) antibody, Phospho- 
p70S6K (Ser389), PKB protein kinase. 
Lymphoprep™.
Phosphate-Buffered Saline (PBS) tablets.
Mouse and human IFN-y, mouse TNF-a.
Micro BCA protein assay kit.
Confluolip™ Continuous Fluorometric Lipase 
kit.
Taq Polymerase, dNTPs, Klenow polymerase, 
firefly luciferase assay system, purified CK2 
enzyme, RNasin® Ribonuclease inhibitor, 
Wizard® miniprep kit, passive lysis buffer, 
MMLV reverse transcriptase, reverse 
transcriptase buffer, recombinant Spl, [3- 
galactosidase assay buffer.
EndoFree™ Maxiprep kit, RNeasy Total RNA 
Isolation kit, Superfect™ transfection reagent. 
Casein kinase 2 (a, a ’ and (3-subunit) antibodies, 
A/G agarose beads.
Ampicillin, apigenin, aprotinin, p-actin antibody, 
benzamidine, bovine serum albumin (BSA) type 
V, p-casein, DTT, bromophenol blue, Ficoll (type 
400), leupeptin, mineral oil, pepstatin A, phorbol 
12-myristate 13-acetate (PMA), PMSF, 
spermidine, spermine, TEMED, tissue culture 
grade water, tissue-culture grade DMSO, Trypan 
Blue, Ethidium bromide, Poly-(dl-dC), Hepes, 
Tween-20.
All PCR prim ers.
SP1 and Sp3 antibodies.
New England Biolabs, Herts, UK (cont.)
Nycomed Pharma, Oslo, Norway 
Oxoid Ltd., Basingstoke, UK 
Peprotech EC, London, UK 
Pierce, Chester, UK 
Progen Biotechnik, GMBH
Promega, Southampton, UK
Qiagen Ltd, Crawley, UK
Santa Cruz Biotechnology Inc, California, 
USA
Sigma, Poole, UK
Sigma Genosys, Cambridgeshire, UK 
Upstate, Dundee, UK
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All stock solutions and subsequent dilutions were prepared using sterile double 
distilled water (ddH2 0 ) unless otherwise stated.
2.2 T issue C u lture T echn iques
2.2.1 Maintenance of cell lines in culture
J774.2 cells were grown in DMEM (with Stablix) and THP-1 and U937 cells were 
grown in RPMI 1640 (with Stablix). All media was supplemented with 10% (v/v) 
heat-inactivated (30 minutes, 56°C) foetal calf serum (HI-FCS) in the presence of 
penicillin (lOOU/ml) and streptomycin (lOOpg/ml). Penicillin and streptomycin and 
HI-FCS were filter-sterilised by passing through a 0.2pm sterile filters prior to use.
It should be noted that the serum was heat-inactivated to eliminate any 
undesirable combination effects between growth factors or other extracellular 
mediators present in the serum and the cytokines added to the cells (Section 2.2.6).
2.2.2 Subculturing of cells
Adherent J774.2 cells, approximately 60% confluent, were washed once with fresh 
DMEM (supplemented with 10% [v/v] HI-FCS), removed from the flask surface 
using a sterile disposable cell scraper, plated into new flasks at a ratio of about 1:4 and 
grown up at 37°C in a humid incubator with an air mixture containing 5% (v/v) CO2 . 
The cell culture media of J774.2 cells was replaced every two to three days until 60% 
confluencey was reached when the above process was repeated.
Suspension cell lines (U937 or THP-1) were centrifuged at 300g for 5 minutes 
every two to three days, the pellet was then washed with RPMI 1640 (pre-warmed to 
37°C). The cells were centrifuged again and the pellet was re-suspended in RPMI 
1640 supplemented with 10% HI-FCS (v/v) at a ratio of about 1:5. The cells were 
then placed in new tissue culture flasks and grown up at 37°C in a humid incubator 
with an air mixture containing 5% (v/v) CO2 .
2.2.3 Counting cells
A haemocytometer (Neubauer chamber) was used to count cells. The haemocytometer 
was covered by a precision ground coverslip. Approximately 7pl of cell suspension 
was placed at the edge of the coverslip and cells within the large square were counted.
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2.2.4 Preservation and storage of cells
Only cells of an early passage were preserved. Following centrifugation of cells at 
300g for 5 minutes, cell pellets were re-suspended in HI-FCS containing 10% (v/v) 
DMSO at a density of approximately 5xl06cells/ml. The cell suspension was 
aliquoted into 1ml cryo-vials which were stored at -70°C overnight and then 
transferred to liquid nitrogen.
2.2.5 Thawing of frozen cells
Frozen cells were warmed at 37°C and then transferred to a centrifuge tube containing 
the appropriate pre-warmed medium (RPMI 1640/DMEM) supplemented with 20% 
(v/v) HI-FCS. Following centrifugation at 300g for 5 minutes, the supernatant was 
discarded and the cells were re-suspended in the appropriate volume of medium 
(supplemented with HI-FCS [10% (v/v)]) before being transferred to tissue culture 
flasks and cultured as normal.
2.2.6 Treatment of cells with cytokines and inhibitors
Cells were allowed to grow until the point of approximately 50% confluencey. Prior 
to treatment with mediators, cells were washed with DMEM/RPMI 1640 and pre­
incubated for 4 hours in medium containing reduced HI-FCS [0.5% (v/v)]. The cells 
were pre-incubated with the inhibitors for 1 hour at 37°C and 5% (v/v) CO2 and then 
with the cytokines for the appropriate period of time. Such incubation at reduced 
serum concentrations prior to the addition of cytokines is routinely employed for 
studies investigating the action of extra-cellular mediators on gene expression (for 
example, Hughes et al, 2002; Nguyan et al, 2001).
2.2.7 Treatment of THP-1 and U937 cells with differentiation agent
U937 and THP-1 monocytes (suspension cells) were seeded into flasks at an 
approximate density of lx l0 6cells/ml. The cells were differentiated by the addition of 
lpM  (U937) and 0.16pM (THP-1) of PMA for the requisite time at 37°C and 5% 
(v/v) C 02.
48
Chapter 2: Materials and Methods
2.2.8 Trypan blue exclusion assays
The viability of cells was assessed using a trypan blue exclusion assay. Briefly, cells 
were adjusted to a density of lx l0 6cells/ml. A small volume (20pl) of this suspension 
was mixed with an equal volume of 0.4% (v/v) trypan blue. The cells were left for 5 
minutes at 37°C and 5% (v/v) CO2 and then placed in a haemocytometer and viewed 
using phase contrast microscopy. At least 200 cells were counted, and the percentage 
of dead cells was estimated from those taking up the stain.
2.2.9 Human monocvte-derived macrophage cell culture
2.2.9.1 Isolation o f  human monocyte-derived macrophages
The separation medium utilised to isolate lymphocytes and other mononuclear cells 
from whole blood comprises of an aqueous solution of dextran (a high molecular 
weight polysaccharide), and sodium diatrizoate (an iodinated non-ionic compound) 
adjusted to a density of 1.077 ± 0.001 g/ml. This medium, known as Lymphoprep™ 
(Nycomed Pharma), was used to isolate lymphocytes and mononuclear cells from 
whole blood. The blood was first collected into a syringe containing an equal volume 
of sterile 2% (w/v) dextran in lx PBS containing 0.8% (w/v) tri-sodium citrate, and 
was allowed to stand for 30 minutes to permit erythrocyte sedimentation. The upper 
layer was collected, under layered with Lymphoprep™ [2:1 (v/v) Supernatant: 
Lymphoprep™] and centrifuged at 800g for 20 minutes. The resultant interface was 
collected and washed 6-8 times with PBS-0.4% (w/v) tri-sodium citrate to remove 
contaminating platelets. Monocytes were plated out in 6-well plates ( lx l0 6cells/well) 
in culture medium (Section 2.2.9.2) and were allowed to adhere to the surface for 6 
hours in a humid incubator at 37°C containing 5% (v/v) CO2 . After this time the cells 
were washed twice with PBS to remove any other mononuclear cells and fresh 
medium was added. The culture routine used for the cells is described in Section
2.2.9.3.
2.2.9.2 Isolation o f  human serum and preparation o f culture medium
Human blood (30ml) was collected from a donor, transferred into a 50ml Falcon tube 
and allowed to clot for 30 minutes in a 37°C incubator. The mixture was then 
centrifuged at 400g for 15 minutes and the serum was collected, mixed with RPMI 
1640 to a final concentration of 10% (v/v) and filter-sterilised.
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2.2.9.3 Culture o f  human primary monocyte-derived macrophages
Every 2-3 days, half of the volume of the medium in which the cells were growing
was removed and replaced with pre-warmed fresh culture medium.
2.2.10 Transfection with Superfect™ reagent
This procedure was carried out as described by the manufacturers (QIAGEN). The 
U937 cell line was used for all transfection experiments. All cells were between 
passages 3 and 8.
Cells were sub-cultured the day before transfection (Section 2.2.2). The 
following day cells were counted, suspended at a density of 7.5x105 cells/ml in RPMI 
1640 supplemented with 3% HI-FCS (v/v), plated out in 6-well plates, and incubated 
for 4 hours at 37°C, 5% CO2 (v/v). Following this incubation, the transfection 
complex was prepared by diluting DNA (2pg of the LPL construct and lpg  CMV-p- 
galactosidase DNA [internal control for transfection efficiency] /1.5xl06 cells) to 
50pl/pg of DNA with RPMI 1640 (containing no penicillin/streptomycin) and adding 
superfect™ solution (4pl/pg DNA). The mixture was vortexed and incubated at room 
temperature for 10 minutes. The complex was diluted with RPMI 1640 (containing 
penicillin/streptomycin and 10% HI-FCS) to 200pl/pg of DNA and the transfection 
complex was added to the cells. These were then differentiated by incubation with 
PMA (lpM ) for 12 hours. The cells were then treated with vehicle or IFN-y 
(lOOOU/ml) and incubated for 12 hours.
In experiments involving the use of dominant negative constructs the cells 
were initially transfected with the dominant negative plasmids and incubated for 
further 8 hours prior to the transfection of the cells with ZPZ-luciferase gene construct 
and the p-galactosidase plasmid.
2.2.11 Preparation of cell extracts for reporter gene assays
Subsequent to transfections, cell extracts were made to enable measurement of the 
luciferase and p-galactosidase activities. The cells were removed from the culture 
vessel surface using a disposable cell scraper, centrifuged in a micro-centrifuge at 
10,000g for 1 minute and the cell pellet was washed twice with 1ml of PBS. The 
washed pellet was re-suspended in 200pl of lx  Passive Lysis Buffer (Promega), 
which had been pre-warmed to 37°C. The solution was then mixed vigorously by
50
Chapter 2: Materials and Methods
pipetting and incubated at room temperature for 10 minutes. The mixture was 
centrifuged for 2 minutes at 10,000g and the supernatant was collected, snap-frozen 
on dry ice and stored at -70°C until the assays for luciferase and P-galactosidase were 
carried out.
2.2.12 Measurement of luciferase activity
The assay was carried out as described by the manufacturer (Promega). Cell extracts 
and firefly luciferase assay reagent were both equilibrated to room temperature. 
Luciferase assay reagent (lOOpl) was added to 20pl of cell extract in measurement 
tubes supplied with the Turner Designs 50/50 Luminometer. The tube was gently 
shaken, inserted into the luminometer and the luminescence reading taken. The 
luminometer was set at a sensitivity value of 70% with a 2 second delay period and a 
20 second integrate period.
2.2.13 Measurement of P-galactosidase activity
Cell extracts were equilibrated to room temperature while the P-galactosidase assay 
buffer was warmed to 37°C. Assay buffer (Promega) was added to 50pi cell extract in 
wells of a 96-well plate that was then covered and placed in a 37°C incubator for 1 
hour. The reaction was stopped by the addition of 1 m  sodium carbonate (150pl) and 
the absorbance of the product was measured at 405nm using a Dynex Technologies 
MRX multiwell plate reader.
2.3 LPL Activity Assay
Assays for heparin-releasable LPL activity were carried out using the Confluolip™ 
Continuous Fluorometric Lipase kit (Progen) in accordance with the manufacturer’s 
instructions. Briefly, primary cultures of human monocyte-derived macrophages 
( lx l0 6/well) were plated out in 6-well plates and subjected to the requisite 
experimental conditions. Following this, heparin (lOU/ml) was added to the culture 
medium for 4 hours, to release LPL bound to HSPG on the cell surface. The 
conditioned medium, containing the heparin-releasable LPL, was collected and either 
used immediately for LPL enzyme assays or frozen at -70°C until required.
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For the assay, conditioned medium (20^1); pre-warmed to 37°C was mixed 
with 2ml of freshly reconstituted substrate (l-trinitrophenyl-amino-dodecanoyl-2- 
pyrendecanoyl-3-0-hexadecyl-sn-glycerol) in a quartz cuvette and placed in the 
thermostated 37°C cuvette holder in a Varian Carey Eclipse Fluorescence 
Spectrophotometer (342nm excitation wavelength and 400nm emission wavelength 
with slit widths of lOnm each). Fluorescence readings were taken after 2 minutes and 
every 20 seconds thereafter. The kinetic increase in fluorescence intensity at 37°C is 
directly proportional to heparin-releasable LPL activity, which was calculated from 
the gradient of a time versus fluorescence graph.
2.4 Isolation and Manipulation of DNA
2.4.1 Preparation of equipment
All ceramics, glassware, plasticware and solutions used in the handling of DNA and 
RNA were autoclaved for 20 minutes at 120°C at a pressure of 975kPa.
2.4.2 Antibiotics
Ampicillin (lOOmg/ml) was filter sterilised using 0.2pM filters and stored in aliquots 
at -20°C.
2.4.3 Host strains and vectors
The bacterial host strain used for the studies presented in this thesis were DH5a and 
its genotype is listed in Table 2.2. The plasmid vectors used are listed in Table 2.3 and 
the restriction maps of these vectors are shown in the appendix.
Table 2.2: Genotype o f Escherichia coli stain used
GENOTYPE REFERENCE
DH5a supE44, AlacU169 (<f>80 lacZAM15) hsd!7 recAl endAl gyrA96 Hanahan,
thi-1 relAl 1983
Table 2.3: DNA constructs used in the study
PLASMID DONATED BY
pSG5-alpha (K68A) Dr Chambez and Dr Cochet (INSERM, Grenoble, France).
pcDNA3 HA-PKB(AAA) Dr B Hemmings, Miescher-Institut, Basel, Switzerland.
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2.4.4 Preparation of competent cells
The method of competent cell preparation was modified from that described by 
Mandel and Higa (1970). LB-medium (5ml) was inoculated with a bacterial colony of 
DH5a and incubated for 12 hours with gentle shaking at 37°C. Subsequently, lOOpl 
of this culture was used to inoculate 10ml of fresh LB-medium. The cells were 
incubated at 37°C and the O.D550 was repeatedly measured until it reached between 
0.5 and 0.6. Then, cells were centrifuged at 300g for 5 minutes at 4°C, and the pellet 
was re-suspended in 5ml of ice cold CaCl2 (50mM) and incubated on ice for 25 
minutes. The cells were then pelleted by centrifugation as above, and then re­
suspended in 10ml of ice cold CaCb (50mM). An equal volume of 40% (v/v) sterile 
glycerol was added to the cells prior to storage at -70°C.
2.4.5 Transformation of competent cells
Competent cells were thawed on ice for 30 minutes prior to transformation. Then 
competent cells (200pl) were incubated with recombinant plasmid DNA (lOng) and 
incubated on ice for 40 minutes. The mixture was heat-shocked by incubation at 42°C 
for 2 minutes. The volume was then made up to 1ml with LB-medium and the mixture 
incubated with shaking at 37°C for 30 minutes. Some of the mixture (200pl) was then 
spread over agar plates (containing lOOpg/ml ampicillin) which were left to air-dry 
for 15 minutes and then incubated overnight at 37°C.
2.4.6 Small-scale preparation of plasmid DNA (Mini-prep method)
The Wizard SV Miniprep kit was used for the small scale preparation of plasmid 
DNA according to the manufacturer’s instructions (Promega) using the solutions 
listed in Table 2.4. For this, 10ml of LB-medium (containing lOOpg/ml ampicillin) 
was inoculated with a single transformed colony and incubated for 6-8 hours at 37°C 
in a shaking incubator. The culture was pelleted by centrifugation at 2,500g for 5 
minutes and the pellet was re-suspended in 250pl of Re-suspension solution. The 
solution was transferred to a micro-centrifuge tube and mixed with 250pl of Lysis 
solution by inverting the tube. Once lysis was complete, 250pl of Neutralisation 
solution was added, mixed by inverting the tube, and centrifuged at 13,000g for 10 
minutes. The supernatant was added to 1ml of Miniprep DNA Purification Resin and 
applied to a Wizard™ Mini Column. The column was washed with 2ml of Wash
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solution and dried by centrifugation at 13,000g for 2 minutes. The DNA was eluted 
from the column by the addition of 50pl of sterile nuclease-free water. After 1 minute, 
the column was centrifuged at 13,000g for 20 seconds. DNA was stored at -20°C.
The concentration and purity of the isolated DNA was determined by 
measuring the O.D. at 260nm and 280nm using U-1800 Hitachi spectrophotometer 
and the quality assessed by analysing a small aliquot by electrophoresis on a 1% 
agarose gel (Section 2.5.2.3).
Table 2.4: Stock Solutions used in small scale preparation o f plasmid DNA
STOCK SOLUTION COMPOSITION
Re-Suspension solution 50mM Tris-HCl (pH 7.5), 0.1 mM EDTA,
lOOpg/ml RNase A
Lysis solution 200mM NaOH, 1% (w/v) SDS
Neutralisation solution 2.5M potassium acetate (pH 4.8)
Wash solution 20mM NaCl, 20mM Tris-HCl (pH7.5), 5mM
EDTA
Miniprep DNA Purification Resin 1.5% (w/v) celite resin in 7M guanidine
hydrochloride (pH 5.5)
2.4.7 Large-scale preparation of plasmid DNA (Maxi-prep method)
The Concert™ Plasmid purification kit was used for the large scale preparation of 
plasmid DNA (Gibco) using the stock solutions shown in Table 2.5.
LB-medium (10ml containing lOOpg/ml ampicillin) was inoculated with a 
single transformed colony and incubated for 6-8 hours at 37°C in a shaking incubator. 
The culture was then added to 200ml of LB-medium (containing lOOpg/ml 
ampicillin) and grown up overnight at 37°C in a shaking incubator. The cells were 
pelleted by centrifugation at 6,000g for 15 minutes at 4°C. The medium was removed 
and the pellet was re-suspended in 10ml of Re-suspension buffer. Lysis buffer (10ml) 
was then mixed by inverting the tube and the solution was incubated at room 
temperature for 5 minutes to allow full lysis to occur. Following the addition of 10ml 
of Neutralisation buffer, the solution was mixed by inversion and centrifuged at 
15,000g at room temperature for 10 minutes. The supernatant was applied to a column 
which had been previously equilibrated using the Equilibration buffer. The flow 
through was discarded and the column washed with 60ml of Wash buffer. The DNA
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was then eluted by the addition of 15ml of Elution buffer. The plasmid DNA was 
precipitated by the addition of 10.5ml of iso-propanol. The mixture was then 
centrifuged at 13,000g for 30 minutes at 4°C. The pellet was washed with 5ml of 70% 
(v/v) ethanol and centrifuged at 15,000g for 5 minutes at 4°C. The ethanol was then 
removed and the pellet air-dried, dissolved in 500pl o f TE buffer and stored at -20°C.
The concentration and purity of the isolated DNA was determined by 
measuring the O.D at 260nm and 280nm using U-1800 Hitachi spectrophotometer and 
the quality assessed by analysing a small aliquot by electrophoresis on a 1% agarose 
gel (Section 2.5.2.3).
Table 2.5: Stock Solutions used in large scale preparation o f  plasmid DNA
STOCK SOLUTION COMPOSITION
Re-Suspension buffer 50mM Tris-HCl (pH 8), lOmM EDTA, 100pg/ml RNase A
Lysis buffer 200mM NaOH, 1% (w/v) SDS
Neutralisation buffer 3M potassium acetate (pH 5.5)
Equilibration buffer 600mM NaCl, lOOmM sodium acetate (pH5.0), 0.15% (v/v)
Triton® X-100
Wash buffer 800mM NaCl, lOOmM sodium acetate (pH 5.0)
Elution buffer 1.25M NaCl, lOOmM Tris-HCl (pH 8.5)
TE buffer lOmM Tris-HCl (pH7.5), ImM EDTA
2.4.8 Restriction endonuclease digestion of recombinant plasmid DNA 
Restriction endonuclease digestion reactions were typically carried out in the presence 
of a two fold excess o f the appropriate restriction endonuclease in buffers 
recommended by the supplier (New England Biolabs). Digestions were carried out 
overnight at 37°C and the products analysed by agarose gel electrophoresis (Section
2.5.2.3).
2.5 RNA-Associated Techniques
2.5.1 RNA Isolation
Total RNA was isolated from cells using the RNeasy® Total RNA isolation kit 
(Qiagen) according to the manufacturer’s instructions. Briefly, cells were pelleted by 
centrifugation at l,000g for 5 minutes. The pellet was lysed by the addition of buffer 
RLT (Qiagen) (containing 10pl/ml of (3-mercaptoethanol) and the pellet was passed
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through a 0.9mm needle to ensure full homogenisation. An equal volume of 70% (v/v) 
ethanol was added to the lysate and the mixture was applied to an RNeasy column, 
which was then centrifuged at l,000g for 15 seconds. The flow-through was discarded 
and buffer RW1 (Qiagen) was used to wash the column by centrifuging the sample for 
15 seconds at 10,000g. Once again the flow-through was discarded and the RNeasy 
column was transferred to a new collection tube. The column was washed again by 
adding buffer RPE (Qiagen) and centrifuging the column for 15 seconds at 10,000g. 
The final wash was carried out using buffer RPE (Qiagen) and centrifuging the 
column for 2 minutes at 10,000g. RNA was eluted by the application of RNase-free 
water directly to the column. Following centrifugation for 1 minute at 10,000g, the 
RNA was collected.
A small amount of the RNA was used to measure the purity and concentration 
by measuring the O.D .2 6 0  and O.D .2 8 0  using U-1800 Hitachi spectrophotometer. RNA 
(lpg) was also analysed by gel electrophoresis using a 1.5% agarose gel (Section
2.5.2.3) to verify its quality.
2.5.2 Reverse Transcriptase- Polymerase chain reaction fRT-PCR)
RT-PCR was carried out in two stages, firstly the synthesis of cDNA from RNA using 
reverse transcriptase (Section 2.5.2.1) followed by the polymerase chain reaction 
(2.5.2.2).
2.5.2.1 Reverse Transcription (RT)
cDNA was synthesised from 1 jag of cellular RNA. Briefly, 1 jag of each RNA sample 
and 200pmoles of random hexamers were made up to a final volume of 13.5pi with 
sterile water and incubated at 72°C for 5 minutes and then chilled on ice for 5 
minutes. Subsequently, the reaction was made up to 20pl with:
-lp l dNTP mixture (lOmM each of dATP, dGTP, dCTP and dTTP)
-lp l of 200U/pl of M-MLV reverse transcriptase (Promega)
-0.5pi of 40U/pl recombinant RNase inhibitor (Promega)
-4pl of 5 X reverse transcriptase buffer (Promega)
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The mixture was then incubated for 1 hour at 42°C and the reaction terminated by 
incubation at 94°C for 2 minutes. The resultant cDNA was diluted 5-fold with 
nuclease free H2 O and was then used in a PCR reaction (Section 2.5.2.2).
2.5.2.2 Polymerase Chain Reaction (PCR)
The primer sets used in the PCRs are shown in Table 2.6.
Table 2.6: PCR primer sequences
mRNA FORWARD PRIMER REVERSE PRIMER
hLPL 5 ’-gagatttctctgtatggcacc-3 ’ 5 ’-CTGC AAATGAGAC ACTTTCTC-3 ’
GAPDH 5 ’-cccttcattgacctcaactacatgg-3 ’ 5 ’-AGTCTTCTGGGTGGCAGTGATGG-3 ’
For each reaction, lOpl of cDNA was made up to a total volume of 50pl using the 
optimised volume of reagents for each primer set (Table 2.7). Subsequently, PCR 
mixtures were covered with mineral oil and reactions were performed on a Biometra 
TRIO Theromoblock. The optimised cycle programmes are shown in Table 2.8. Each 
programme was chosen because the products were generated in the exponential phase 
of amplification (thus providing a direct correlation between the amount of product 
and the original cDNA template). PCR products were then size-fractionated by using 
agarose gel electrophoresis as described in Section 2.5.2.3.
Table 2.7: Optimised PCR volumes for each primer set
REAGENT H LPL GAPDH
Forward primer (1 OOpM) 0.5pl 0.5pl
Reverse primer (lOOpM) 0.5pl 0.5pl
dNTPs (1 OmM of each) lpl 0.5pl
MgCl2 (50mM) 2pl 2 pi
10X PCR Buffer (50mM KC1, lOmM Tris- 5 pl 5 pl
HCl [pH 9.0], 1% [v/v] Triton® X-100)
Taq polymerase (5U/pl) 0.25pl 0.25pl
cDNA lOpl lOpl
ddH20 30.75pl 31.25pl
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PCR PROGRAMME HLPL GAPDH
Initial melting 96°C 96°C
5min 5 min
Annealing 55°C 60°C
1 min 1 min
Extension 72°C 72°C
2 min 2 min
Melting 93 °C 93°C
30sec 30sec
Final long extension step 72°C 72°C
10 min 10 min
Number of cycles 24 18
2.5.2.3 Agarose gel electrophoresis o f DNA and RNA
Size fractionation of PCR products and RNA was carried out by agarose gel 
electrophoresis using a 1.5% gel in 0.5xTBE buffer containing 0.5pg/ml of ethidium 
bromide. DNA loading dye (Table 2.9) was added to each sample at a ratio of 1:10 
before being loaded in to the wells.
Table 2.9: Solutions used in agarose gel electrophoresis
SOLUTION COMPOSITION
10X DNA loading dye 1XTBE, 50% (v/v) glycerol, 0.25% (w/v) bromophenol
blue
10XTBE 890mM, Tris-HCl, 890mM boric acid, 20mM EDTA
pH8.0
2.5.2.4 Densitometric analysis o f RT-PCR products
The gels in which the RT-PCR products were size-fractionated were photographed 
using a Syngene gel documentation system and the signals were quantified using the 
Quantiscan computer package (Biosoft, Caimbridge, UK).
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2.6 Protein Analysis
2.6.1 Preparation of nuclear and whole cell extracts
Cells were pelleted by centrifugation at 1,000# for 5 minutes at 4°C. From here the 
method differed depending on the extract required.
2.6.1.1 Nuclear Extracts
The pellet was washed twice with ice-cold PBS. The pellet was then re-suspended in 
50pl of buffer A (Table 2.10) and incubated for 15 minutes on ice prior to cell lysis by 
drawing through a lOOpl Hamilton syringe five times. Thereafter, the mixture was 
pelleted by centrifugation at 10,000# for 5 minutes and then re-suspended in 60pl of 
buffer C (Table 2.10) prior to incubation at 4°C for 30 minutes. To harvest the nuclear 
extracts, the mixture was centrifuged at 10,000# for 5 minutes at 4°C. Extracts were 
either used immediately or stored at -70°C.
2.6.1.2 Whole Cell Extracts
The pellet was washed twice with ice-cold PBS and then snap-frozen in dry ice. 
Whole cell extraction buffer (Table 2.10) was added and the cells were lysed by 
vigorous pipetting and vortexing. The extracts were then harvested by centrifugation 
at 10,000# for 10 minutes. Extracts were either used immediately or stored at -70°C.
2.6.1.3 Phosphatase-free Whole Cell Extracts
Where the maintenance of proteins in the phosphorylated state was required, cell 
extracts were prepared using phosphatase and protease inhibitors (Table 2.10) as 
described by Hipskind et al, 1994. The cell pellet was washed twice in ice-cold PBS 
(containing lOmM NaF and lOOpM sodium ortho vanadate). Phosphatase-free whole 
cell extraction buffer was added to the pellet and the extracts were prepared and 
harvested as above (2.6.1.2). Extracts were either used immediately or stored at - 
70°C.
In all cases, protein concentration was determined using BCA protein assay reagents 
(Section 2.6.1.4).
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Table 2.10: The composition of whole cell and nuclear extraction buffers 
SOLUTION COMPOSITION
Phosphate-buffered saline 
(PBS)
Nuclear Isolation buffer A
Nuclear Isolation buffer C
Whole cell extraction buffer
Phosphatase-free whole cell 
extraction buffer
137mM NaCl, 2.7mM KC1, 8.1mM Na2HPC>4 , 1.5mM 
KH2P04
lOmM HEPES (pH 7.9), lOmM KC1, 1.5mM MgCl2, 0.5mM 
DTT, 0.5mM PMSF, lpg/ml pepstatin A, lOpg/ml 
Aprotinin, 10pg/ml leupeptin, lOpg/ml Type I-S soybean 
inhibitor made up with ddH20
20mM HEPES (pH 7.9), 420mM NaCl, 1.5mM MgCl2, 
0.5mM DTT, 4M NaCl, 0.2mM EDTA, 25% (v/v) glycerol, 
0.5mM PMSF, lmg/ml pepstatin A, lOpg/ml Aprotinin, 
10pg/ml leupeptin, lOpg/ml Type I-S soybean inhibitor 
lOmM HEPES (pH 7.9), 400mM NaCl, 0.5mM DTT, 5% 
(v/v) glycerol, 0.5mM PMSF, lOpg/ml aprotinin, 2mM 
benzamidine, O.lmM EDTA
lOmM Tris-HCl (pH 7.05), 50mM NaCl, 50mM NaF, 1% 
(v/v) Triton X-100, 30mM Na4P20 7 5pM ZnCl2, lOOpM 
Na2V0 3 , ImM DTT, 2.8pg/ml aprotinin, 2.5jug/ml each of 
leupeptin and pepstatin, 0.5mM benzamidine, 0.5mM PMSF
2.6.1.4 Determination of protein concentration
The concentration of total protein in the extracts was determined using the Micro 
BCA protein assay reagent kit (Pierce) in accordance with the manufacturer’s 
instructions. Briefly, a standard curve was produced for each assay using suitable 
dilutions of 2mg/ml bovine serum albumin solution (BSA) in order to give 
concentrations of 0p.g/ml, 5(j.g/ml, 10|ug/ml, 15|ig/ml, 20|ig/ml and 25(j,g/ml (using 
the cell extraction buffer as the diluent). The standards were placed into the wells of a 
96-well plate. Both the standards and the test samples were then diluted in PBS. To 
each well, a 100pJ o f the BCA working reagent was added and, after mixing the plate, 
was left to incubate at 37°C for 2 hours to allow any colour change to occur. The 
absorbance of each sample was read at 595nm using a Dynex Technologies MRX 
microplate reader. The protein concentration of each sample was then calculated from 
the standard curve.
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2.6.2 Electrophoretic Mobility Shift Assay (EMSA)
2.6.2.1 Generation o f double-stranded oligonucleotides
The sequences of the oligonucleotides used for EMSA analysis are shown in Table 
2.11. Forward and reverse oligonucleotides (200ng of each) were first incubated at 
100°C for 10 minutes in the presence of a medium salt buffer, in a final volume of 
200pl, and then allowed to cool to room temperature.
Table 2.11: Sequences o f oligonucleotides used in EMSA analysis
SITE SEQUENCE
+9/+49 (F) 5 -CTCGATTTCTCCTCCTACTCCTCCTCCGAGGAATTC-3 ’
(R) 5 -GGGCAG AATTCCTCGGAGGAGCAGTAGC AGG AG AAA-3 ’
+46/+90 (F)5 -GCCCCCTGCAACTGTTCTGCCCTCCCCTTTAAAGGT-3 ’ 
(R) 5 -GGCAAGTCAACCTTTAAAGGGGAGGGCAGAACAGTT 3’
Oligonucleotides used in EMSA analysis were designed to leave 5 ’ overhangs, 
containing G residues, following annealing. The G residues present in the overhangs 
could then complementarily bind to [a-n P]-dCTP.
2.6.2.2 Radiolabelling o f double-stranded oligonucleotides
The labelling reaction consisted of 40ng of double-stranded annealed oligonucleotide 
in 35pl H2 O, lOpl of labelling buffer (Megaprime labelling kit, Amersham 
Pharmacia-Biotech), 30pCi o f [a-32P]-dCTP and 2pl of Klenow polymerase 
(Megaprime labelling kit, Amersham-Pharmacia Biotech). The labelling reaction 
mixture was incubated for 30 minutes at 37°C. Subsequently, the reaction was 
terminated by the addition of lxTE and the labelled probe was separated from 
unincorporated nucleotides using a Sephadex G50 nick column (Amersham- 
Pharmacia Biotech). After the column had been equilibrated with 9ml of lx  TE buffer 
the reaction mixture was loaded onto the column. This was followed by the addition 
of 300pl of lxTE buffer. The eluted unincorporated nucleotides were collected and 
discarded. A further 400pl of lxTE was added to the column to elute the labelled 
probe. The total activity of the probe was measured using a liquid scintillation counter 
and the probe was then stored at -20°C.
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2.6.2.3 Binding reactions fo r  EMSA
The binding of radiolabelled double-stranded oligonucleotides to proteins present in 
nuclear or whole cell extracts (Section 2.6.1) was carried out according to Ramji et al. 
(1993). Briefly, 5pg of extracts were mixed with lOx dilution buffer (Table 2.12) to 
make a final volume of 13pl. Then, 2pl of lOx binding buffer (Table 2.12) and 3pi of 
lpg/ml poly (dl-dC) were added to the mixture, which was incubated on ice for 10 
minutes. Subsequently, 3pi o f [ P]-labelled double-stranded oligonucleotides 
(typically 50,000-100,000 cpm) were added and the reaction mixture was incubated at 
room temperature for 20 minutes, to allow binding of proteins to DNA to occur. 
Protein/DNA complexes were then resolved by electrophoresis (Section 2.6.2.4).
Table 2.12: Stock solutions used in EMSA analysis
SOLUTION COMPOSITION
Dilution buffer 40mM KC1, O.lmM EDTA
lOx binding buffer 340mM KC1, 50mM MgCl2, ImM DTT
2.6.2.4 Electrophoresis o f DNA-protein complexes
Electrophoresis to separate DNA-protein complexes was carried out using 4% (v/v) 
non-denaturing polyacrylamide gels (29:1 acrylamide:bisacrylamide) containing 
0.5xTBE. Prior to electrophoresis, approximately 5pl of 20% (w/v) ficoll was added 
to facilitate gel loading of the reaction. Electrophoresis was carried out at 150 V for 3 
hours at 4°C using 0.5xTBE as the running buffer. Following electrophoresis, the gel 
was transferred on to Whatman 3MM paper, covered with Saran Wrap and dried 
under vacuum using a Gel Dryer (Model 583, Biorad). DNA-protein complexes were 
visualised by autoradiography (Section 2.6.2.5).
2.6.2.5 A utoradiography
Dried Gels or western blot membranes (Section 2.6.3.2) were exposed to Kodak film 
at -70°C in a lightproof cassette for a given time. X-ray films were developed using a 
Grevamatic 60 automatic developer.
62
Chapter 2: Materials and Methods
2.6.3 SDS-PAGE and Western Blot Analysis
2.6.3.1SDS-PAGE
SDS-PAGE was performed following the method of Laemmli (1970). The 
concentration of acrylamide in separating gels varied according to the molecular 
weight of the protein to be analysed. All stacking gels contained 5% (w/v) acrylamide. 
The composition of the gels and buffers are shown in Tables 2.13 and 2.14 
respectively.
Electrophoretic transfer of proteins was carried out using a Bio Rad Trans Blot 
Electrophoretic transfer cell (BioRad Laboratories). The gel apparatus was assembled 
as described by the manufacturer. The separation gel was poured to within 1.5cm o f 
the top of the inner glass plate. Butanol was layered on top of the gel to prevent 
oxygen interfering with the polymerisation reaction. Following polymerisation of the 
separating gel, the butanol was removed, and the gel was washed with ddH20 and the 
surface dried with filter paper. The stacking gel was then poured on top and the well- 
forming comb inserted. The gels were then placed in the electrophoresis tank and the 
upper and lower chambers filled with lx ‘running’ buffer containing 0.1% (w/v) SDS 
(Table 2.14). Protein samples were mixed with an equal volume of SDS loading 
buffer (Table 2.14) and then heated to 100°C for 3 minutes. Solubilised protein 
samples were then cooled to room temperature and loaded onto the gel along with 
rainbow protein size markers (1 Optl) (Amersham-Pharmacia Biotech). Electrophoresis 
was carried out at a constant voltage of200V for 30-45 minutes.
Table 2.13: Compositions o f stacking and separating gels used for SDS-PAGE_______
GEL COMPONENT SEPARATING STACKING GEL
GELS
7.5% (w/v) 10% (w/v) 14% (w/v) 5% (w/v)
Upper buffer - - - 2.5ml
Lower buffer 5 ml 5 ml 5ml -
acrylamide:
bisacrylamide
(37.5:1)
3.6ml 5 ml 7 ml 1.25ml
ddH20 - 10ml - 6.14ml
10% (w/v) APS 200pl 200pl 200pl lOOpl
TEMED 20p.l 20pl 20pl lOpl
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Table 2.14: Compositions o f buffers used in SDS-PAGE and Western Blot analysis
SOLUTION COMPOSITION
SDS-PAGE gel loading buffer 50mM Tris-HCl (pH 6.8), lOOmM DTT, 2% (w/v) SDS, 0.1% 
(w/v) bromophenol blue, 10% (v/v) glycerol
SDS-PAGE running buffer 25mM Tris (pH7.4), 250mM glycine, 0.1% (w/v) SDS
Western blot transfer buffer 25mM Tris-HCl (pH7.4), 192mM glycine, 20% (v/v) methanol
lx TBS lOmM Tris-HCl (pH7.4), 200mM NaCl (pH7.4)
SDS-PAGE lower gel buffer 1.5M Tris-HCl (pH 8.8), 10% (w/v) SDS
SDS-PAGE upper gel buffer 1M Tris-HCl (pH 6.8), 10% SDS
2.6.3.2 Western blotting
The transfer of protein to PVDF membranes was performed as described by the 
manufacturer (Millipore). Briefly gels were equilibrated by incubation in transfer 
buffer (Table 2.14) for 15 minutes at room temperature. The PVDF membrane was 
then placed on the gels and sandwiched between Whatman 3 MM paper and sponge 
pads (which had both been pre-soaked with transfer buffer) before being placed in the 
blotting cassette. The cassette was then subjected to electro-blotting in a tank 
containing transfer buffer at 4°C at a constant voltage of 15V for 12-18 hours. Protein 
transferred to the PVDF membranes was immunodetected as described in Section
2.6.3.3.
2.6.3.3 Immunodetection o f proteins
Blotted PVDF membranes were probed immunochemically. The membrane was 
incubated in a blocking solution (lx  TBS [Table 2.14] containing 5% or 10% [w/v] 
skimmed milk powder/BSA and 0.05% or 0.1% [v/v] Tween-20). The composition of 
the blocking solution depended on the antibody used. The membrane was then washed 
three times, for 5 minutes each, in lx  TBS containing 0.1% (v/v) Tween-20. The 
membrane was incubated with primary antibody which was diluted (Table 2.15) in 
blocking solution. BSA was used for primary antibodies requiring overnight 
incubation at 4°C. The membrane was then washed (as above) and incubated with 
secondary antibody (Table 2.15). After another set of washes, detection of membrane 
bound antigen-antibody complexes was carried out using an Enhanced Chemi- 
iuminescence (ECL) detection kit as described by the manufacturer (Amersham). 
Films were developed using autoradiography (Section 2.6 2.5). The size of the
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immunodetected proteins was determined by comparison of their migration with 
rainbow markers that were size-fractionated along side the samples.
Table 2.15: Antibodies used in the immunodetection o f  proteins and their dilution 
factors
primary Antibody PRIMARY SECONDARY
ANTIBODY ANTIBODY
DILUTION DILUTION
Rabbit anti-casein kinase 2 1/1,000 1/10,000
(a, a ’ and p subunits)
Anti-PKB (Total, Ser473 and Thr308) 1/5,000 1/10,000
Anti-phospho-PTEN (Ser380) 1/5,000 1/10,000
Anti-phospho-PDKl (Ser241) 1/5,000 1/10,000
Anti-phospho-GSK-3p (Ser9) 1/5,000 1/10,000
Anti-phospho-FKHD (Ser256) 1/5,000 1/10,000
Anti-phospho-p70S6K (Thr389) 1/5,000 1/10,000
phospho-GSK-3a/p (Ser9/21) 1/5,000 1/10,000
Anti-SPl 1/2,000 1/20,000
Anti-Sp3 1/2,000 1/20,000
Anti-p-actin 1/12,000 1/8,000
2.6.4 Immunoprecipitation of Proteins
Whole cell extracts (150-300pg) that had been prepared using the phosphatase-free 
buffer (Table 2.10) were incubated overnight with gentle rolling with an antibody 
raised against the desired protein (2pg/ml). The resulting protein-antibody complex 
was immunoprecipitated by the addition of 20pl of Protein A/G agarose beads (Santa- 
Cruz) with gentle rocking for 2 hours at 4°C. The beads, containing the captured 
immunocomplex, were collected by centrifugation (13,000g for 3 minutes at 4°C) and 
washed with phosphatase-free extraction buffer (without Triton X-100) (Table 2.10). 
At this point, the protocol differed according to the desired use o f the 
immunoprecipitated protein.
For the CK2 and PI3K assays, the beads containing the captured 
immunocomplex were immediately incubated with the substrate mixtures (Section 
2.6.5).
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For co-immunoprecipitation analysis, the bead/immunocomplex was re­
suspended in 50pl of 0.1 M Glycine (pH2.5). The sample was centrifuged at 9,000g 
for 2 minutes at 4°C. The supernatant was collected and 5pl o f 1M Tris (pH7.4) and 
30pl of SDS-PAGE loading buffer (Table 2.14) was added to it. The sample was then 
boiled and subjected to SDS-PAGE and western blot analysis (Section 2.6.3.1 and 
2.6.3.2).
2.6.5 Kinase Assays
2.6.5.1 Casein Kinase 2 activity assay
This method was a combination of those used by Sung et al., (2001) and Lodie et al., 
(1997) with minor modifications. The immunocomplex (Section 2.6.4) was re­
suspended in 25pl of kinase buffer containing the appropriate substrate (Table 2.16). 
The reactions were incubated for 15 minutes at 37°C and then stopped by the addition 
of lOpl of SDS-PAGE loading buffer (Table 2.14). Samples were immediately 
subjected to SDS-PAGE (Section 2.6.3.1) using 14% or 7% (w/v) acrylamide gels 
(Table 2.13) according to the molecular weight of the product. After electrophoresis, 
gels were fixed for 20 minutes in a solution containing 40% (v/v) methanol and 10% 
(v/v) acetic acid. These were washed once with distilled water before being dried 
under vacuum and visualised using autoradiography (Section 2.6.2.5).
Table 2.16: Composition o f buffers used in CK2 kinase assays
KINASE BUFFERS COMPOSITION
p-casein Kinase Buffer 5pCi [y-32P]-ATP, lOOpM sodium orthovanadate, lOOmM Tris- 
HC1 (pH 8.0), lOOmM NaCl, 20mM MgCl2, 50mM KC1, 5mg/ml
p-casein
Sp 1 Kinase Buffer 5pCi [y-32P]-ATP, 100pM sodium orthovanadate, lOOmM Tris- 
HC1 (pH 8.0), lOOmM NaCl, 20mM MgCl2, 50mM KC1, 0.5pg 
Spl
Calmodulin Kinase 5fj.Ci [y-32P]-ATP, 100pM sodium orthovanadate, lOOmM Tris-
Buffer HC1 (pH 8.0), lOOmM NaCl, 20mM MgCl2, 50mM KC1, 2pg 
calmodulin
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2.6.5.2 PKB Activity Assay
This was performed according to the manufacturer’s instructions (New England 
Biolabs). The extracts were prepared using the phosphatase-free method (Section
2.6.1). Whole cell extracts (150pg) were then incubated with 20p.g of immobilised 
PKB antibody slurry (provided in the kit) for 3 hours at 4°C with gentle rocking. 
Subsequently, the mixture was centrifuged at 10,000# for 30 seconds. The resultant 
pellet was washed with 300p.l o f phosphatase-free whole cell extraction buffer 
(without Triton-X) and then twice with lx  PKB kinase buffer (Table 2.17). The pellet 
was incubated with 40pl of the lx PKB kinase buffer (supplemented with 200pM 
ATP and lpg of GSK-3 fusion protein) for 30 minutes at 30°C. The reaction was 
terminated with 20pl of SDS-PAGE loading buffer (Table 2.14), and the mixture was 
then vortexed and centrifuged at 10,000# for 2 minutes. The supernatant was 
collected, boiled for 5 minutes and subjected to SDS-PAGE using a 14% (w/v) 
acrylamide gel. After electrophoresis, gels were subjected to western blotting using 
the phospho-GSK-3oc/p antibody.
Table 2.17: Composition o f buffers used in PKB assay
KINASE BUFFER COMPOSITION
PKB Kinase buffer ImM Tris-HCl (pH 7.5), 5mM P-glycerophosphate, 2mM DTT, 
0.1 mM Na3V04, lOmM MgCl2
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Chapter 3- Studies on the regulation o f macrophage LPL expression in response to IFN-y
3.1 Introduction
LPL, secreted by macrophages within the arterial wall, contributes to the development 
of atherosclerosis. LPL therefore represents an excellent target for therapy against the 
disease. A plethora of evidence has demonstrated the importance of cytokines in the 
regulation of LPL gene expression during pathophysiological conditions, such as 
atherogenesis (see Mead and Ramji, 1999 for review).
Several studies have shown that IFN-y decreases macrophage LPL mRNA 
expression, enzymatic activity and protein levels in several cell lines and primary 
isolates (Table 3.1). IFN-y is present in the atherosclerotic lesion and is likely to 
modulate the rate of foam cell formation and the pathogenesis o f atherosclerosis, at 
least in part, through its regulation of LPL. It is therefore necessary to investigate the 
IFN-y-mediated reduction of LPL in more detail.
Table 3.1: Effect o f IFN-y on LPL gene expression
Cel l  type Effe c t  o f  iFN-y o n  lpl R efe r e n c e s
J774.2 •I Activity, mRNA Tengku-Muhammad et al.,
1996; Hughes et al., 2002
Human primary monocyte- i  Activity, mRNA Jonasson et al., 1990
derived macrophages
Rat NR8383 -I Activity, mRNA Hughes et al., 2002
Primary cultures of rat ■I Activity, mRNA Hughes et al., 2002; Tengku-
alveolar macrophages Muhammad e ta l,  1998 (b)
Human U937 i  Promoter activity Hughes et al., 2002
Murine RAW264.7 •I Activity Tengku-Muhammad et al.,
1998 (b)
3T3L1 T Activity Gregoire et al., 1992
3T3-F442A i  Activity, mRNA Doerrler etal., 1994
The IFN-y-mediated regulation of LPL gene expression has been shown to be 
due to transcriptional control (Tengku-Muhammad et al., 1998 [d]). A detailed 
understanding of the regulatory sequences that are required for the response has been 
achieved using a panel of DNA constructs containing various 5’ fragments o f the LPL 
promoter, with a common 3’ end point at position +187, that are linked to the
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luciferase reporter gene (Figure 3.1). Transfection analysis has located the minimal 
IFN-y-responsive element (IFN-y-RE), to the -31 to +187 region of the LPL promoter 
(Hughes et al., 2002). Electrophoretic Mobility Shift Assays (EMSA) revealed that
the IFN-y-RE binds to the transcription factors Spl and Sp3. Following the
administration of IFN-y, binding of these transcription factors to the IFN-y-RE is 
reduced dramatically and this results in a decrease in the activity of the LPL promoter 
(Hughes et al, 2002). Spl and Sp3 interact with three highly conserved recognition 
sequences in the LPL promoter. The importance of these sites in the IFN-y response
was confirmed by mutational analysis and analysis of their ability to confer the
response to a heterologous promoter (Hughes et al., 2002). It was shown that the IFN- 
y-mediated decrease in the binding of Spl and Sp3 to the IFN-y-RE in the LPL gene 
promoter could be prevented, at least in part, by the CK2 inhibitor apigenin (Hughes 
et al., 2002). Several studies have used this inhibitor to specifically block the action of 
CK2 (Romieu-Mourez et al., 2001; Song et al., 2000; Shen et al., 2001; Ford et al., 
2000).
The aims of the studies presented in this chapter were to confirm the role of 
CK2 in the IFN-y-mediated decrease in the binding of Spl and Sp3 to the IFN-y-RE in 
the LPL gene promoter, and to investigate the potential role for the PI3K and JAK- 
STAT pathways. As described in the Introduction, the role of the JAK-STAT pathway 
in IFN-y signalling is well established. However, its involvement in the IFN-y- 
mediated regulation of LPL gene expression has not been previously investigated. The 
role of the PI3K pathway was also investigated because previous studies had shown 
that wortmannin, an inhibitor of this pathway, could prevent the IFN-y-mediated 
decrease in LPL activity and mRNA expression in the J774.2 cell line (Tengku- 
Muhammad et al., 1999 [b]).
Previous studies in the laboratory have also shown that IFN-y and TNF-a act 
synergistically to inhibit LPL gene expression (Tengku-Muhammad et al., 1998 [a]). 
Such synergism could potentially be mediated through Spl and Sp3. Another aim of 
the studies presented in this chapter was, therefore, to investigate this possibility.
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+187
LPLI -1824 h
C/EBPp CJ£BCHOP
LPL2 -I25I
Oa-IC/EBPp
-564LPL3
LPL4 -I8I
-IOI \LPL5
LPL6
O a-I TATA IRE Spl
LPL7 -31
NF-T O a-I TATA IRE Spl 
- 5 4  |  r  I I LUOFERASE
LUOFERASE
LUOFERASE
LUOFERASE
LUOFERASE
LUOFERASE
TATA IRE Spl
Figure 3.1: A  schematic representation o f  the hum an LPL promoter-luciferase 
DNA constructs used to delineate the regulatory sequences required fo r  the IF N -y  
response
Abbreviations: AP-1, Activator Protein-lj C/EBPp, CCAAT/Enhancer Binding 
Protein ft; CHOP, C/EBP Homologous Protein; CREB, cAMP-Responsive Element 
Binding Protein; FSE2, Fat Specific Element 2j IRS, Insulin Responsive Sequence; 
LSE, LPL Silencing Element; NF-Y, Nuclear Factor Yj Oct-1, Octamer Binding 
Protein-lj PPARy Peroxisome Proliferator-Activated Receptor-% Spl, Specificity 
protein l j  TATA, TATA box; TRE, Thyroid Responsive Element. For a more complete 
list o f  cis-acting elements, and their exact within the LPL promoter, see Table 1.5.
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3 .2  R e s u l t s
3.2.1 Effect of IFN-y on LPL enzymatic activity levels in human monocvte-derived 
macrophages
Previous studies on the action of IFN-y on macrophage LPL expression has been 
carried out on a range of cell lines and primary isolates (Table 3.1). Previous studies 
in our laboratory on the effect of IFN-y on LPL enzymatic activity were carried out in 
the murine J774.2 cell line, rat alveolar macrophage NR8383 cell line and primary 
cultures of rat alveolar macrophages (Tengku-Muhammad et al., 1996 [c]; Hughes et 
al., 2002; Tengku-Muhammad et al., 1998 [b]). Because atherosclerosis is a human 
pathology, it was decided first to confirm the IFN-y-mediated decrease in LPL 
enzymatic activity in primary cultures of human monocyte-derived macrophages.
For this analysis, human peripheral blood monocytes were isolated from whole 
blood using Lymphoprep™, following the manufacturer’s instructions (Section
2.2.9.1). The isolated cells were allowed to adhere to tissue culture plates for 6 hours 
and then differentiated for 7 days in RPMI 1640 (supplemented with 5% serum). The 
cells were then either left untreated or stimulated with IFN-y for 20 hours. Following 
treatment with heparin, which releases the enzyme into the medium from its 
interaction with HSPG (Khoo et al., 1981), LPL activity was measured using the 
Confluolip™ Continuous Fluorometric Lipase kit (Progen) (Section 2.3). The assay 
utilises 1 -trinitrophenyl-amino-dodecanoyl-2-pyrendecanoyl— 3 -0-hexadecyl-sn-
glycerol (12-TA-10-P-H6) as its substrate. This is a triglyceride in which the pyrene 
fluorescence is intramolecularly quenched by the trinitrophenyl group (Zandonella et 
al., 1995; Duque et al., 1996). The addition of LPL causes the hydrolysis of the 
quencher and pyrene fluorescence can be detected. A Varian Carey Eclipse Fluoresce 
Spectrophotometer recorded the fluorescence emission automatically every 20 
seconds for 20 minutes. The increased fluorescence intensity of the sample was then 
plotted against time. The gradients represent the rates of activity of the enzyme. It can 
be seen that enzyme activity in human monocyte-derived macrophages treated with 
IFN-y was 55% less than that of untreated cells (Figure 3.2). The result therefore 
confirms that the exposure of human monocyte-derived macrophages to IFN-y also 
results in a substantial decrease in LPL activity.
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3.2.2 Effect of IFN-y on the binding of Spl/Sp3 to the IFN-v-REs in the LPL gene 
promoter
The main aim of the studies presented in this chapter was to identify the signalling 
pathways responsible for the IFN-y-mediated reduction in the binding of Spl/Sp3 to 
the IFN-y-REs present in the regulatory region of the LPL gene. However, it was first 
necessary to verify the IFN-y-mediated reduction of Spl and Sp3 binding shown in a 
previous publication from the laboratory (Hughes et al., 2002). Changes in the DNA 
binding of proteins to their recognition sequences can be monitored using EMSA. 
This technique relies upon the principle that a fragment of DNA to which a protein is 
bound will move more slowly during gel electrophoresis than the same DNA 
fragment without any bound protein. A radio-labelled DNA oligonucleotide 
containing the DNA sequence of interest is incubated with nuclear or whole cell 
extracts. The DNA-protein complex(es) and free probe are then separated by 
electrophoresis on a non-denaturing polyacrylamide gel and visualised by 
autoradiography.
Although previous studies have revealed that the IFN-y-mediated reduction of 
LPL expression occurs in a number of cell lines and primary cultures (Table 3.1), 
most of the studies analysing the binding of Spl and Sp3 to the LPL promoter have 
used the murine J774.2 cell line (described in Ralph et al, 1975). It was therefore 
decided that the majority of studies in this chapter should also be performed in these 
cells.
Similar to numerous studies examining the action of cytokines (e.g. Tengku- 
Muhammad et al, 1998 [b], Hughes et al, 2002), it is routine for J774.2 macrophages 
to be incubated with reduced serum concentration prior to cytokine treatment. This is 
to prevent any undesirable combination effects between growth factors or other 
extracellular mediators present in the serum with the cytokine. Thus, J774.2 
macrophages were incubated for 4 hours in DMEM containing reduced HI-FCS (0.5% 
[v/v]), prior to treatment with IFN-y for 20 hours; control cells were left untreated. 
Nuclear- or whole cell-extracts were prepared and EMSA were carried out using the 
+9/+49 and +46/+90 oligonucleotides (containing the regions found to interact with 
Spl and Sp3) (Figure 3.3). The reaction mixture was separated by polyacrylamide gel 
electrophoresis. The gels were dried and visualised by autoradiography.
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Similar to the previous study (Hughes et al., 2002) at least three DNA-protein 
complexes were obtained when whole cell- and nuclear-extracts were used 
(designated C1-C3; Figure 3.4). None of these complexes were present when only the 
radio-labelled probe was used (data not shown). Competition EMSA in the previous 
study (Hughes et al., 2002) has confirmed that the binding of the proteins to the two 
oligonucleotide sequence was specific (Figure 3.5 [A]). In addition, the use of 
antibodies showed that complex Cl was composed of Spl whereas complexes C2 and 
C3 were composed of Sp3 (Hughes et al., 2002; Figure 3.5 [B]). Figure 3.4 shows that 
all of the complexes were present at relatively high levels when extracts from 
untreated cells were used and this decreased dramatically following the addition of 
IFN-y. Therefore, the results verify the previously noted IFN-y-mediated reduction in 
the binding of Spl/Sp3 to IFN-y-REs in the LPL gene (Hughes et al., 2002). An 
experimental system was therefore now in place to analyse the impact of signal 
transduction pathways on this binding.
+9/+49 (F) 5’-CTCGATTTCTCCTCCTACTCCTCCTCCGAGGAATTC-3’
(R) 5 ’ -GGGCAG A ATTCCTCGG AGG AGC AGT AGCAGG AG AAA-3 ’
+46/+90 (F) 5 ’ -GCCCCCT GC A ACT GTTCTGCCCICCCCTTT A A AGGT-3 ’
(R) 5 ’-GGCAAGTCAACCTTTAAAGGGGAGGGCAGAACAGTT-3 ’
Figure 3.3: Sequences o f  oligonucleotides used for the EM SA
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A
Cont IFN^y Cont IFN-y
+9/+49 +46/+90
B
Cont IFN-y Cont IFN-y
+9/+49 +46/+90
Figure 3.4: Effect of IFN-y on the binding of proteins from J774.2 macrophages to 
the IFN-y-REs
J774.2 macrophages were either left untreated (Cont) or incubated with IFN-y (IFN- 
y, lOOOU/ml) for 20 hours. Whole cell- (5pg) (A) or nuclear-extracts (5pg) (B) were 
subjected to EMSA using radiolabelled oligonucleotides that recognise Spl and Sp3. 
Three complexes were detected and are denoted C1-C3. C l represents binding by Spl 
whereas C2 and C3 represent binding by Sp3. These results are representative o f at 
least five independent experiments.
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+9/+49 +46/+90
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+9/+49 +46/+90
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3.2.3 Effect of IFN-y and TNF-ot on DNA-protein interactions at the LPL IFN-y-REs 
Interactions between cytokines in the regulation of macrophage function are well 
known (Neta et al., 1992). It has been established that the effects of cytokine 
combinations are sometimes more important in the pathogenesis of a disease than 
those of any given single cytokine (Kimball, 1991; Neta et al., 1992). Due to the 
presence of multiple cytokines in the atherosclerotic lesion, it is likely that this is also 
the case in this disease. The effect of cytokine combinations on LPL enzymatic 
activity, mRNA levels and protein content has been previously studied (Tengku- 
Muhammad et al., 1998 [a,b,c]). A major finding to emerge from these studies was a 
strong synergism between IFN-y and TNF-a. Such a synergism was seen in the J774.2 
cell line, the rat alveolar NR8383 cell line, and primary cultures of rat alveolar 
macrophages (Tengku-Muhammad et al., 1998 [a]). The synergism was seen at a 
range of concentrations of IFN-y and TNF-a (Tengku-Muhammad et al, 1998 [a]). In 
addition, IFN-y could prime macrophages for the enhanced action by TNF-a 
(Tengku-Muhammad et al., 1998 [a]). Such a priming action of IFN-y and synergism 
between this cytokine and TNF-a has been reported in several studies (e.g. Dery and 
Bissonette, 1999; Robinson et al., 2003; Berner et al., 2005).
The synergism between IFN-y and TNF-a was shown to be mediated at the 
level of gene transcription (Figure 3,6; Tengku-Muhammad et al, 1998 [d]). As the 
action of IFN-y was mediated through Spl and Sp3, it was possible that the synergism 
with TNF-a was also mediated through these two transcription factors. This 
possibility was therefore investigated. As the effect of TNF-a on Spl/Sp3 binding to 
the LPL gene regulatory sequences is not known, this was analysed first by using 
extracts of macrophages that were either left untreated or stimulated with different 
concentrations of TNF-a. As shown in Figure 3.7, TNF-a did not decrease the 
binding of Spl/Sp3 to the LPL regulatory region. The batch of TNF-a used in these 
experiments was active since it has been shown to inhibit the expression of C/EBPa 
gene transcription in HEP3B cells (Foka, 2002). Thus, the action of TNF-a was not 
mediated through Spl/Sp3. However, it was possible that the situation would be 
different when combinations of IFN-y and TNF-a are present, where the decrease in 
Spl/Sp3 binding could be much greater than that produced by IFN-y alone. To 
investigate this possibility, J774.2 cells were incubated with 50U/ml of IFN-y and
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15U/ml TNF-a, either alone or together, and protein extracts were used for EMSA. 
Previous studies had shown a synergism at these concentrations at the level o f LPL 
mRNA expression (Figure 3.6) and enzymatic activity (Tengku-Muhammad et al., 
1998 [a]). In addition, it was expected that at the lower concentration o f IFN-y used, 
only a partial inhibition of Spl/Sp3 binding would be seen, thereby allowing any 
enhanced action of TNF-a to be seen. As shown in Figure 3.8 it was not possible to 
derive any conclusions on the binding of proteins to the +46/+90 sequence because an 
almost complete inhibition of DNA binding was observed with IFN-y treatment. On 
the other hand, only a partial reduction of DNA binding to the +9/+40 sequence was 
seen with IFN-y and this was not decreased further by TNF-a. This suggests that the 
previously noted synergism between IFN-y and TNF-a in the regulation of LPL 
expression is unlikely to be mediated through Spl/Sp3.
p-actin
LPL/p-actin
Ratio
100% 70% 76% 19%
Figure 3.6: Northern blot analysis of the LPL mRNA expression by treatment of  
J774.2 macrophages with IFN-y and TNF-a
Cells were either left untreated (Cont) or stimulatedfor 20 hours with 50U/ml IFN-y, 
15U/ml TNF-a or 50U/ml IFN-y and 15 JJ/ml TNF-a. Samples o f  RNA (15 pg) were 
size-fractionated on a denaturing agarose gel, blotted onto nylon and pre-hybridized 
to a 32P-labelled'LPL cDNA probe. The membranes were then re-probed with a 
radiolabelled P-actin cDNA insert. LPL and P-actin signals were determined by 
densitometry. The LPL/p-actin ratio in untreated cells was designated 100% and the 
ratio o f the remaining samples are compared to this control value. The values shown 
represent a mean o f four independent experimental series. (Figure taken from  
Tengku-Muhammad et al., 1998 [d])
81
Chapter 3- Studies on the regulation of macrophage LPL expression in response to IFN-y
15U 50U 500U Cont 15U 50U 500U
+9/+49 +46/+90
Figure 3.7: Effect of TNF-a on the binding of Spl/Sp3 to LPL regulatory 
sequences
J774.2 macrophages were either left untreated (Cont), or incubated with different 
concentrations o f TNF-a (15U/ml, 50U/ml and 500U/ml) for 20 hours. Whole cell 
extracts (5/ug) were subjected to EMSA using radiolabelled oligonucleotides 
corresponding to the +9/+49 (A) or +46/3-90 (B) region o f  the LPL promoter. Three 
DNA-protein complexes were detected (C1-C3). These results are representative o f at 
least three independent experiments.
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C3
+9/+49 +46/+90
Figure 3.8: Effect o f IFN-y and TNF-a on binding of Spl/Sp3 to LPL regulatory 
regions
J774.2 macrophages were either left untreated (Cont), incubated with IFN-y or TNF- 
a  (50U/ml and 15U/ml respectively) alone or in combination fo r  20 hours. Whole 
cell extracts (5jug) were subjected to EMSA using radiolabelled oligonucleotides that 
correspond to the +97+49 (A) or +467+90 (B) region o f  the LPL promoter. Three 
complexes were detected denoted C1-C3. These results are representative o f  three 
independent experiments.
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3.2.4 Effect of pharmacological inhibitors of signalling pathways on the IFN-y 
mediated reduction of binding in Spl/Sp3 to IFN-y-REs
There are a wide range of pharmacological inhibitors available that block specific 
signal transduction pathways, some of which are listed in the Table 3.2. As described 
previously, the CK2 inhibitor apigenin prevented, at least in part, the IFN-y-mediated 
decrease in binding of Spl and Sp3 to regulatory sequences in the LPL promoter 
(Hughes et al., 2002) thereby implicating a role for this enzyme. In addition, a 
previous study showed that the IFN-y-mediated decrease in LPL enzymatic activity 
and mRNA expression was not affected by H8, H89 and bisindolymaleimide, 
inhibitors of cyclic-nucleotide-dependent protein kinase, protein kinase A (PKA) and 
protein kinase C (PKC) respectively (Tengku-Muhammad et al, 1999 [b]). In contrast, 
wortmannin and herbimycin A, inhibitors of PI3K and tyrosine kinase respectively, 
prevented the response (Tengku-Muhammad et al, 1999 [b]). Since JAK kinases are 
members o f the protein tyrosine kinase family (Section 1.8.3.1), it is possible that 
herbimycin A is inhibiting the JAK-STAT pathway, which is known to be involved in 
IFN-y signalling. Overall, these studies suggest a potential role for CK2, PI3K and 
JAK-STAT in the IFN-y-mediated decrease in LPL gene transcription. The action of 
these pathways could be mediated through changes in Spl/Sp3 binding. This 
possibility was therefore investigated.
Table 3.2: List o f inhibitors o f signalling pathways and their mechanisms o f  action 
Signalling pathway Inhibitor Mode of Action
CK2
PI3K
PI3K
JAK2
Cyclic-nucleotide-
Apigenin
LY294002
Wortmannin
AG490
H8
dependent protein kinase 
PKA H89
PKC Bisindoylmaleimide
Reversible ATP/GTP-competitive 
inhibitor
Competes with ATP for its substrate 
binding site
Covalently binds to catalytic subunit 
Substrate inhibitor
Competes with ATP for its active site
Competes with ATP for its substrate 
binding site
Competes with ATP for its substrate 
binding site
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311A2 cells that had been incubated in reduced serum concentration for 4 
hours were pre-treated with different concentrations of the inhibitors for 1 hour to 
ensure cellular uptake and inhibition of the target enzyme. Following this, the cells 
were either left untreated or exposed to IFN-y for 20 hours. All of the inhibitors used 
were solubilised in DMSO so that the final concentration of DMSO was less than 
0.1% (v/v) to ensure that it had a minimal effect on the viability of the cells. This was 
confirmed by the use of trypan blue exclusion assays (data not shown). In addition, all 
control samples were treated with an equal volume of DMSO present in the maximal 
dose of inhibitor to verify that any changes seen were due to the inhibitor and not the 
DMSO. The concentration of inhibitors used were based on previous work in our 
laboratory, and in previously published studies that used the inhibitors to investigate 
the regulation of macrophage gene expression (Liang et al., 1999; Hughes et al., 
2002; Liu et al., 2001; Poteser and Wakabayashi, 2004). Whole cell extracts at the 
end of the incubation period were prepared (Section 2.6.10) and subjected to EMSA 
(Section 2.6.2).
It has already been shown that CK2 is involved in the IFN-y-mediated 
decrease in the binding of Spl/Sp3 to LPL regulatory regions (Hughes et al., 2002). 
To verify this, the effect of apigenin, a CK2 pharmacological inhibitor, on the binding 
of Spl/Sp3 to the IFN-y-RE in the LPL promoter was assessed. As can be seen in 
Figure 3.9, apigenin treatment was able to prevent the IFN-y-mediated reduction in 
the binding of Spl and Sp3 to both the +9/+49 and +46/+90 regions. The inhibitor 
acted in a concentration dependent manner. The results therefore confirm that the 
CK2 pathway is involved in this response, and this provided further support to the use 
of the experimental strategy involving the use of pharmacological agents and EMSA.
We subsequently investigated the role of the PI3K and JAK-STAT pathways 
in the response. For the PI3K pathway, the inhibitor LY294002 was employed. This 
inhibitor was used instead of wortmannin, which was employed in the previous study 
on LPL activity and mRNA expression (Tengku-Muhammad et al, 1999 [b]) because 
it is more stable in solution. Wortmannin is unstable; it requires multiple additions to 
cells. It also has a tendency to interact with serum proteins (Vanhaesbroeck and 
Waterfleld, 1999). In the case of the JAK-STAT pathway, the JAK2 inhibitor AG490 
was employed (Table 3.2). As shown in Figures 3.10 and 3.11, the IFN-y-mediated 
decrease in the binding of Spl and Sp3 to their recognition sequence in the LPL
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promoter could be prevented, at least in part, in a concentration dependent manner by 
LY294002 and AG490. These results therefore indicate that the action of IFN-y on the 
binding of Spl and Sp3 to the LPL promoter is also dependent on PI3K and JAK2.
B
Apigenin lOpM 20pM lOpM 20pM
 'i.
Cont IFN-y IFN-y IFN-y Cont IFN-y IFN-y IFNy
+9/+49 +46/+90
Figure 3.9: The effect of apigenin on the IFN-y-mediated changes in the binding of 
factors to the LPL promoter
J774.2 macrophages were either left alone (Cont) or incubated for 20 hours with 
IFN-y (lOOOU/ml) in the absence or the presence o f the indicated concentration o f 
apigenin. Whole cell extracts (5/ug) were subjected to EMSA using radiolabelled 
oligonucleotides corresponding to +97+49 (A) or +467+90 (B) regions o f  the LPL 
promoter. The three DNA-protein complexes are denoted C l to C3. These results are 
representative o f four independent experiments.
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B
LY294002 0.05|iM  0.5|xM 5|aM 0.05nM  0.5nM  5jiM
Cont IFN-y IFN-y IFN-y IFN-y Cont IFN-y IFN-y IFN-y IFN-y
+9/+49 +46/+90
Figure 3.10: The effect of LY294002 on the IFN-y-mediated decrease in the binding 
of Spl/Sp3 to the LPL IFN-y-RE
J774.2 macrophages were either left alone (Cont), or incubated with IFN-y 
(lOOOU/ml) for 20 hours in the absence or the presence o f  the indicated 
concentrations o f LY294002for 20 hours. Whole cell extracts (5 pg) were subjected to 
EMSA using radiolabelled oligonucleotides that recognise +97+49 (A) or +467+90 
(B) regions o f the LPL promoter. The three DNA-protein complexes are denoted C l to 
C3. These results are representative o f three independent experiments.
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B
AG490 5fxM 50|iM  150|iM 5(iM 50|iM  150|j.M
Cont IFN-y IFN-y IFN-y IFN-y Cont IFN-y IFN-y IFN-y IFN-y
C3
+9/+49 +46/+90
Figure 3.11: The effect of AG490 on binding of Spl/Sp3 to the LPL IFN-y-RE
J774.2 macrophages were either left alone (Cont) or incubated fo r  20 hours with 
IFN-y (lOOOU/ml) in the absence or the presence o f  the indicted concentrations o f  
AG490. Whole cell extracts (5jug) were subjected to EMSA using radiolabelled 
oligonucleotides that recognise +97+49 (A) or +46/+90 (B) regions o f  the LPL 
promoter. Three complexes were detected denoted C1-C3. These results are 
representative o f three independent experiments.
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3.2.5 Effect of inhibitors of signalling pathways on the IFN-y-mediated reduction of 
LPL mRNA expression
Studies in the previous section showed that the IFN-y-mediated decrease in the 
binding of Spl and Sp3 to their recognition sequence in the LPL promoter could be 
prevented by apigenin, LY294002 and AG490. The action of these inhibitors on the 
IFN-y-mediated decrease in the expression of the endogenous LPL gene has not been 
investigated, and was therefore studied. The IFN-y-mediated decrease in LPL mRNA 
expression in J774.2 macrophages is only about 60%, as determined by northern blot 
analysis (Tengku-Muhammad et al., 1996 [d]). The effect of inhibitors on this 
relatively smaller reduction by semi-quantitative RT-PCR proved difficult (data not 
shown). Previous studies had shown that the action of IFN-y on LPL expression was 
more extensive in rat alveolar NR8383 cell line, primary cultures of rat alveolar 
macrophages and primary cultures of human monocyte-derived macrophages 
(Tengku-Muhammad et al., 1998 [a]; Jonasson et al., 1990). Because of the previous 
difficulties with J774.2 macrophages, it was decided to carry out experiments on 
human THP-1 macrophages, which have been used for numerous studies in the 
laboratory. This cellular system was also a better model than J774.2 cells for the 
investigation of gene expression relevant to human atherosclerosis.
THP-1 is a monocytic cell line. It has been shown that LPL is expressed at 
virtually undetectable levels in monocytes and induced transiently at the 
transcriptional level during their differentiation into macrophages (Auwerx et al., 
1988; 1989). The differentiation of these cells is initiated by treatment with the 
phorbol ester 12-mvristate 13-acetate (PMA). Phorbol esters are agonists of the a , 8, 
6, and isoforms of the PKC family of kinases that are implicated in the regulation 
of cell proliferation, differentiation and other cellular functions (Schwende et al., 
1996; Parker et al., 1989; Ono et al., 1988).
Before analysing the action of pharmacological inhibitors, the effect of IFN-y 
on LPL mRNA expression in these cells was investigated. For this, THP-1 monocytes 
were allowed to differentiate for 24 hours by the addition of PMA (0.16pM). This 
time corresponds to the maximal expression of the LPL gene (Auwerx et al., 1989) 
which would therefore allow the inhibitory action of IFN-y to be seen. The action of 
PMA was confirmed by the attachment of the monocytes to the tissue culture plate, 
the expected morphology of differentiating macrophages (i.e. irregular and flattened
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in shape) (Figure 3.12) and by the observation that proliferation had ceased. After 
differentiation and pre-incubation for 4 hours with reduced serum concentrations in 
the presence of PMA, the cells were treated with IFN-y for different time periods for 
up to 20 hours. Total RNA was isolated and RT-PCR was performed using LPL and 
GAPDH specific primers (Section 2.5.2). Subsequent to agarose gel electrophoresis 
and densitometric analysis, the expression of LPL mRNA was normalised against the 
housekeeping gene GAPDH. As shown in Figure 3.13, IFN-y-produced a time 
dependent decrease in LPL mRNA expression with maximum reduction of about 70% 
seen at 20 hours after treatment. This point of maximal suppression by IFN-y was 
used for subsequent studies.
The action of the inhibitors apigenin, LY294002 and AG490 on this IFN-y- 
mediated decrease in LPL mRNA expression in THP-1 macrophages was next 
investigated. For this, monocytes were allowed to differentiate into macrophages by 
treatment with PMA (0.16pM) for 24 hours. THP-1 macrophages were then incubated 
for 4 hours with 0.5% (v/v) HI-FCS in the presence of PMA, and then pre-treated for 
1 hour with the corresponding inhibitor. The cells were then either left alone or treated 
with IFN-y for 20 hours. As can be seen in Figures 3.14 to 3.16, IFN-y caused a 
decrease in LPL mRNA expression of between 70% and 90%.
Apigenin, but not LY294002 or AG490 inhibited the constitutive expression 
of LPL mRNA induced by the differentiating agent PMA (Figures 3.14) this suggests 
that CK2 is involved in the PMA signal transduction pathway involved in macrophage 
differentiation of THP-1 cells. More importantly, the dramatic IFN-y-mediated 
reduction of LPL mRNA expression seen in the absence of all three inhibitors was not 
observed in the presence of apigenin, LY294002 or AG490 (Figures 3.14-3.16). This 
confirms a key role for the CK2, PI3K and the JAK-STAT pathways in the action of 
IFN-y on LPL mRNA expression.
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24h
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Figure 3.12: Effect of PMA on the morphology of THP-1 cells
THP-1 cells were grown in 10% (v/v) HI-FCS and treated with PMA (0.16pM). The
cells were observed using phase contrast microscopy and photographed at the times
indicated.
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Figure 3.13: Effect of IFN-y on LPL mRNA expression in THP-1 cells
THP-1 monocytes were differentiated with PMA (0.16fjM) in 10% (v/v) HI-FCS fo r  
24 hours. Macrophages were then incubated in reduced concentration (0.5% [v/v] 
HI-FCS) for 4 hours in the presence o f PMA and left alone (Cont) or exposed to IFN- 
y (lOOOU/ml) fo r  the indicated periods o f time. RT-PCR was carried out using primers 
against LPL (A) and GAPDH (B). The reaction included a control from  the untreated 
20 hour sample (20h Cont) in which no reverse transcriptase was added during the 
cDNA synthesis step (-RT). No signal was obtained from this sample, indicating that 
there was no genomic DNA contamination o f the samples. PCR products were 
subjected to electrophoresis using a 1.5% (w/v) agarose gel. Product size was 
confirmed using lOObp molecular weight markers (M). The signals fo r  each sample 
were determined by densitometric analysis and plotted on a bar chart (C). The 
LPL/GAPDH ratio for the 20 hours control sample (20h Cont) has been designated 
100% with ratios o f other samples represented relative to this value. Ihese results are 
representative o f  two independent experiments.
LPL
GAPDH
92
Chapter 3- Studies on the regulation o f macrophage LPL expression in response to IFN-y
Api (20pM )
IFN-y
LPL
GAPDH
120
c  100oo
H -o
0
1
Q0.
<O
80
60
40
20
0
Cont IFN API API + IFN
Figure 3.14: Effect of apigenin on the IFN-y-mediated reduction of LPL mRNA 
expression in THP-1 cells
THP-1 monocytes were differentiated with PMA (0.16/jM) in 10% (v/v) HI-FCS for  
24 hours. Macrophages were then incubated with reduced concentrations (0.5% [v/v] 
HI-FCS) for 4 hours, and left untreated (Cont) or exposed to IFN-y (IFN; lOOOU/ml) 
in the absence or presence o f apigenin (Api; 20pM) fo r  20 hours. RT-PCR was 
carried out using primers against LPL (A) and GAPDH (B). The reaction included a 
control (-RT) from the untreated sample (Cont) in which no reverse transcriptase was 
added during the cDNA synthesis step. No signal was obtained from  these samples, 
indicating that there was no genomic DNA contamination. PCR products were 
subjected to electrophoresis using a 1.5% (w/v) agarose gel. Product size was 
confirmed using lOObp molecular weight markers (M). The signals fo r  each sample 
were determined by densitometric analysis and plotted on a bar chart (C). The 
LPL/GAPDH ratio from control cells (Cont) has been designated as 100% with ratios 
from cells treated from IFNy represented relative to this value. These results are 
representative o f two independent experiments.
93
Chapter 3- Studies on the regulation of macrophage LPL expression in response to IFN-y
M -RT Cont IFN-y IFN-y
LPL
GAPDH
C
1 2 0  -i
C on t IFN LY LY + IFN
Figure 3.15: Effect o f  LY294002 on IFN-y-mediated decrease in LPL mRNA 
expression in THP-1 cells
Differentiated THP-1 macrophages were left untreated (Cont) or exposed to IFN-y 
(IFN; lOOOU/ml) in the absence or presence o f LY294002 (LY; 5pM) fo r  20 hours 
essentially as described fo r  Figure 3.14. The reaction included a control (-RT) from  
the untreated sample (Cont) in which no reverse transcriptase was added during the 
cDNA synthesis step. No signal was obtained from these samples, indicating that 
there was no genomic DNA contamination. RT-PCR and densitometry were carried 
out exactly as described in Figure 3.14. The LPL/GAPDH ratio in control cells (Cont) 
has been designated as 100% with ratios from cells treated with IFNy represented 
relative to this value (C). These results are representative o f  two independent 
experiments.
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Figure 3.16: Effect o f  AG490 on IFN-y-mediated reduction o f  LPL mRNA  
expression in THP-1 cells
Differentiated THP-1 macrophages were left untreated (Cont) or exposed to IFN-y 
(IFN; lOOOU/ml) in the absence or presence o f AG490 (5pM) fo r  20 hours essentially 
as described in Figure 3.14. The reaction included a control (-RT) from the untreated 
sample (Cont) in which no reverse transcriptase was added during the cDNA 
synthesis step. No signal was obtained from these samples, indicating that there was 
no genomic DNA contamination. RT-PCR and densitometry were carried out exactly 
as described in Figure 3.14. The LPL/GAPDH ratio in control cells (Cont) has been 
designated as 100% with ratios from other samples represented relative to this value 
(C). These results are representative o f two independent experiments.
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3 .3  D i s c u s s io n
Previous studies in our laboratory have shown that IFN-y reduces the heparin- 
releasable LPL activity in J774.2 macrophages, rat alveolar NR8383 cell line and 
primary cultures of rat alveolar macrophages (Tengku-Muhammad et al., 1998 [b]; 
Hughes et al., 2002). The initial objective of this study was to repeat this experiment 
in primary cultures of human-monocyte derived macrophages, and it has been shown 
here that IFN-y treatment could indeed cause a decrease in LPL activity in these cells, 
of approximately 55% (Figure 3.2). Since this response is similar to that seen in 
murine i l l  A 2  cells (Tengku-Muhammad et al., 1998 [a]), the results support the 
proposition that the murine cell line acts as a good model for investigating the action 
of IFN-y in macrophages. Of the commercially available monocyte-macrophage cell 
lines, the J774.2 cell most closely represents differentiated macrophages (Ralph et al, 
1975; Ralph and Nakoinz, 1975). Cultures of i l l  A 2  cells are homogenous compared 
to primary cultures and, additionally, the yield of RNA and proteins are substantially 
greater with this cell line. Indeed, the J774.2 cell line has been used extensively to 
investigate the regulation of macrophage gene expression with demonstrated 
conservation of responses with what is seen in primary cultures (e.g. Tengku- 
Muhammad et al., 1998 [a]; Keimer and Vollamar, 1997).
It has been shown that the mechanisms responsible for the IFN-y-mediated 
decrease in LPL enzymatic activity occur at the transcriptional level (Tengku- 
Muhammad et al., 1998 [d]). A novel finding in our laboratory has defined the ex ­
acting elements responsible for the IFN-y-mediated reduction of LPL promoter 
activity as highly conserved Spl and Sp3 recognition sequences (Hughes et al., 2002; 
Figure 3.17).
+35 +75
Human LPL AAGCTGCCCACTTCTAGCTGCCCTGCCATCCCCTTTAA 
Mouse LPL AATTCTGCCCCCTGTAACTGTTCTGCCCTCCCCTTTAA 
Rat LPL AATTCTGCCCCTTGTAGCTGTTCTGCCCTCCCTTTAA
Figure 3.17: Sequences o f  Sp l/Sp3  recognition sequences fr o m  hum an m ouse and  
rat LPL
Comparison o f  the regions from human mouse and rat promoters showing 
conservation o f  Spl/Sp3 sites (shown in bold and underlined) (Figure taken from  
Irvine et al., 2005)
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These transcription factors have been shown to bind to regions in the LPL 
promoter and this binding is reduced by IFN-y treatment of the cells. IFN-y reduces 
the DNA binding activity of Spl and decreases the expression of Sp3 (Hughes et al., 
2002). This is then responsible for the reduced transcription of the LPL gene. Indeed, 
the kinetics of IFN-y-mediated changes in Spl/Sp3 DNA binding are similar to that 
for the expression of the LPL gene (Hughes et al., 2002). Interestingly, a reduction of 
Spl/Sp3 binding has also been shown to be involved in other modes of gene 
regulation, for example, in the regulation of Toll-like receptor expression in 
endothelial cells in response to lipopolysaccharide (LPS) and TNF-a (Dunzendorfer 
et al, 2004).
A major aim of this thesis was to analyse the mechanisms of IFN-y action on 
LPL in more detail. Before such an analysis could be carried out, it was necessary to 
reproduce the EMSA that showed the binding of Spl/Sp3 to the LPL IFN-y-RE and 
the decrease in binding in response to IFN-y treatment. As shown in Figure 3.4, such 
an IFN-y-mediated reduction in the binding of Spl/Sp3 could be independently 
reproduced. It was, therefore, decided to use this EMSA approach to obtain further 
insight into the mechanism of IFN-y action.
The role o f  Spl/Sp 3 in the synergism between IFN-y and TNF-a 
Interactions between cytokines are thought to be more important than the effect of a 
single mediator in the progression of disease (Kinball, 1991; Neta et al., 1992). This 
should be particularly relevant to atherosclerosis given the high levels of different 
factors present in the lesion (Table 1.2). TNF-a, a 17-kDa cytokine, has a diverse 
range of biological properties and has been found to play a role in infection, cancer 
and inflammation. Not surprisingly therefore, it has been shown to play a key role 
during atherogenesis (Osterud and Bjorklid, 2003). The cytokine also contributes to 
the decrease in macrophage LPL mRNA expression (Tengku-Muhammad et al., 1998
M ).
Synergism between IFN-y and TNF-a in the suppression of macrophage LPL 
mRNA expression, protein levels, and activity has been observed and studies have 
found that the responses occur primarily at the level of transcription (Tengku- 
Muhammad et al, 1998 [d]).
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Studies on the mechanisms through which TNF-a inhibits LPL gene 
expression have been investigated, in part, in 3T3-L1 adipocytes (Morin et al., 1995). 
Using DNA fragments spanning the -190 to +44 sequence for EMSAs, it was shown 
that there was a loss of several DNA-protein complexes after TNF-a treatment, 
including the binding of NF-Y and Oct-1 (Morin et al., 1995). A major problem 
associated with this study was that no functional data was presented on the impact of 
such changes in DNA-protein interactions on LPL gene transcription. For example, it 
was not shown that mutations of the NF-Y and Oct-1 sites abolish the response and 
that multimers of the sites confer the response to a heterologous promoter. As the 
action of IFN-y was mediated through the changes in the binding of Spl/Sp3, it was 
possible that the IFN-y/TNF-a synergism was also mediated through Spl/Sp3. Indeed 
synergism between IFN-y and TNF-a via the regulation of key transcription factors is 
relatively common. For example, it has been demonstrated that co-treatment of these 
cytokines significantly enhances the nuclear translocation of NF-kB in a vascular 
endothelial cell line (Cheshire and Baldwin, 1997). Likewise, the synergistic action of 
these two cytokines on mterl_eukin-6 (IL-6) gene transcription has been found to 
involve NF-kB, IFN-y-regulatory factor (IRF) and possibly Spl (Sanceau et al., 
1995).
It was shown here that no reduction in the binding of Spl and Sp3 to the 
+9/+49 and +46/+90 regions occurred with TNF-a treatment, even at high 
concentrations (500U/ml) (Figure 3.7). These results suggest that TNF-a down- 
regulates LPL mRNA expression via other transcription factors. It was also shown 
that the combination of IFN-y and TNF-a had no synergistic effect on the binding of 
Spl/Sp3 to these regions (Figure 3.8) suggesting that the synergism observed 
previously also acted through other transcription factors, such as NF-Y and or Oct-1.
The signal transduction pathways involved in the action o f  IFN-y on LPL expression 
The initiation of signal transduction pathways and their importance in response to 
extracellular signals is well documented, and has been discussed in the General 
Introduction. Several pathways can contribute to the regulation of gene expression 
and, given the importance of macrophage LPL expressed in the atherosclerotic lesion, 
it is essential to obtain an extensive picture of its regulation. Likewise, due to the 
importance of IFN-y in the regulation of LPL expression, it is necessary to gain an
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insight into the mechanisms of regulation by the cytokine. Therefore the signal 
transduction pathways involved in the IFN-y-mediated regulation of LPL was studied.
It has already been shown that a pharmacological inhibitor of CK2, apigenin 
prevents the IFN-y-mediated reduction in the binding of Spl/Sp3 to the regulatory 
sequences in the LPL gene (Hughes et al., 2002). This experiment was repeated to 
verify the involvement of the pathway. Indeed, apigenin prevented the IFN-y- 
mediated reduction in the binding of Spl/Sp3, in a concentration depended manner 
(Figure 3.9). Apigenin also prevented the IFN-y-mediated reduction of endogenous 
LPL mRNA expression in THP-1 macrophages (Figure 3.14). The studies on LPL 
were the first to show a role of CK2 in IFN-y signalling. Other IFN-y-regulated genes 
have subsequently been shown to require CK2. For example, IFN-y has been shown to 
increase CK2 activity and the level of phosphorylated cAMP response-element 
binding protein, which is necessary for the induction of inducible cAMP early 
repressor (ICER) gene transcription (Mead et al, 2003). Furthermore, it has been 
demonstrated that the CK2 pathway is necessary for the nuclear translocation of Y 
box-binding protein (YB-1), which is important for mediating the effects of IFN-y on 
a2(I) procollagen gene transcription (Higashi et al., 2003).
It has been shown previously that PI3K is also involved in the IFN-y-mediated 
reduction of LPL mRNA expression (Tengku-Muhammad et al., 1999 [b]). It was 
possible that this pathway could act through the mechanism of decreased Spl and Sp3 
binding to the LPL promoter. This was confirmed using the PI3K inhibitor, 
LY294002. The inhibitor affected the binding of the transcription factors in a 
concentration-dependent manner (Figure 3.10). In addition, LY294002 inhibited the 
IFN-y-mediated decrease in LPL mRNA expression (Figure 3.15). A potential role for 
the PI3K pathway in IFN-y signalling has been shown in several studies. For example, 
the activation of PI3K in response to IFN-y is necessary for the phosphorylation of 
STAT1 on serine 727 (required for maximal activity) (Nguyen et al., 2001). 
Furthermore, PI3K has been shown to modulate the ability of the cytokine to regulate 
monocyte adhesion (Navarro et al., 2003). However, to our knowledge, this is the first 
example that shows a potential role of this pathway in the suppression of gene 
transcription by this cytokine and in the regulation of Spl/Sp3.
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Over the last decade, a central role for the JAK-STAT pathway in regulating 
the effects of IFN-y has been extensively demonstrated (Chapter 1). It was therefore 
plausible to assume that this pathway may also be involved in the IFN-y-mediated 
reduction of macrophage LPL expression. It is also possible that in response to IFN-y, 
the JAK-STAT pathway could trigger the same mechanisms as CK2 and PI3K, that is, 
to decrease the binding of Spl and Sp3 to the IFN-y-REs in the LPL promoter. The 
commercially available inhibitor of JAK2, AG490, was used to support this 
hypothesis. Again the inhibitor prevented, at least in part, the IFN-y-mediated 
decrease in binding of Spl/Sp3 to the regulatory sequence in the LPL promoter in 
J774.2 macrophages and the expression of endogenous LPL mRNA expression in 
THP-1 macrophages (Figures 3.11 and 3.16).
The results presented in this chapter have, therefore, confirmed the 
involvement of CK2 and suggest that the PI3K and JAK2 signal transduction 
pathways are also involved in the IFN-y-mediated reduction of Spl and Sp3 binding 
to the LPL promoter (Figure 3.18). This has not been reported previously. It has also 
been shown that these findings are not restricted to a single murine cell line, but also 
apply to a human cell line and so are of potentially greater importance. It should be 
noted that whilst JAK2 is commonly associated with promoting the diverse cellular 
responses by IFN-y (Ramana et al., 2002), the involvement of the CK2 and PI3K 
pathways are more novel and are therefore considered in more detail in the following 
chapters.
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Figure 3.18: Schematic representation o f  mechanisms involved in the regulation o f  
LPL gene transcription by IFN-y
The results presented in this chapter have confirmed the involvement o f CK2, PI3K 
and JAK2 signalling transduction pathways in the regulation o f  Spl/Sp3 binding to 
the LPL promoter, causing a reduction in LPL mRNA expression.
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4.1 I n t r o d u c t i o n
The work presented in chapter 3 shows that CK2 is involved in the IFN-y-mediated 
reduction of LPL mRNA transcription through the binding of the transcription factors 
Spl and Sp3 to its promoter. CK2 was initially distinguished from other protein 
kinases for its ability to phosphorylate serine (Ser) or threonine (Thr) residues. CK2 
phosphorylates sites typically located within acidic stretches of proteins with -  
Ser/Thr-Xaa-Xaa-Acidic- as a consensus where the acidic residue may be glutamine, 
asparginine, phospho-serine or phospho-tyrosine (Meiggo et al., 1984; Marin et al., 
1986; Lorenz et al., 1999). Basic residues close to the Ser/Thr residues have been 
shown to play a negative role on phosphorylation by this enzyme (Marin et al., 1992). 
Although few substrates have been shown not to conform to this (Pinna, 1990), the 
rules do apply to the majority of substrates.
CK2 was first identified in liver extracts but it has since been found in the 
nucleus and cytoplasm of all eukaryotic cells (Bodenbach et al., 1994). In general, the 
expression of CK2 proteins appears to be kept quite constant and deviations have been 
related to disease state (Krehan et al., 2000). For example, levels of CK2 are elevated 
in a wide variety of tumors (Guerra and Issinger, 1999). Moreover, the inclusion of 
many viral proteins as targets of CK2 (Table 4.1) suggest a role for CK2 in virus- 
mediated pathologies (Pinna and Meiggo, 1997).
In humans two catalytic subunits (designated CK2-a and CK2-a’) have been 
well characterised, while a third CK2-a” has only recently been identified (Litchfield 
et al., 2001; Shi et al., 2001). The enzyme often exists as a tetrameric complex, 
consisting of two identical (-a-a  or - a ’- a ’) or two non-identical (-a-of) catalytic 
subunits and two regulatory subunits (-p). The catalytic subunits can also exist free 
from the regulatory subunits (Litchfield, 2003).
The components working upstream of the CK2 pathway are not well 
understood. In contrast the enzyme has a vast array of candidate physiological targets 
including 307 proteins, many of which have been shown to be phosphorylated in vivo 
(Meggio and Pinna, 2003). The substrates are involved in a variety of cellular 
functions including signal transduction and transcriptional regulation (Table 4.1; 
Meggio and Pinna, 2003).
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The aim of the studies presented in this chapter was to confirm the activation 
of CK2 by IFN-y and to gain a more detailed understanding of the mechanisms 
responsible for the IFN-y-mediated reduction of Spl and Sp3 binding to the LPL 
promoter through this pathway.
Table 4.1: Different classes o f CK2 targets
F u n c t io n a l  c a t e g o r ie s
NO. OF 
PROTEINS
R e f e r e n c e s
Signalling proteins 87 Song etal., 2000; Pinna, 1990;
(e.g. p-catenin, calmodulin, CD44, Pinna and Meiggo, 1997; Formby
CD45, dishevelled-1 and -2, IRS1, and Stem, 1998; Pinna etal., 1995;
PTEN) Torres and Pulido, 2001.
Transcription factors 60 Pinna et al., 1995, Westmark et al.,
(e.g. CREB, CREM, c-Jun, TFIIIA, Tal- 2002; Pinna and Meggio, 1997; Chu
l,p53, IkB-P) etal., 1996.
Proteins affecting DNA/RNA functions 50 Pinna, 1990; Pinna and Meggio,
and protein synthesis 1997; Maldonado and Allende,
(e.g. RNA polymerase I, RNA 1999; Pinna et al., 1995.
polymerase III, TBP, ribosomal proteins
P0, PI and P2)
Viral proteins 38 Sanz-Ezquerro et al., 1998; Pinna
(e.g. influenza virus, HIV-1 Rev, SV40 and Meiggo, 1997; Pinna et al.,
large T antigen) 1995.
Cytoskeleton and structural proteins 14 Pinna, 1990; Yin etal., 2000.
(e.g. spectrin, tubulin P, connexion)
Metabolic enzymes 9 Pinna, 1990; Han etal., 2001.
(e.g. acetylCoA carboxylase,
phospholipase Al)
Miscellaneous 49 Pinna, 1990; Pinna and Meggio,
(e.g. myosin light chain, complement C3) 1997; Pinna etal., 1995.
Abbreviations: CD44, Yaluronate receptor; CD45, Receptor tyrosine phosphatase; c-jun, 
APl-incucible transcription factor; Connexin, Avian lens GAP junctions component; 
CREB, cAMP-responsive element binding protein; CREM, cAMP-responsive element 
modulator transcription factor; HIV-1, herpes simplex virus; IRS-1, Insulin receptor 
substrate; p53. tumor suppressor phosphoprotein 53j PTEN, phosphate and tensin 
homology deleted on chromosome ten; Tal-1, Basic helix-loop transcription factor; TBP, 
TATA box binding protein (Adaptedfrom Meggio and Pinna, 2003).
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4 .2  R e s u l t s
4.2.1 Involvement of CK2 in the IFN-y-mediated regulation of LPL
4.2.1.1 Effect o f dominant negative CK2 on LPL promoter activity
To corroborate that CK2 is involved in the IFN-y-mediated suppression of LPL gene 
transcription, it was decided to analyse the effect of a dominant negative CK2 
(DNCK2) construct on the activity of the LPL promoter. Within the laboratory, an 
optimised system has been set-up whereby luciferase-linked LPL promoter constructs 
(Figure 3.1) can be transiently transfected into macrophages. Such an approach has 
been successful at delineating the IFN-y-REs in the LPL promoter (Hughes et al., 
2002). Because macrophages are relatively difficult to transfect with exogenous DNA, 
a range of macrophage cell lines and transfection methods have been examined and it 
was found that the pro-monocytic human U937 cell line in combination with the 
SuperFect™ transfection reagent was the most superior (Hughes et al., 2002).
The human monoblastic U937 cell line represents an immature cell of the 
monocyte-macrophage cell lineage (Abrink et al., 1994). This cell line has been used 
extensively to delineate the regions required for regulation of gene transcription in 
macrophages (Table 4.2).
Table 4.2: Genes for which the regulatory regions have been
determined through the use o f U937 cells
G ene  R eg ula ted Reference
Glutathione ^-transferase Duvoix et al., 2004
Human insulin receptor Maestro et al., 2002
LPL Hughes etal., 2002
Urokinase type Plasminogen Activator receptor Park et al., 2000
MMP-12 Wu etal., 2001
PU-1 Li etal., 2001
CDIIb Chen etal., 1993
NF-IL6 Berrier etal., 1998
Abbreviations: MMP-12, Matrix metalloproteinase-12; PU-1, a 
member o f the Ets family o f transcription factors; CDIIb, an intergrin; 
NF-IL6, a member o f the CCAA T/enhancer binding protein (C/EBP) 
family o f transcription factors.
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Monocytes express only very low levels of LPL (Section 3.2.5) and it was therefore 
necessary to differentiate these cells into more mature macrophages. Similar to THP-1 
cells, the U937 cell line can be induced to fully differentiate into mature macrophages 
by the addition of PMA. As can be seen from Figure 4.1, with PMA treatment cells 
become irregular and flattened in shape. In addition the proliferation of the cells 
ceases and they become more adherent to the tissue culture plastic.
SuperFect™ transfection reagent is a specifically designed activated dendrimer. 
These are highly branched, spherical molecules with branches radiating from a central 
core and terminating at charged amino groups (Tang and Szoka, 1997). The positively 
charged amino groups of SuperFect™ interact with DNA creating compact structures. 
The complexes posses an overall net positive charge that allows them to bind to the 
negatively charged cell membrane. The complexes are taken up by non-specific 
endocytosis. Once inside the cell, the SuperFect™ reagent buffers the lysosome 
leading to pH inhibition of lysosomal nucleases and stability of SuperFect™-DNA 
complexes ensuring efficient transport into the nucleus.
The DNCK2 construct (CK2-a-K68A-HA) consists of the plasmid pSG5 
encoding a kinase-inactive mutant of CK2-a. It also contains a HA epitope at the C- 
terminus (Appendix). The construct has been described previously (Heriche et al., 
1997; Lebrin et al., 2001). Briefly, the lysine residue (present in the kinase domain), 
that is considered to be essential for the phosphotransfer reaction, has been substituted 
with an alanine residue, rendering the mutant enzyme inactive. It has been shown that 
the exogenous inactive mutant has the capacity to integrate with the endogenous CK2 
regulatory subunit pools to form an inactive tetrameric form of CK2, thereby exerting 
a dominant negative effect on CK2 cellular function (Lebrin et al., 2001). This 
DNCK2 has been employed successfully in several studies. For example, Lebrin et 
al., (2001) used the construct to demonstrate an important role of CK2 in cell cycle 
progression in mammalian fibroblasts.
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Figure 4.1: Effect o f  PMA on the morphology o f  U937 cells
U937 cells were treated with PMA (lpM), observed using phase contrast microscopy 
and photographed at the times indicated.
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To analyse its effect on LPL promoter activity, U937 cells were co-transfected 
with the DNCK2 construct or the parent pSG5 vector (control) followed by the LPL
TM .
promoter construct using SuperFect according to the manufacturer’s instructions 
(Section 2.2.10). The CMV-p-galactosidase plasmid was included to provide an 
internal standard for transfection efficiency. Of the promoter constructs, LPL 1 was 
used because this construct spans the region of interest, from -31 to +188, which 
contains the Spl/Sp3 recognition sequence (Figure 3.1). Immediately after 
transfection, cells were incubated with PMA and allowed to differentiate for 12 hours 
(taken from Hughes et al., 2002). Cells were then either left alone or treated with IFN- 
y for 12 hours, this time point has been shown to cause the expected reduction in 
promoter activity (Hughes et al., 2002). Subsequent to treatment, the luciferase 
activity was recorded and normalised to the (3-galactosidase activity. As shown in 
figure 4.2, when cells were co-transfected with the LPL promoter construct and the 
control vector, IFN-y treatment caused a 65% decrease in the relative luciferase 
activity. This was abrogated in the presence of DNCK2.
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Figure 4.2: Effect o f  CK2DN on IFN-y-mediated reduction o f  LPL promoter 
activity. U937 cells were transfected with the dominant negative CK2 construct 
(DNCK2) or the control vector (pSG5) followed by the LPL promoter-luciferase 
construct and CMV-fi-galactosidase plasmid as described in Section 2.2.10. Cells 
were treated with PMA (ljuM) and allowed to differentiate fo r  12 hours. Cells were 
then either left alone or exposed to IFN-y ( 1 OOOU/ml) fo r  12 hours. Luciferase activity 
was then normalised to /3-galactosidase activity and expressed as relative luciferase 
activity. Data shown is mean ±SD from three independent experiments each carried 
out in triplicate. Data was analysed by students-t-test. * represents the significant 
inhibition o f  IFN-y-mediated suppression o f relative luciferase activity seen in cells 
transfected with thepSG5 vector (p<0.05).
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4.2.1.2 Effect o f  IFN-y on CK2 activity in J774.2 macrophages 
CK2 has been found to be constitutively active in virtually all eukaryotic cells 
analysed (Pinna, 2002). In addition, there is substantial evidence to suggest 
stimulation or inhibition of its activity by specific factors (Sayed et al., 2000). Studies 
presented so far have shown that the activation of CK2 is necessary for the IFN-y- 
mediated decrease of LPL mRNA expression, promoter activity and changes in the 
binding of Spl/Sp3 (Figure 3.14; 4.2; 3.9). In addition, a previous study from the 
laboratory has shown that the activity of CK2 in J774.2 cells increases upon exposure 
to IFN-y (Mead et al., 2003). However, this study was restricted to a single time point 
and a single subunit of the enzyme (-a). It was therefore decided to confirm this 
finding and to determine whether the activity of the second catalytic subunit of CK2, - 
a ’, is also induced by IFN-y, and to determine the kinetics of the response.
J774.2 cells were incubated for the appropriate time periods with IFN-y and 
whole cell extracts were prepared using a buffer containing phosphatase and protease 
inhibitors. The CK2 subunits were immunoprecipitated (section 2.6.4) using the 
appropriate antibody and subjected to an assay where the ability to phosphorylate the
T9p-casein substrate was measured (Section 2.6.5). This assay utilised [y ] P-labelled 
ATP (which CK2 uses as a phosphate donor). The reaction was incubated for 15 
minutes at 37°C and subsequently size-fractionated on a SDS-PAGE gel (Section
2.6.3.1). The phosphorylated p-casein was assessed by autoradiography. A positive 
control reaction was performed using purified CK2 enzyme and the negative control 
contained substrate only.
Figure 4.3 A and C show that CK2-a and CK2-a’ immunoprecipitated from 
cells treated with IFN-y can phosphorylate p-casein more dramatically compared with 
CK2 immunoprecipitated from untreated cells. For CK2-a, this phosphorylation of 
the P-casein substrate reaches maximum at 3 hours following treatment of the cells 
with IFN-y, remains at high levels up to 12 hours, and decreases thereafter (Figure 4.3 
[A]). On the other hand, the activity of the CK2-a’ reaches maximal levels at 1 hour 
after stimulation of the cells with IFN-y and remains at high levels throughout the 20 
hour incubation period (Figure 4.3 [C]). Such an increase in the phosphorylation of p- 
casein substrate with extracts from IFN-y treated cells could be due to an increase in 
either enzymatic activity or protein levels. Western blot analysis of the extracts was 
carried out to distinguish between these possibilities. As shown in Figure 4.3 [B] and
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4.3 [D], the steady state levels of both CK2 subunits did not increase upon stimulation 
of the cells with IFN-y, thereby indicating that the cytokine causes a dramatic 
induction of CK2 activity.
IFN-y
Cont Oh lh  3h 6h 12h 20h + ’ve - ‘ve
r
P-casein
(24kDa)
B
CK2-a
(42kDa)
IFN-y
Cont Oh lh 3h 6h 12h 20h + ’ve - ‘ve
p-casein
(24kDa)
C K 2-a’
(45kDa)
Figure 4.3: Effect o f  IFN-y on CK2 activity and protein levels in J774.2 
macrophages
J774.2 macrophages were either left untreated (Cont) or exposed to IFN-y 
(lOOOU/ml) for the indicated time periods. The -a  and - a ’ subunits were then 
immunoprecipitated and subjected to in vitro kinase assays as described in Section 
2.6.5.1. The kinase reactions were size fractionated on SDS-PAGE gels [15% (v/v)] 
and the phosphorylation status o f /3-casein assessed by autoradiography (A and C). 
The immunoprecipitated proteins were subjected to western blot analysis using 
antisera against CK2-a (B) or CK2-a’ (D). The results shown are representative o f  
two independent experiments.
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4.2.2 The involvement of JAK2 and PI3K in the activation of CK2 
As mentioned previously, studies during the past decade have established a central 
role for JAK-STAT signalling in the promotion of diverse ‘early’ cellular responses 
induced by IFN-y (Section 1.8.2). Also, PI3K has been shown to be involved in some 
responses triggered by IFN-y (Nguyen et al., 2001). Results from the previous chapter 
showed that CK2, JAK2 and PI3K were all involved in the IFN-y-mediated reduction 
of Spl/Sp3 binding to the LPL promoter. In addition Figure 4.3 shows that IFN-y 
induces the activity of both CK2 subunits in macrophages. Such an IFN-y-mediated 
activation of CK2 could be either dependent or independent of PI3K and/or JAK2. To 
investigate this, the effect of the PI3K inhibitor LY294002 and the JAK inhibitor 
AG490 on the IFN-y-mediated activation of CK2 was determined. The CK2 inhibitor 
apigenin was included as a positive control.
Whole cell extracts using the phosphatase- and protease-free buffer were 
prepared from J774.2 cells which had been pre-treated for 1 hour with the appropriate 
inhibitors prior to stimulation with IFN-y for 3 hours. This time point was chosen 
because the activity of both the -a  and - a ’ subunits were high. CK2 was then 
immunoprecipitated from the extracts using antibodies against the specific catalytic 
subunits. Immunoprecipitates were then subjected to the CK2 kinase assay (Section
2.6.5.1).
Consistent with previous studies (Figure 4.3), the phosphorylation of the p- 
casein substrate was substantially higher when immunoprecipitated protein from the 
IFN-y treated cells was used (Figure 4.4 [A], [C]). As expected, the CK2 inhibitor, 
apigenin, prevented such an increase in the phosphorylation of the p-casein substrate. 
In contrast, such an inhibitory action was not seen with LY294002 or AG490 (Figures
4.4 [A], [C]). The lack of action of these inhibitors was not due to a problem with the 
inhibitors themselves as they had successfully inhibited the IFN-y-mediated decrease 
in Spl/Sp3 binding to regulatory sequences in the LPL gene promoter and the IFN-y- 
mediated decrease in LPL mRNA expression (Chapter 3). Western blot analysis was 
also carried out to investigate whether any of the treatments affected the steady state 
levels of CK2-a and - a ’ polypeptides. Figure 4.4 [B] and [D] show that the levels of 
CK2-a or - a ’ remained constant in all the samples analysed.
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Figure 4.4: The effect o f  inhibitors on the action o f on CK2 activity and steady state 
protein levels
J774.2 macrophages were left untreated (Cont) or pre-treated with the indicated 
inhibitor for 1 hour and then exposed to IFN-y (lOOOU/ml) fo r  3 hours. CK2-a and - 
a  ’ were then immunoprecipitated from whole cell extracts and subjected to in vitro 
kinase assays (Section 2.6.5.1). The kinase reactions were size-fractionated on SDS- 
PAGE gels [15% (v/v)] and the phosphorylation status o f  p-casein assessed by 
autoradiography (A and C). B and D show the outcome o f  western blots probed with 
antisera against CK2-a and CK2-a’ respectively. The results are representative o f  
two independent experiments.
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4.2.3 The interaction of CK2 with Spl/Sp3 in J774.2 macrophages 
CK2 has many substrates including Spl and Sp3 (Armstrong et al., 1997). In many 
instances CK2 has been shown to interact with a number of proteins, including its 
substrates (Table 4.3; Litchfield, 2003).
Table 4.3: Some o f the substrates that CK2 interacts with
S u b s t r a t e s  of C K 2 R e f e r e n c e s
p53 Appel etal., 1995
HDAC2 Sun et al., 2002
Calmodulin Marin et al., 1997 (a)
TBP Ghavidel and Schultz, 2001
PP2A Heriche et al., 1997
Tubulin Faust ef al., 1999
Nucleolin Li etal., 1996
Spl Black et al., 2001
Abbreviations: p53, tumor suppressor phosphoproteinp53: 
HDAC2, histone deaceetlyase 2j TBP, TATA box binding
protein; PP2A, protein phosphatase 2A;
Since CK2 has been shown to be involved in the IFN-y-mediated decrease in Spl/Sp3 
binding to the LPL promoter, it is possible that these two factors also interact with 
CK2. This possibility was therefore investigated. For this, co-immunoprecipitation 
assays were performed. J774.2 cells were either left untreated or stimulated with IFN- 
y for 3 hours; a time point corresponding to maximal CK2 activity in cells (Figure
4.3). Whole cell extracts were then prepared using the protease- and phosphatase-free 
buffers. The transcription factors were then immunoprecipitated from the extracts 
using the appropriate antibodies (Section 2.6.4). Immunoprecipitates were then 
separated by SDS-PAGE and transferred to a PVDF membrane, which was then 
incubated with the appropriate CK2 antibody. Antigen/antibody complexes detected 
using the ECL system.
As shown in Figures 4.5 and 4.6, both Spl and Sp3 interacted with the CK2-a 
and - a ’ subunits, and this interaction was increased when cells were treated with IFN- 
y. Equal amounts of cell extracts were used in these experiments. It was however, not 
possible to verify that equal amounts of Spl and Sp3 were present in the 
immunoprecipitates because of technical problems in western blots (data not shown).
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It was, therefore, decided to confirm that the IFN-y-mediated increased association of 
Spl/Sp3 with CK2 subunits was not due to increased expression of the proteins. For 
this, time-course western blot analysis was carried out. Consistent with previous 
results, the steady state levels of CK2-a, CK2-a’ and Spl levels were not affected by 
IFN-y (Figure 4.7 [A-C]). On the other hand, IFN-y produced a time-dependent 
decrease of the steady state levels of all four major Sp3 polypeptides (Figure 4.7 [D]), 
which is also consistent with previous findings (Hughes et al., 2002).
C K 2-a
(42kDa)
C K 2-a’
(45kDa)
Figure 4.5: Co-immunoprecipitation assays to determine interactions between CK2 
and Spl. J774.2 macrophages were either left untreated (Cont) or exposed to IFN-y 
(lOOOU/ml) for 3 hours. Immunoprecipitations o f the extracts (150pg) was performed 
using an anti-Spl antibody. The Immunoprecipitates were subjected to western blot 
analysis with antibodies against CK2-a (A) or CK2-a’ (B). The results are 
representative o f three independent experiments.
C K 2-a
(42kDa)
B
Figure 4.6: Co-immunoprecipitation assays to determine interactions between CK2 
and Sp3. Immunoprecipitation o f the extracts from above (Figure 4.5) were 
performed using an anti-Sp3 antibody. The Immunoprecipitates were then subjected 
to western blot analysis with antisera against CK2-a (A) or C K 2-a’ (B). These results 
are representative o f  three independent experiments.
C K 2 -a ’
(45kDa)
Cont IFN-y
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Figure 4.7: Effect o f  IFN -y on steady state levels o f CK2, S p l and Sp3 in J774.2 
macrophages
J774.2 macrophages were exposed to IFN-y (lOOOU/ml) for the indicated period o f  
time. Untreated cells at the start and the end o f the experimental period were included 
for comparative purposes (0 hour [Oh Cont] and 20 hour [20h Cont], respectively). 
Western blot analysis was carried out using 60pg o f whole cell extracts. The blotted 
membranes were incubated with primary antibodies (A) CK2-a (B) C K 2-a’ (C) Spl 
and (D) Sp3. Antigen/antibody complexes were detected using the ECL system. The 
results are representative o f three independent experiments.
C K 2-a
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4.2.4 Effect of CK2 from J774.2 macrophages on the phosphorylation of Spl 
The Spl protein is known to be subject to regulation by two forms of post- 
translational modifications. It can be glycosylated with 0-linked sugars (Jackson and 
Tijan, 1988), or phosphorylated (Jackson et al, 1990; Armstrong et al., 1997). Whilst 
glycosylation does not appear to affect the ability of Spl to bind to DNA but instead 
influences the degradation of the protein (Han and Kudlow, 1997; Yang et al., 2001; 
Armstrong et al., 1997), phosphorylation has a profound effect on DNA binding 
(Philipsen and Suske, 1999). Spl has been shown to be phosphorylated by multiple 
cellular kinases including CK2 (Dunzendorfer et al., 2004; Black et al., 2001).
Previous studies showed that IFN-y induced CK2 activity without affecting the 
steady-state polypeptide levels (Figure 4.3). Therefore, if CK2 is responsible for the 
phosphorylation of Spl, the phosphorylation of recombinant Spl in vitro will be 
higher when immunoprecipitated CK2 from IFN-y-stimulated cells is used compared 
to that from untreated control cells. This possibility was therefore investigated.
Whole cell extracts were immunoprecipitated with the appropriate catalytic 
subunit of the enzyme and subjected to an assay where its ability to phosphorylate 
human recombinant Spl was measured. This assay also utilised [y ] P-labelled ATP. 
The reaction was incubated for 15 minutes at 37°C, size-fractionated by SDS-PAGE 
(Section 2.6.3.1), and the phosphorylated Spl was assessed by autoradiography 
(Section 2.6.2.5).
Two polypeptide species were seen with recombinant Spl (Figure 4.8). The 
molecular weights of the bands are approximately 85kDa and 57kDa; this is lower 
than the molecular weight of the protein expressed in mammalian cells. A reason for 
this could be due to different styles of glycosylation in mammalian cells and the viral 
cells in which the recombinant Spl was expressed (Promega). The precise reason(s) 
for the presence of two polypeptides is currently unclear but may be due to some post- 
translational modification produced during the generation of the protein. The 
phosphorylation of both Spl polypeptides by immunoprecipitated CK2-a and CK2-ot’ 
was increased when extracts from IFN-y treated cells was used (Figure 4.8).
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Figure 4.8: Phosphorylation o f  Sp l by CK2 subunits
Purified recombinant Spl was used as a substrate in kinase assays with 
immunoprecipitated CK2-a (A) and CK2-a’ (B) (Section 2.6.5) from untreated or 
IFN-y stimulated cells. The kinase reactions were size fractionated by SDS-PAGE 
[7% (v/v) gels] and the phosphorylation status o f  Spl was assessed by 
autoradiography. The results shown are representative o f three separate experiments.
4.2.5 Effect of recombinant CK2 on binding of Spl/Sp3 to the LPL promoter
4.2.5.1 Effect o f CK2 on the binding o f Spl/Sp3 from J774.2 macrophages 
The results so far reveal that the association of Spl/Sp3 with the CK2 catalytic 
subunits increases upon exposure of J774.2 cells to IFN-y, and this is accompanied by 
a marked increase in the phosphorylation of Spl. The location of a CK2 consensus 
site within the second zinc finger of Spl suggests a possible mechanism by which 
phosphorylation of Spl directly by CK2 could interfere with binding of Spl to DNA 
(Armstrong et al., 1997). This suggests that the binding of Spl/Sp3 to regulatory 
sequences present in the LPL promoter obtained with extracts from untreated cells 
should decrease following phosphorylation with recombinant CK2. This possibility 
was therefore investigated.
Whole cell extracts from J774.2 cells, that had been prepared using the 
phosphatase- and protease- free buffer (Section 2.6.1), were incubated with the 
recombinant enzyme for 30 minutes at 30°C (taken from Armstrong et al, 1997) prior 
to EMSA. Control extracts were treated similarly except no recombinant CK2 was 
present. The initial experiment used a radiolabelled oligonucleotide containing all
Cont IFN-y
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three Spl/Sp3 binding sites (+36/+90). In addition, two different concentrations of 
CK2 were used (0.1U and 0.2U).
As shown in Figure 4.9, both concentrations of CK2 decreased the binding of 
Spl/Sp3 to levels seen in IFN-y-treated cells. Further experiments utilised the +9/+49 
and +49/+90 oligonucleotide probes. As shown in Figure 4.10 [A], a similar CK2- 
mediated decrease in the binding of extracts from untreated cells to that for the 
+36/+90 sequence was seen. Representative analysis was also carried out using 
oligonucleotides containing the C/EBP recognition sequence for comparative 
purposes. As shown in Figure 4.10 [B], in contrast to Spl/Sp3, only a slight change in 
the binding was seen. This suggests that the dramatic CK2-mediated decrease in DNA 
binding is specific to Spl/Sp3 and not a general phenomenon.
CK2
Cont 0.1U 0.2U IFN-y
+36/+90
Figure 4.9: Effect o f  CK2 enzyme on DNA binding by Spl/Sp3
J774.2 macrophages were either left untreated (Cont) or incubated with IFN-y 
(lOOOU/ml) for 20 hours (IFN-y). Whole cell extracts (5jug) were subjected to a kinase 
reaction with CK2 (0.1 and 0.2U) and used in an EMSA with radiolabelled 
oligonucleotides corresponding to the +36/+90 region o f  the LPL gene. Extracts from  
IFN-y treated cells, and those from untreated cells that were also subjected to the 
kinase reaction in the absence o f CK2 were included for comparative purposes. Three 
complexes were detected (CI-C3). Cl is due to Spl whereas C2 and C3 are because 
o f Sp3. These results are representative o f two independent experiments.
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Figure 4.10: Effect o f  CK2 enzyme on DNA binding by Spl/Sp3
J774.2 macrophages were either left untreated (Cont) or incubated with IFN-y 
(lOOOU/ml) for 20 hours (IFN-y). Whole cell extracts (5pg) were subjected to a kinase 
reaction with CK2 and used in an EMSA with radiolabelled oligonucleotides 
containing the +97+49 or +497+90 sequence (panel A) or the C/EBP recognition 
sequence from the C/EBP a  promoter (panel B). For the +97+49 and +467+90 
sequences, three DNA-protein complexes were seen. Complex C l is due to Spl 
whereas complexes C2 and C3 are because o f  Sp3. The DNA-binding protein 
complexes obtained using the C/EBP binding site oligonucleotides are denoted as B. 
The results are representative o f two independent experiments.
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4.2.5.2 Effect o f  CK2 on the binding o f recombinant Spl
The experiments above showed that phosphorylation of extracts from untreated cells 
with recombinant CK2 leads to a decrease in DNA binding to levels seen in IFN-y 
treated cells. This suggests that phosphorylation of recombinant Spl with CK2 should 
also lead to a decrease in DNA binding. It was therefore decided to investigate this 
possibility.
Whole cell extracts were substituted with recombinant Spl protein and EMSA 
analysis was performed as usual. A radiolabelled oligonucleotide spanning the entire 
region (+36/+90) was used to determine the optimal concentration of Spl, after which 
the usual +9/+49 and +46/+90 probes were tested. Figure 4.11 reveals that a 
DNA/protein complex of weak intensity is formed with 0.5pg of Spl protein whereas 
a complex of substantially greater intensity is seen with 1 pg of protein. Therefore, 
1 pg of Spl protein was used in further experiments.
To analyse the effect of CK2 on Spl binding, the protein was incubated with 
the enzyme for 30 minutes prior to EMSA. Spl treated in a similar manner but 
without the CK2 enzyme was included for comparison. As shown in Figure 4.12, CK2 
also caused a substantial decrease in Spl DNA binding.
Spl
+36/+90
Figure 4.11: DNA binding by recombinant Spl.
Recombinant Spl was subjected to EMSA using radiolabelled oligonucleotides which 
span the +36/+90 sequence. The results are representative o f  two independent 
experiments.
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Spl
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Figure 4.12: Effect o f  CK2 on binding by recombinant Sp l
Recombinant Spl protein was subjected to a kinase reaction with CK2 (CK2 0.1U) 
before being used in an EMSA with radiolabelled oligonucleotides that recognise 
+9/+49 (A) or +46/+90 regions o f the LPL promoter. Spl treated in a similar manner 
without the enzyme was included for comparison (Cont). The results are 
representative o f  three independent experiments
4.2.6 Effect of CK2 on phosphorylation of calmodulin
CK2 protein substrates can be grouped into different categories; those which are 
readily phosphorylated by isolated catalytic subunits or the holoenzyme, and 
substrates that can be phosphorylated by isolated catalytic subunits but not the 
holoenzyme. Calmodulin (CaM), one of the key signal transducers used by cells in 
response to increased intracellular calcium levels, is a substrate of CK2. CaM is 
phosphorylated in vivo and in vitro by CK2 in a manner that is unique among CK2 
substrates. Its phosphorylation is inhibited by the regulatory subunit and therefore, 
used in the field to determine the existence of active isolated catalytic subunits of 
CK2 in cells (Arrigoni et al., 2004).
In order to gain a clearer understanding of the mechanisms in our system, it 
was decided to investigate whether CK2 present within J774.2 cells could 
phosphorylate CaM, if so it would suggest that the CK2 enzyme consists of catalytic 
subunits only. If the CaM could not be phosphorylated it would suggest that the 
enzyme acts as a holoenzyme.
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Whole cell extracts from J774.2 cells, that had been left untreated or incubated 
with IFN-y, were prepared using the phosphatase- and protease-free buffer (Section
2.6.1). The extracts were subjected to immunoprecipitation with the appropriate 
subunits and subjected to an assay where its ability to phosphorylate CaM was 
assessed. Since no phosphorylation of the CaM substrate was observed (results not 
shown), the results suggest that CK2 acts as a holoenzyme in J774.2 macrophages. 
However, no positive control was used and so the experiment needs to be repeated 
using the specific catalytic subunits as positive controls to verify that the assay system 
was functional.
4.2.7 The role of regulatory subunits of CK2
The observation that CK2 cannot phosphorylate CaM suggests that CK2 acts as part 
of a holoenzyme in our cellular system, this means that the regulatory and catalytic 
subunits associate. It was decided to confirm this using immunoprecipitation analysis. 
Whole cell extracts were prepared (Section 2.6.1) which had been left either untreated 
or exposed to IFN-y for 3 hours. Extracts were immunoprecipitated using antisera 
against the regulatory subunit (-P) of CK2 (Section 2.6.4). Immunoprecipitates were 
subjected to SDS-PAGE and western blot analysis using the antibodies against the 
catalytic subunits of CK2 (-a and - a ’) (Section 2.6.3.2). Figure 4.13 shows that the 
regulatory subunits of CK2 did associate with the catalytic subunits and this was 
induced upon exposure to IFN-y, although only slightly. This result suggests that CK2 
exists as a holoenzyme in J774.2 macrophages and that IFN-y is unlikely to exert its 
action by affecting the composition of the CK2 enzyme.
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CK2-a
(42kDa)
CK 2-a’
(45kDa)
Figure 4.13: Co-immunoprecipitation assays to determine interactions between 
CK2 subunits
J774.2 macrophages were either left untreated (Cont) or exposed to IFN-y 
(lOOOU/ml) for 3 hours. Immunoprecipitations o f  the extracts (200pg) were 
performed using antibodies against CK2-/1. The Immunoprecipitates were subjected to 
western blot analysis using antibodies against CK2-a (A) or CK2-a’ (B). The results 
are representative o f  three independent experiments.
123
Chapter 4-Role o f  CK2 in the IFN-y-mediated reduction o f  LPL gene expression
4 .3  D is c u s s io n
A mechanism for the regulation of macrophage LPL gene expression by CK2 has 
been described. It has been shown that IFN-y mediates a reduction in the binding of 
two transcription factors (Spl and Sp3) to the LPL promoter through CK2 and that 
this results in decreased LPL gene transcription (Chapter 3; Hughes et al., 2002). The 
aim of this chapter was to confirm this and enhance the understanding of CK2s 
involvement in this response.
First of all, we investigated the effect of a DNCK2 construct on the activity of 
the LPL promoter. The DN construct was specific for the CK2-a subunit and had 
been used successfully in a number of studies (e.g. Heriche et al., 1997; Lebrin et al., 
2001). It was found that co-transfection of the LPL promoter construct with the 
DNCK2 plasmid in U937 cells abolished the consistently noted reduction in LPL 
promoter activity normally seen with IFN-y treatment (Figure 4.2). This confirmed 
that the enzyme is involved in the IFN-y-mediated response and, since the LPL 
construct contains the Spl and Sp3 sites (Figure 3.1), supports a link between CK2 
and these two transcription factors. Although CK2 consists of two catalytic subunits, 
time restraints prevented the study of a DNCK2-a’ on LPL promoter activity which 
may be necessary in future.
A previous study has examined the activity of CK2-a in response to IFN-y. 
However this experiment was restricted to a single time point and a single subunit 
(Mead et al., 2003). To gain a clearer insight into the IFN-y-mediated changes in CK2 
activity, it was decided to asses the kinetics of changes in its activity in more detail, 
and to extend the studies to both catalytic subunits. There is evidence of functional 
distinction between the subunits of CK2 in mammalian cells (Litchfield, 2003). For 
example, CK2-a is phosphorylated at unique sites within its C-terminal domain in a 
cell cycle dependent manner, since these sites are not present in CK2-a’ it suggests 
that the subunits are differentially regulated during the cell cycle (Litchfield, 2003; 
Litchfield et al., 1992; Bose et al., 1995). However it was shown here that IFN-y 
induced the activity of both catalytic subunits (Figure 4.3).
The maximal activity of CK2-a was observed after approximately 3 hours of 
IFN-y treatment and remained relatively constant until 12 hours whilst that of CK2-a’ 
reached maximal at 1 hour and remained at similar levels throughout the 20 hour
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incubation period (Figure 4.3). Several factors have been found to regulate CK2, for 
example stress signalling agents, including TNF-a, stimulate the activity of the 
enzyme (Sayed et al., 2000). In addition, the stimulatory effects of TGF-P on type IV  
collagen gene transcription are mediated through CK2 activity (Zdunek et al., 2001).
It has been shown that two other signalling pathways are involved in the IFN- 
y-mediated decrease in binding of Spl/Sp3 to LPL promoter, these are PI3K and 
JAK2 (Chapter 3). It is assumed that IFN-y exerts its effects through its cognate 
receptor and given that JAKs are commonly associated with the IFN-y receptor, it was 
of no surprise that JAK2 was involved. Also the phosphorylation of the IFN-y 
receptor by JAKs creates potential docking sites for the regulatory subunit of PI3K. 
For this reason, the PI3K pathway has been found to be associated with the JAK 
pathway in some modes of regulation (Rane and Reddy, 2000). Moreover, PI3K 
activity has been found to be regulated by IFN-y (Nguyen et al., 2001).
There are several examples that show cross-talk between signal transduction 
pathways. For example, Choudhury (2004) provides evidence that IFN-y stimulates 
PKCs in a PI3K sensitive manner, which then activates MAPK. More relevant is the 
recent evidence showing a link between CK2 and PKB (a downstream effector of 
PI3K), whereby CK2 is thought to phosphorylate and up-regulate the activity of the 
latter (Di Maria et al., 2005). It was, therefore, possible that JAK2 and/or PI3K acted 
upstream of CK2. However, both the JAK2 inhibitor AG490 and the PI3K inhibitor 
LY294002 had no effect on the IFN-y-mediated increase in CK2 activity. This 
suggests that the action of IFN-y on CK2 is independent of JAK2 and PI3K.
It is assumed that IFN-y exerts its effects through its cognate receptor. 
However, this may not be the case for example IFN-y may exert its effects through an 
uncharacterised receptor that is independent of the JAK kinases. It will therefore be 
necessary to verify that IFN-y acts through its own receptor. This could be achieved 
through the incubation of the cells with a neutralising anti-IFN-y receptor antibody 
prior to IFN-y treatment and subsequent analysis of CK2 activity. The existence of 
IFN-y-mediated, JAK-STAT independent pathways is supported by several recent 
studies. For example, Iwata et al., 2001 showed that when the action of all of the 
JAKs was blocked with a global tyrosine kinase inhibitor, IFN-y could still induce 
intracellular adhesion molecule (I-CAM) gene expression in human comeal cells. In 
addition, mircoarray analysis has revealed a number of genes that are suppressed by
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IFN-y in STAT null macrophages (Ramana et al., 2002). The IFN-y-mediated 
activation of CK2 could therefore be a novel JAK-STAT-independent mechanism. It 
should however be noted that as AG490 is an inhibitor of JAK2, the results do not 
exclude the possibility of a role of JAK1 or JAK3 (Zhang et al., 2000). Further 
experiments will be required to investigate these possibilities.
The mechanisms of CK2 activation by IFN-y are not fully understood and so it 
would be interesting to find out which pathways function upstream of CK2. This may 
be achieved through inhibitor and/or dominant negative studies and/or RNA 
interference analysis. In addition, the existence of interactions with other potential 
binding partners of CK2 could be studied using co-immunoprecipitation assays or the 
yeast two hybrid system. However, in line with the main objectives of the chapter it 
was decided that CK2 should be investigated in more detail with respect to Spl and 
Sp3. Indeed, the possibility existed that the action of JAK2, CK2 and PI3K converged 
on downstream effectors such as Spl and Sp3.
Many known substrates of CK2 are transcription factors. In fact the primary 
sequence of both Spl and Sp3 contain a number of consensus sites for CK2 (Pinna, 
1990; Faust and Montenarh, 2000; Allende and Allende, 1995; Litchfield and Lusher, 
1993). The consensus CK2 site in Spl has been shown to be phosphorylated by the
c 7Q
enzyme at amino acid threonine in the second zinc finger motif (Armstrong et al., 
1997). This phosphorylation has been shown to result in the decreased activity of Spl 
binding and is correlated with reduced synthesis of 4 Spl site’-dependent genes in 
differentiated liver cells (Armstrong et al., 1997). In addition, CK2 has been shown 
to phosphorylate several general transcription factors including TFIIA and TFIIF 
(Cabrejos et al., 2004).
Numerous studies suggest that active CK2 actually interacts with its substrates 
(Table 4.1; Pawson and Scott, 1997; Pawson and Nash, 2000). For example, TNF-a 
activation of the enzyme mediates its interaction with p38a MAP kinase and the 
phosphoprotein 53 (p53) (Sayed et al., 2000). In addition, the activation of CK2 due 
to serum and cisplatin (an alkylating agent used to treat some cancers) leads to an 
association of the enzyme with p53 and the ribosomal protein L5 (Guerra and 
Issinger, 1998). Therefore it was possible that IFN-y could, upon activation of CK2, 
induce its increased association with Spl and Sp3. Immunoprecipitation assays
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confirmed this (Figure 4.5 and 4.6). To ensure that this was not due to increases in the 
protein levels of the enzyme and/or transcription factors, western blot analysis was 
performed, which revealed that IFN-y did not affect protein levels in such a way 
(Figure 4.7). In fact, it was shown that the level of Sp3 polypeptides were reduced 
upon IFN-y stimulation, and this is confirmed elsewhere (Hughes et al., 2002).
The antisera against Sp3 detected four polypeptide species that formed two 
doublets with approximate molecular masses of 110 and 65kDa (Figure 4.7). The 
presence of four polypeptides maybe accounted for by alternative use of translation 
initiation codons and/or post-translational modifications. Indeed, Sp3 mRNA has been 
shown to specify for at least three polypeptides through the former mechanism 
(Philipsen and Suske, 1999). Full length Sp3 (110 kDa) is initiated at a non-AUG 
codon, whereas the smaller species arise from internal translational sites (Hughes et 
al., 2002; Philipsen and Suske, 1999; Kennett et al., 2001). The levels of the Sp3 
polypeptides decrease soon after IFN-y treatment and maximal reduction is seen at 20 
hours. The kinetics of decreased Sp3 protein levels are therefore similar to decreased 
binding of factors to IFN-y-REs in the LPL gene promoter and LPL mRNA 
expression, suggesting that decreased Sp3 protein also contributes to IFN-y-mediated 
reduction of LPL mRNA expression.
Levels of Sp3 mRNA levels are not affected by IFN-y (Dr K Greenow, 
personal communication) whereas the protein levels are decreased (Figure 4.7). One 
possibility for such regulation is that IFN-y interferes with Sp3 translation. This could 
be due to either a modification leading to an untranslatable transcript or the 
translational silencing of an intact transcript. Indeed IFN-y has been shown to inhibit 
the translation of ceruloplasmin (a copper containing protein) through the activation 
of a translational repressor (Mazumder and Fox, 1999). Alternatively, Sp3 peptides 
may be degraded as a result of IFN-y treatment. For example Spl has been shown to 
be degraded by the proteosomal pathway (Mortensen et al., 1997). Prior to 
degradation by proteosomes, most proteins are ubiquitinated (Van Antwep and 
Verma, 1996; Su et al., 1999; Han and Kudlow, 1997). Phosphorylation of proteins 
has been shown to act as a signal for their degradation by triggering ubiquitination 
(Van Antwep and Verma, 1996; Su et al., 1999). It is therefore possible that IFN-y 
induces the phosphorylation and ubiquitination of Sp3 through the activation of CK2.
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This needs to be investigated further. Whilst it has been shown that CK2 does interact 
with Sp3 in response to IFN-y (Figure 4.6) it will need to be investigated whether 
CK2 actually induces the phosphorylation of the transcription factor.
In contrast to Sp3, Spl protein levels remain relatively constant with IFN-y 
treatment (Figure 4.7). This suggests that Spl DNA binding activity is regulated by 
CK2 in a post-translational manner. The observation that IFN-y increases the 
association of Spl with the CK2 catalytic subunits (Figure 4.5), and the fact that CK2 
is known to phosphorylate a number of its substrates, adds further indirect support for 
such a potential post-translational mechanism. Phosphorylation of recombinant Spl 
by both of the CK2 catalytic subunits was increased upon exposure of J774.2 
macrophages to IFN-y (Figure 4.8) thereby suggesting that Spl is modified by 
phosphorylation as a result of CK2. Indeed it was shown that when whole cell extracts 
are treated with the recombinant CK2 holoenzyme, the changes in binding of Spl/Sp3 
to the LPL promoter mimics that seen when the cells are treated with IFN-y (Figure 
4.9 and 4.10). To ensure that this was specific to Spl/Sp3 binding, the effect of the 
enzyme on C/EBP binding was also investigated and was shown to have a marginal 
effect.
It was also shown that when the CK2 enzyme was incubated with recombinant 
Spl prior to EMSA, there was a reduction in the binding of the protein to the IFN-y- 
REs in the LPL promoter (Figure 4.12). These results confirm that Spl acts as a 
substrate for CK2 and that this is associated with reduced Spl DNA binding activity. 
This is therefore a novel mechanism of regulation. Interestingly, a potential role for 
CK2-medaited phosphorylation of Spl has been implicated in the regulation of other 
genes for example toll-receptor 2 (Dunzendorfer et al, 2004).
Krehan et al., 2000 has shown that Spl sites are key regulatory elements in the 
promoter of the CK2-a subunit suggesting a feedback mechanism by which CK2 may 
regulate its own expression through Spl (Krehan et al, 2000). However, as can be 
seen in Figure 4.7, the expression of CK2 in response to IFN-y remains constant, so 
this is unlikely to be the case in J744.2 cells.
The general consensus is that the catalytic subunits of CK2 are constitutively 
active with or without their regulatory (3-subunit (Pinna, 2002). However, there are
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exceptions, such as the phosphorylation of CaM, which is inhibited by the presence of 
the regulatory subunit. In vitro kinase assays using CaM as a specific substrate 
revealed that whole cell extracts were unable to phosphorylate it suggesting that CK2- 
a  and CK2-ot’ subunits act as part of a holoenzyme in J774.2 cells (it could also be 
that CK2 lacks the polybasic peptides necessary for calmodulin phosphorylation. The 
presence of a holoenzyme is supported by immunoprecipitation assays using the 
subunits of the enzyme. It was shown that these regulatory and catalytic subunits did 
interact (Figure 4.13).
The high resolution structure of tetrameric CK2 has shown that the ATP 
analogue, adenosine 5’-[p,y-imido] triphosphate, occupies the ATP binding site of 
only one of the catalytic CK2 subunits within the tetramer, indicating that only one 
subunit is active (Litchfield, 2003). The significance of this remains unknown. 
However, taking into account that the holoenzyme consists of two identical or two 
non-identical subunits and that it has been shown here that the pattern of activity and 
association of the catalytic subunits upon exposure to IFN-y is similar, it may be 
speculated that that the subunits are similarly active.
In conclusion, the results presented in this chapter confirm that CK2 plays a 
critical role in the IFN-y-mediated reduction of Spl/Sp3 binding to the LPL promoter. 
In response to IFN-y treatment, the activities of the CK2 catalytic subunits increase, as 
does their association with Spl and Sp3. This leads to an induction of the 
phosphorylation of at least Spl (and maybe Sp3). Phosphorylation of Spl is 
responsible for its decreased binding to regions within the LPL promoter (Figure 
4.14).
These results provide novel findings and, given the fact that CK2 has been 
implicated in the regulation of Spl activity in response to several signals (Sayed et al., 
2000; Zdunek et al., 2001; Dunzendorfer et al., 2004), suggest that the mechanism of 
Spl regulation by CK2 may be widespread.
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IF N -y
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Sp1/I CK2
binding
LPL
Figure 4.14: Schematic representation o f  mechanisms involved in the regulation o f  
LPL gene transcription by IFN-y based on results from  this chapter
It has been shown that IFN-y increases the activity o f the catalytic subunits o f CK2. 
IFN-y also increases the interaction o f CK2 to Spl and Sp3. CK2 phosphorylates Spl, 
this interferes with its binding to the LPL promoter, resulting in a decrease o f  LPL 
promoter activity and decreased LPL expression. Sp3 may be phosphorylated by CK2, 
which may then be degraded through the proteosomal pathway.
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5.1 INTRODUCTION
PI3K signalling mediates a multitude of cellular responses following stimulation by 
extracellular mediators and, as with CK2, dysregulation of the pathway has been 
associated with diseases such as cancer and diabetes (Toker and Newton, 2000). For 
example, the activity of PI3K is up-regulated in many cancers (Hidalgo and 
Rowinsky, 2000; Cantley, 2002) and this contributes to the phosphorylation of several 
proteins that leads to cell survival (Ghobrial et al, 2005). PI3K is also necessary for 
insulin-mediated metabolic effects such as increased glucose uptake and glycogen 
synthesis, and so defects in the pathway can lead to type II diabetes (Jiang and Zhang, 
2002; Cantley, 2002).
PI3K is responsible for the phosphorylation and activation of multiple and 
distinct secondary signalling molecules (Figure 5.1). Such molecules in turn can cause 
profound alterations in the cell such as altered gene transcription, cytoskeletal 
remodelling and protein synthesis, which can influence fundamental cellular functions 
including cell growth, motility and differentiation (Toker and Newton, 2000).
Of the three classes of PI3K, class I are the most relevant to this study because 
of their involvement in cell signalling in response to growth factors and cytokines 
(Chapter 1). Class I PI3Ks are heterodimeric proteins consisting of a catalytic subunit 
and a regulatory subunit. Class I can be sub-grouped into Class U and Class Ib. In 
Class Ia the catalytic subunit has three isoforms (pi 10a, -P and -5; encoded by three 
separate genes) and five regulatory isoforms (p85a, p85p and p55y are encoded by 
distinct genes; p55a or p50a are produced from alternate transcripts of the p85a 
gene). In contrast class Ib (y) is made up of a pi 1 Oy catalytic subunit and a p i01 
regulatory subunit (Fruman and Cantley, 2002; Vanhaesebroeck et al, 2002).
The regulatory subunits have no catalytic activity but possess two SH2 
domains and a SH3 domain. The N-terminus of the catalytic subunit binds to a region 
between these SH2 domains (Kapeller and Cantley, 1994). The SH2 domains of the 
regulatory subunits also modulate activation of the enzyme by directly interacting 
with phosphorylated tyrosine residues of activated receptors. The SH2 domains can 
also interact with non-receptor tyrosine kinases in the cytoplasm; for example the Src 
family kinases (Fruman and Cantley, 2002).
Active PI3K catalyse the addition of a phosphate moiety to the 3’-OH position 
of the inositol rings of Ptdlns (Section 1.8.2.3). The preferred substrate in vivo is
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PtdIns-(4,5)-P2, which is phosphorylated to produce PtdIns-(3,4,5)-P3 (Cantrell, 
2001). PtdIns-(3,4,5)-P3 acts as a second messenger, directly binding and activating 
several downstream targets, initiating the signalling cascade of PI3K (Figure 5.1). In 
turn the production of PtdIns-(3,4,5)-P3 is regulated by the phosphatase mammalian 
phosphate and tensin homology deleted on chromosome ten (PTEN) which catalyses 
the de-phosphorylation of the lipid (Leslie and Downes, 2002) (Figure 5 .1).
1 mTOR I I Raf 11 eNOS 
BAD || F O O  GSK3 1
Figure 5.1: Schematic representation o f  the PI3K pathway
The activation o f PI3K leads to the generation o f PIP3. PIP3 can then interact with 
PKB this causes an alteration in PKB conformation allowing PDK1 access to 
previously hidden residues, which become phosphorylated resulting in PKB 
activation. Active PKB translocates from the cytosol to the nucleus where it interacts 
with a range o f downstream targets including GSK3-/3, mTOR and eNOS. PTEN acts 
antagonistically to PI3K converting PIP3 back to PIP2. Abbreviations: P, Phosphate 
residue; PI3K, Phosphoinositide-3-kinase; PIP2, Phosphatidylinositol-(3,4)- 
diphosphate; PIP3, Phosphati_dylinositol-(3,4,5)-triphosphate; PTEN, Phosphate and 
tensin homology deleted on chromosome ten: PDK1, 3 ’-phosphoinositide-dependent 
kinase-1; PKB, Protein kinase B; mTOR, Mammalian target o f  rapamycin; Raf, 
MAPK kinase; eNOS, Endothelial nitric oxide synthase; BAD, Bcl-associated death 
promoter; FOX, Forkhead transcription factors; GSK3, Glycogen synthase kinase 3.
Whilst a potential mechanism by which CK2 regulates the IFN-y-mediated reduction 
of LPL expression has been established (Chapter 4), relatively little has been 
investigated in relation to PI3K. Through the use of the pharmacological inhibitor
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LY294002, it has been shown that the pathway is involved in the IFN-y-mediated 
regulation of LPL mRNA expression through decreased Spl and Sp3 binding 
(Chapter 3). It was thus decided to investigate this mechanism further.
The primary objectives of studies presented in this chapter were therefore to 
characterise the role of the PI3K pathway in the IFN-y-mediated suppression of LPL 
expression and changes in DNA binding to Spl/Sp3, and to identify downstream 
targets of the pathway that were involved in this response.
5 .2  R e s u l t s
5.2.1 Involvement of PKB in IFN-y-mediated regulation of LPL
5.2.1.1 Effect o f  dominant negative PKB on LPL promoter activity
There are several downstream effectors of PI3K, the prototype is the Ser-Thr protein 
kinase B (PKB). There are three isoforms of PKB (-a, -p and -y), all of which have a 
broad tissue distribution. The three isoforms are composed of an N-terminal PH 
domain, a central catalytic domain, and a C-terminal hydrophobic domain which is a 
characteristic of the cyclic AMP-dependent, cyclic GMP-dependent and PKC (AGC) 
kinases (Hanada et al., 2004).
PKB is located in the cystol of unstimulated cells, but in response to lipid 
phosphorylation it accumulates at the plasma membrane because of its ability to 
associate with the newly 3’-OH-phosphorylated Ptdlns through its PH domain 
(Franke et al., 1997). At the membrane PKB becomes phosphorylated and therefore 
active; it initiates various responses via phosphorylation of key downstream proteins. 
Since activation of PKB and subsequent stimulation of other proteins is directly 
dependent on 3’-OH-phosphorylated Ptdlns derived from PI3K (Nguyen et al., 2001), 
several studies have used PKB as an effective indicator of PI3K activity (e.g. Ma et 
al., 2004; Wang et al., 1999; Qiu et al., 2004). To determine whether PKB was one of 
the downstream targets of the PI3K pathway activated in response to IFN-y and 
involved in the regulation of LPL gene expression, it was decided to analyse the effect 
of a dominant negative PKB (DNPKB) construct on LPL promoter activity in 
macrophages.
The DNPKB used was a triple mutant in which the activating phosphorylation 
sites (Ser473 and Thr308) along with a Lysine residue (Lys179) had been mutated to 
alanine residues rendering it unable to bind ATP to be activated (Jin and Woodgett).
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The construct has been used successfully in a number of studies to demonstrate a key 
role for PI3K (e.g. Ma et al., 2004; Wang et al, 1999; Stoll et a l, 2005).
U937 cells were co-transfected with the DNPKB construct (or the control 
vector, pCDNA) followed by the LPL promoter-luciferase construct (LPL7) (Figure
3.1) using SuperFect™ as described in Section 2.2.10. Immediately after transfection, 
PMA was added and the cells were allowed to differentiate for 12 hours. Cells were 
then incubated with IFN-y for 12 hours. Subsequent to treatment, the luciferase 
activity (Section 2.2.12) was determined and normalised to the protein concentration. 
As shown in Figure 5.2, treatment with IFN-y resulted in a dramatic decrease of 
luciferase activity in cells which had been transfected with the control vector. 
However, the luciferase activity of cells treated with the DNPKB was not affected by 
IFN-y. Thus, DNPKB blocks the IFN-y-mediated decrease in LPL promoter activity, 
thereby implicating a crucial role for the enzyme in the response.
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Figure 5.2: Effect o f  DNPKB on IFN-y-mediated changes in LPL promoter activity
U937 cells were transfected with the dominant negative construct (DNPKB) or the 
control vector (pcDNA) followed by the LPL promoter-luciferase DNA construct 
(Section 2.2.10). Cells were then treated with PMA (lpM) and allowed to differentiate 
for 12 hours. Cells were then either left alone or exposed to IFN-y (lOOOU/ml) for 12 
hours. Luciferase values were normalized to protein concentration and expressed as 
relative luciferase activity. Data shown is mean ~SD from three independent 
experiments each carried out in triplicate. Data was analysed by students-t-test. * 
indicates the significant inhibition o f IFN-y-mediated suppression o f LPL promoter 
activity in cells transfected with pcDNA (p<0.05).
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5.2.1.2 Effect o f  IFN-y on phosphorylation o f PKB in J774.2 macrophages 
The regulation of PKB is complex and involves phosphorylation of multiple sites. 
Ser124 and Thr450 are constitutively phosphorylated and appear to contribute to protein 
stabilisation. However, upon stimulation by extracellular mediators, the binding of 
Ptdlns to PKB relieves auto-inhibition in the active site of the kinase (Milbum et al,
2003). Relief from auto-inhibition allows the phosphorylation of the Thr308 residue 
(within the catalytic core) and a Ser473 residue (close to the C-terminus). 
Phosphorylation of both of these residues is necessary to achieve maximal activity of 
the kinase (Filippa et al., 2000). It has also been reported that phosphorylation of 
tyrosine residues (Tyr and Tyr ) can be important in PKB activation. However, 
this appears to be specific to stimulation by epidermal growth factor (Chen et al., 
2001; Hanada et al., 2004).
The phosphorylation of PKB-Thr by 3 ’-phosphoinositide-dependent kinase 
i  (PDK1) (Section 5.2.2.1) is now widely accepted, whereas that of Ser473 is less well 
understood. It is known that phosphorylation of this site is PI3K-dependent and so it 
has been proposed that a kinase upstream of PI3K is required. PDK1 does not seem to 
be responsible but the unknown kinase is often referred to as PDK2. Despite extensive 
biochemical analysis, the identification of PDK2 remains to be determined 
(Vanhaesebroeck and Alessi, 2000; Alessi et al., 1996).
It was decided to determine the phosphorylation status of PKB to give an 
indication of PKB activity. For this J774.2 cells were first incubated with IFN-y for 
several timed periods. Untreated cells at the start and the end of the experimental 
period were included for comparison. Whole cell extracts were prepared using a 
buffer containing phosphatase- and protease-inhibitors (Section 2.6.1). Proteins were 
size-fractionated by SDS-PAGE, transferred to PVDF membranes and incubated with 
phospho-PKB-Ser473 and -Thr308 antibodies (Section 2.6.3.2). To ensure that the 
results were not due to fluctuating levels of PKB, a western blot using the total PKB 
antibody was performed. As can be seen from Figures 5.3 and 5.4, total PKB levels 
remained relatively constant throughout the incubation period. In contrast, levels of 
phospho-PKB-Ser473 increased steadily for the duration of IFN-y treatment (Figure
TOR5.3). On the other hand, levels of PKB phosphorylated at Thr increased upon 
exposure to IFN-y for 3 hours and returned to control levels there after (Figure 5.4).
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Figure 5.3: Effect o f  IFN-y on the levels o f  phospho-PKB-Ser473 in J774.2 
macrophages
J774.2 macrophages were exposed to IFN-y (JOOOU/ml) fo r  the indicated periods o f 
time. Untreated cells at the start and end o f the experimental period were also 
included for comparative purposes (Oh and 2Oh Cont). Western Blot analysis was 
carried out using 60pg o f whole cell extracts. Blotted membranes were incubated with 
primary phospho-PKB-Ser473 (A) or total PKB rabbit polyclonal IgG antibodies (B) 
and detected using an anti-rabbit horseradish peroxidase secondary antibody. The 
phospho-PKB-Ser473 and total PKB protein levels were determined by densitometric 
analysis and the ratios are plotted on a bar chart (C). These results are representative 
o f two independent experiments.
137
Chapter 5- Role o f PI3K in the IFN-y-mediated reduction o f LPL gene expression
Cont IFN-y
Oh 20h Oh 3h 6 h 12 h 20h
B
|  3 . 5 -  
m
2  2 . 5  -
CD
</>
1 . 5  -
0 . 5  -
Oh C o n t  2 0 h  C o n t  Oh IFN 3 h  IFN 6 h  IFN 1 2 h  IFN 2 0 h  IFN
Figure 5.4: Effect of IFN-y on the levels o f phospho-PKB- T h /08 in J774.2 
macrophages.
The experimental approach was identical to that described in Figure 5.3 except that 
blotted membranes were incubated with phospho-PKB-Thr08. The result is 
representative o f two independent experiments.
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5.2.1.3 Effect o f  IFN-y on PKB activity in J774.2 macrophages
Whilst phospho-specific antibodies are generally useful tools in monitoring PKB 
activation, results shown here indicate that PKB is phosphorylated differently at the 
key residues in response to IFN-y and so the impact of this on the activity of the 
kinase was not clear. It was therefore decided to monitor the PKB activity directly. 
This was achieved using a non-radioactive kit in which the ability of the kinase to 
phosphorylate GSK3-a/p-Ser2179 was measured. For this, whole cell extracts prepared 
using the phosphatase- and protease-free buffers (Section 2.6.1) were 
immunoprecipitated using an immobilised PKB antibody and the kinase assay was 
performed as described by the manufacturer (New England Biolabs; Section 2.6.5). 
The reaction was incubated for 15 minutes at 37°C and subsequently size-fractionated 
by SDS-PAGE. The levels of the phosphorylated GSK3 substrate was then assessed 
by western blot analysis (Section 2.6.3.2).
A representative autoradiograph is shown in Figure 5.5 [A], with the 
histogram showing the outcome of three independent experiments. It can be seen that 
PKB activity began to increase after IFN-y treatment and that maximal activity was 
reached at 20 hours. The maximal activity was about 70% higher than that in control 
cells. This was not due to de novo protein synthesis as western blots using an antibody 
which detects the total levels of PKB protein remained fairly constant (Figure 5.5 
[B]).
5.2.1.4 Effect o f  recombinant PKB on the binding o f Spl and Sp3 to the LPL promoter 
It has been demonstrated that IFN-y mediates its effects on LPL gene expression 
through the transcription factors Spl and Sp3 (Chapter 3). It has also been shown that 
PKB regulates the action of several transcription factors, including forkhead (FOX) 
and cyclic AMP response element binding protein (CREB), and evidence suggests 
that this contributes to altered gene transcription (Burgering and Kops, 2002; Du and 
Montminy, 1998). In fact, Spl has been found to be involved in the PKB-mediated 
regulation of vascular endothelial growth factor (VEGF) gene expression (Pore et al.,
2004). Therefore, since IFN-y had been shown to stimulate PKB activity, it was 
possible that this enzyme could also contribute directly to the binding of transcription 
factors regulated by the cytokine. Because the binding of Spl and Sp3 has been
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shown to be decreased by IFN-y, it was decided to investigate whether PKB could 
play a role in this response.
Whole cell extracts were prepared from untreated cells using the phophatase- 
and protease-free buffer (Section 2.6.1). The extracts were incubated with increasing 
concentrations of the recombinant PKB enzyme (New England Biolabs) for 30 
minutes at 30°C (as recommended by the manufacturer). Extracts that were treated in 
a similar manner but without any enzyme were used as a control. In addition, extracts 
from IFN-y treated cells were included for comparison. The DNA binding of the 
extracts was then examined by EMSA (Section 2.6.2). Figure 5.6 [A, B] shows that 
there was a concentration-dependent decrease in binding following phosphorylation of 
extracts from untreated cells with PKB. The level of binding seen following such in 
vitro phosphorylation was similar to that attained following incubation of the cells 
with IFN-y.
To further evaluate the action of phosphorylation of extracts with recombinant 
PKB, the binding to an Ap-1 consensus site was also studied. As shown in Figure 5.6 
[C], at least one DNA-protein complex was seen. Incubation of the extracts from 
untreated cells with 0.2pg PKB led to a slight reduction in this binding, which was not 
inhibited further when 0.4pg was used. Thus the action of PKB on Spl/Sp3 and Ap-1 
are slightly different.
5.2.1.5 Effect o f  PKB enzyme on the binding o f recombinant Spl 
It was decided to determine whether PKB was sufficient to decrease the binding of 
recombinant Spl protein directly. For this, the recombinant Spl protein was incubated 
with PKB (and ATP) for 30 minutes at 37°C prior to EMSA (Section 2.6.2). The Spl 
protein that was treated in a similar manner, but without PKB, was used as a control.
Figure 5.7 reveals that phosphorylation by PKB did not result in a decrease in 
the binding of recombinant Spl, implicating that other factors present in the whole 
cell extracts are necessary to produce the decrease in Spl DNA binding seen in IFN-y- 
treated cells.
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Figure 5.5: The effect of IFN-y on PKB activity in J774.2 macrophages.
The kinase assay was carried out using 150pg o f whole cell extracts as described in 
section 2.6.3.2 and blotted membranes were incubated with phospho-GSK3-a//3- 
Ser2J/9 and total PKB primary antibodies. Antigen-antibody complexes were detected 
using the ECL detection system. Results are representative o f three separate 
experiments. The mean ±SD was calculated form three independent experiments. Data 
was analysed using the Students-t-test * represents the significant difference 
compared to control cells (p<0.05).
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B
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Figure 5.7: Effect of PKB on Spl binding to recognition sequences in the LPL 
promoter
Recombinant Spl protein (ljug) was subjected to a kinase reaction with PKB (0- 
0.4pg) and ATP (200juM) for 30 minutes at 30°C and then used in an EMSA with 
radiolabelled oligonucleotides corresponding to the +9Z+49 (A) or +46/+90 (B) 
regions o f the LPL gene. These results are representative o f  two independent 
experiments.
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5.2.2 Effect of IFN-y on proteins upstream of PKB in the PI3K signalling pathway
5.2.2.1 Effect o f  IFN-y on the level ofphosphorylated PDK1 in J774.2 macrophages 
A number of studies have shown that the activation of PKB is dependent upon PDK1 
activity (Anderson et al., 1998; Alessi et al., 1997; Stokoe et al., 1997). PDK1 is a 
Ser/Thr protein kinase composed of an N-terminal catalytic domain and a C-terminal 
PH domain that is responsible for its interaction with phosphorylated Ptdlns 
(Vanhaesebroeck and Alessi, 2000). The association of PDK1 with the 
phosphorylated Ptdlns brings the protein within close proximity of PKB, thereby 
facilitating the phosphorylation of PKB that is essential for the activity of this kinase 
(Lawlor and Alessi, 2001).
Several residues of PDK1 become phosphorylated in vivo upon activation. Of 
these, the phosphorylation at Ser241 has been shown to be one of the most critical 
(Casamayor et al., 1999). Ser241 is present in the activation loop of the kinase and 
phosphorylation occurs through auto-phosphorylation (Casamayor et al., 1999). It was 
therefore decided to analyse the phosphorylation status of this residue in response to 
IFN-y.
J774.2 cells were treated with IFN-y for different time periods. Untreated cells 
from the start and the end of the experiment were included as controls. Whole cell 
extracts were prepared (using buffers containing phosphatase- and protease- 
inhibitors) (Section 2.6.1) and subjected to western blot analysis using an antibody 
specific for PDKl-Ser241 (Section 2.6.3.2). The membrane was then re-probed with an 
antibody specific for p-actin to ensure equal loading of samples.
Alternatively spliced isoforms of PDK1 have been described and this is likely 
to account for the presence of two bands after immunoblotting with the antibody. As 
can be seen from Figure 5.8 IFN-y treatment caused a marked increase in the level of 
PDK1 phosphorylated at this residue. For example, after 20 hours of IFN-y treatment 
the level of PDKl-Ser241 was about 60% greater than that from untreated cells. Thus, 
the time period of maximal activation of PDK1 corresponds to that of PKB (Figure 
5.8).
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Figure 5.8: Effect of IFN-y on phospho-PDKl-Ser241 levels in J 774.2 macrophages
J774.2 macrophages were exposed to IFN-y (lOOOU/ml) for the indicated periods o f 
time. Untreated cells at the start and the end o f the experiment were included as 
controls (Cont). Western blot analysis was carried out using 60pg o f whole cell 
extracts. The blotted membrane was incubated with primary phospho-PDKl-Ser241 
(A) antibody and antigen/antibody complexes detected using an anti-rabbit 
horseradish peroxidase secondary antibody. The membrane was then washed and 
incubated with anti-p-actin antibody (murine monoclonal IgG) and detected using an 
anti-murine horseradish peroxidase conjugate (B). The phospho-PDKl-Ser241 and (3- 
actin protein levels were determined by densitometric analysis. The 0 hour control (oh 
Cont) sample was designated 1 with all other samples are relative to this value (C). 
The mean ±SD was calculated from three independent experiments. Data was 
analysed using the Students-t-test. * represents significant activation compared to 
control cells (p<0.05).
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5.2.2.2 Effect o f  IFN-y on the levels ofphosphorylated PTEN in J774.2 macrophages 
The activation of PI3K is counteracted by phosphoinositide phosphatases such as 
PTEN. Although PTEN belongs to the duel specificity phosphatase (DSP) family of 
‘protein’ phosphatases, its physiological target is a phospholipid; specifically, the 3’- 
phosphate group of PtdIns-(3,4,5)-P3 (Miller et al., 2002). The antagonistic actions of 
PTEN on PI3K are evolutionary conserved in fruitflies (Huang et al., 1999) and
nematodes (Ogg and Ruvkum, 1998) as well as in various mammalian tissues (Oudit
et al., 2004). Mutations of PTEN are often found in many cancers and together with 
p53 serve as essential and ubiquitous modulators of proliferation, differentiation and 
apoptosis (Oudit et al., 2004).
The mechanism of PTEN regulation is not fully understood. It is possible that 
PTEN is regulated by phosphorylation. Indeed, the C-terminal PTEN domain in the 
protein is rich in putative phosphorylation sites and it has been proposed from
i o a  98 9  98Smutation studies that the cluster of Ser , Thr and Ser are the predominantly 
phosphorylated residues (Vazquez et al, 2000). The phosphorylation of these residues 
has been reported to affect enzyme stability and function (Vazquez et al., 2000). 
However the kinase responsible for such phosphorylation is not known with certainty. 
The general consensus from several studies is that phosphorylation of PTEN keeps it 
stable but less active, whereas de-phosphorylation activates it (Torres and Pulido, 
2001; Tolkacheva et al., 2001). Given that PI3K phosphorylates lipids to form Ptdlns- 
(3,4,5)-P3 and that this is the preferred substrate of PTEN it may follow that an 
increase in the activity of PI3K leads to an increase in the activity of PTEN.
It was decided therefore to analyse the phosphorylation status of PTEN in 
response to IFN-y to give an indication of its activity. For this, J774.2 macrophages 
were incubated with IFN-y, whole cell extracts were prepared using the phosphatase- 
and protease-free buffers (Section 2.6.1), and these were subjected to western blot 
analysis using an antibody specific for PTEN-Ser380 (Section 2.6.3.2). The membrane 
was then re-probed with anti-p-actin antibody to ensure equal loading of samples. 
Figure 5.9 shows that IFN-y caused a rapid and significant (approximately 50%) 
decrease in the phosphorylation (and so increase in activity) of the enzyme. The levels 
of phosphorylated protein returned to that seen in untreated cells between 12 to 20 
hours.
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Figure 5.9: Effect o f  IFN-y on levels o f  phosho-PTEN-Ser380 in J774.2 
macrophages
The experimental approach was identical to that described in Figure 5.8 except that 
an antibody against phospho-P TEN Ser380 was used. The mean ~SD was calculated 
form three independent experiments. Data was analysed using the Students-t-test. * 
represents the significant inhibition compared to untreated cells (p<0.05).
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5.2.2.3 Effect o f  IFN-y on the level ofphosphorylated p70S6K in J774.2 macrophages 
Whilst PDK1 was originally identified to be necessary for the phosphorylation of 
PKB-Thr308, and this is still widely accepted (Alessi et al., 1997), it is now clear that 
PDK1 is a more versatile kinase, involved in a variety of cellular functions such as 
protein synthesis, cell adhesion and migration (Taniyama et al, 2003). In fact, PDK1 
represents a pivotal point in divergence in the pathway, and can lead to the activation 
of multiple members of the cyclic AGC superfamily including PKA, PKC and p70 
ribosomal S6 kinase (p70S6K) (Taniyama et al., 2003).
As mentioned previously, studies using pharmacological inhibitors have 
shown that PKA and PKC are not involved in the IFN-y mediated reduction of LPL 
expression (Table 3.2). However, no such studies have investigated the role of 
p70S6K.
The mechanisms of phosphorylation seem to be different for PKB and p70S6K 
(Biondi et al., 2001; Collins et al., 2003). Co-localisation to the plasma membrane 
through the PH domains of PDK1 and PKB is necessary for the phosphorylation of 
PKB-Thr308 whereas PDK1 phosphorylates p70S6K in the cytosol, and the interaction 
is mediated by a PIF-binding pocket in PDK1 binding to a hydrophobic motif in 
p70S6K (Biondi et al., 2001).
P70S6K, a serine kinase, regulates the phosphorylation of the 40S S6 
ribosomal protein, which plays a key role in the regulation of cell growth by 
controlling the biosynthesis of components of the translational machinery (Figure 
5.10; Shima et al., 1998; Dufner et al., 1999). Whilst p70S6K is widely accepted to be 
important for the stimulation of protein synthesis by insulin (Chung et al, 1994), 
there is also evidence that it regulates gene expression in response to a number of 
factors. For example, it has been shown to be involved in the regulation of type I  
collagen and matrix metalloproteinase expression by TGF-pi (Lechuga et al, 2004). 
In addition, it has recently been demonstrated that the enzyme is rapidly 
phosphorylated and activated in an IFN-y-dependent manner (Lekmine et al, 2004). 
Furthermore, p70S6K has been shown to play a role in the regulation of LPL 
expression (Kraemer et al, 1998). It was therefore possible that IFN-y mediated the 
activation of p70S6K (maybe through PDK1) and that p70S6K might contribute to the 
regulation of LPL expression in response to this cytokine.
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Figure 5.10: Schematic representation o f  involvement ofp70S6K and mTOR in the 
PI3K signalling pathway and its role in the regulation o f  translation
Stimulation o f the PI3K pathway leads to PDK1 activation. PDK1 can phosphorylate 
PKB andp70S6K. mTOR can also phosphorylate p70S6K. Active p70S6K leads to the 
phosphorylation o f  4OS ribosomal subunit protein S6 and the stimulation o f the 
translation ofproteins. In addition, mTOR can lead to the inactivation o f the inhibitor 
4E-BP1 (by sequential phosphorylation). Inactivation o f 4E-BP1 causes the release o f 
eIF4E, which can also induce translation. Negative regulators also act on the 
pathway these include PTEN, TSC1 and, TSC2. Abbreviations: mTOR, mammalian 
target o f rapamycin; 4E-BP1, 4E binding protein: eIF4E, eukaryotic initiation factor; 
TSC1, TSC2, tuberous sclerosis complex proteins.
The regulation of p70S6K is complex and, as with many kinases, the 
phosphorylation of several sites is required for its full activation. An important 
phosphorylation site is Thr389 (located in the catalytic loop of the p70 domain). 
Phosphorylation of this residue most closely correlates with p70S6K activity in vivo 
(Pullen et al., 1998; Weng et al., 1998). The phosphorylation status of p70S6K at this 
residue is commonly used as an indicator of p70S6K activity (e.g. Aoki et al., 2001) 
and it was also employed in this study.
J774.2 macrophages were treated with IFN-y for several time periods, whole 
cell extracts were prepared (using buffers containing phosphatase- and protease- 
inhibitors) (Section 2.6.1), and these were subjected to western blot analysis using an 
antibody specific for p70S6K-Thr389 (Section 2.6.3.2). The antibody detects p70S6K 
at residue Thr389 and also detects p85S6K (phosphorylated at the analogous site, 
Thr412). p85S6K is a second form of p70S6K, which is derived from the same gene
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and is identical to p70S6K except for 23 extra residues at the amino-terminus that 
encode a nuclear localisation signal (Aoki et al., 2001). Extracts from untreated cells 
at the start and the end of the experiment were included for comparison. Figure 5 .11 
shows that IFN-y causes an increase in the phosphorylation of the kinase at this 
residue, with the maximal activity being attained at 20 hours. Control western blots 
with antibodies against P-actin showed that the amount of protein in each sample 
remained constant.
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Figure 5.11: Effect of IFN-y on phospho-p 70S6K- Thr389 phosphorylation in J774.2 
macrophages
The experimental approach was identical to that described in Figure 5.8 except that 
an antibody against phospho-p 70S6KThr389 was used. The graph was constructed 
using results from two separate experiments.
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5.2.2.4 Effect o f  an inhibitor o f mTOR/p70S6K on the binding o f  Spl/Sp3 to the LPL 
promoter
Figure 5.11 reveals that p70S6K is potentially involved in IFN-y-mediated signalling 
in J774.2 macrophages. Besides PDK1, the phosphorylation and activation of p70S6K 
is also commonly dependent on mammalian target of rapamycin (mTOR) (Stolovich 
et al., 2002). The mTOR protein (Mr 290kDa) is highly conserved from yeast to 
mammals. Its C-terminus is homologous to the catalytic domain of PI3K, so mTOR is 
actually a member of the phosphoinositide kinase-related kinase (PIKK) family 
(Bjomsti and Houghton, 2004). The C-terminus of mTOR catalyses the 
phosphorylation of hydrophobic residues in p70S6K (Kozma and Thomas, 2002) 
while the N-terminus contains a series of protein interaction motifs referred to as 
HEAT (after the proteins that contain these motifs, these are Huntingtin, EF3, A 
subunit of protein phosphatase 2A and TOR) (Kozma and Thomas, 2002).
PKB phosphorylates the tuberous sclerosis complex proteins TSC1 (hamartin) 
- TSC2 (Tuberin), which normally negatively regulate mTOR (Figure 5.10) and so 
indirectly, PKB modulates the activity of mTOR (Gao and Pan, 2001; Bjornsti and 
Houghton, 2004).
It is known that mTOR controls the transcription and translation of proteins 
via the increased phosphorylation of the eukaryotic initiation factor (eIF4E) inhibitor, 
4E binding protein (4E-BP1) (Figure 5.10; Brunn et al., 1997) and recent studies 
indicate that mTOR is a central controller, integrating a plethora of signalling 
pathways (Bjomsti and Houghton 2004). In addition to its critical function in insulin 
signalling (Jiang and Zhang, 2002), the protein has also been shown to be involved in 
IL-2-induced activation of human telomerase reverse transcriptase (Kawauchi et al.,
2005). Furthermore, LPS and IFN-y have been shown to activate the mTOR pathway 
which converges with the PI3K pathway to regulate STATI-dependent transcription 
of pro-apoptotic and pro-inflammatory genes (Kristof et al., 2003).
To determine whether mTOR was also involved in the IFN-y-mediated 
regulation of LPL gene expression, the effect of an inhibitor of the pathway, 
rapamycin, on the binding of Spl/Sp3 to the LPL promoter was investigated. 
Rapamycin functions by binding to mTOR forming a gain-of-function inhibitory 
complex that selectively blocks p70S6K phosphorylation (Thomas and Hall, 1997).
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Whole cell extracts were prepared from J774.2 cells that were incubated with 
IFN-y in the absence or the presence of different concentrations of rapamycin. The 
choice of the rapamycin concentration was based on previous work in our laboratory 
and previously published studies; for example Lehman et al., 2003. The control 
sample was treated with an equal volume of DMSO present in the maximal dose of 
the inhibitor. EMSA was carried out using the +9/+49 and +46/+90 oligonucleotides, 
and the reaction mixture was separated by polyacrylamide gel electrophoresis 
(Section 2.6.2.4). The gels were dried and visualised by autoradiography. Figure 5.12 
shows that the IFN-y-mediated decrease in the binding of Spl/Sp3 to the recognition 
sequence in the LPL promoter was inhibited by rapamycin, thereby indicating a role 
of mTOR-p70S6K in the response.
5.2.2.5 Effect o f  rapamycin on the IFN-y-mediated reduction o f  LPL mRNA 
expression in THP-1 macrophages
So far it has been shown that IFN-y activates PKB (Figure 5.5) and that this leads to a 
decrease in the binding of Spl and Sp3 to their recognition sequence in the LPL gene 
(Figure 5.6) and a reduction in its promoter activity (Figure 5.2). In addition to PKB, a 
role for another downstream target of PI3K, mTOR/p70S6K, has been identified. 
However, these studies were restricted to the analysis of phospho-p70S6K levels and 
the effect of the inhibitor, rapamycin, on the binding of Spl/Sp3 to the LPL promoter. 
The action of an inhibitor of these pathways on the IFN-y-mediated decrease in the 
expression of the endogenous LPL gene has not been investigated, and was therefore 
studied.
For this, THP-1 monocytes were differentiated into macrophages by treatment 
with PMA for 24 hours (Section 2.2.7). THP-1 macrophages were then pre-treated for 
1 hour with rapamycin prior to treatment with IFN-y for 20 hours. Since 500nm of 
rapamycin was the minimum concentration required to significantly inhibit IFN-y- 
mediated Spl/Sp3 binding, this concentration of inhibitor was used in this 
experiment. RT-PCR was performed with primers against LPL or GAPDH and the 
products were analysed by agarose gel electrophoresis (Section 2.5.2.3). Figure 5.13 
shows that rapamycin prevents the IFN-y-mediated reduction of LPL expression by 
approximately 50%.
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Figure 5.12: The effect o f  rapamycin on IFN-y-mediated changes in binding to the 
LPL promoter
J774.2 macrophages were either left untreated or incubated with IFN-y (lOOOU/ml) 
alone or in combination with the indicated concentration o f rapamycin (Rapa) for 20 
hours. Whole cell extracts (5pg) were subjected to EMSA using radiolabelled 
oligonucleotides corresponding to the +9Z+49 (A) or the +46/+90 (B) regions o f  the 
LPL gene. These results shown are representative o f  two independent experiments.
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Figure 5.13: Effect of rapamycin on IFN-y-reduced expression of LPL mRNA in 
THP-1 macrophages
THP-1 monocytes were differentiated with PMA (0.16pM) fo r  24 hours. Macrophages 
were then either left untreated (Cont), or exposed to IFN-y (IFN; lOOOU/ml) in the 
absence or presence o f rapamycin (500nM) fo r  20 hours. RT-PCR was carried out 
using primers against LPL (A) and GAPDH (B). PCR products were subjected to 
electrophoresis using a 1.5% (w/v) agarose gel. Product size was confirmed using 
lOObp molecular weight markers (M). The reaction included a control (-RT) with 
RNA from untreated cells (Cont) in which no reverse transcriptase was added during 
the cDNA synthesis step. No signal was obtained from this sample, indicating that 
there was no genomic DNA contamination in the samples. The signals fo r  each 
sample were determined by densitometric analysis and plotted on a bar chart (C). The 
LPL/GAPDH ratio in macrophages not treated with IFN-y has been designated as 
100% with ratios o f other samples represented relative to this value. These results are 
representative o f two independent experiments.
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5 .2.3 Effect of IFN-y on downstream effectors of PKB
In order to further elucidate the role of the PI3K/PKB pathway in the IFN-y-mediated 
regulation of LPL gene expression, it was necessary to get further insights into the 
downstream targets of the pathway. More than fifty proteins have been identified as 
putative substrates for PKB (Hanada et al, 2004; Figure 5.14). It was not possible to 
determine the role o f each of these downstream components in the IFN-y-mediated 
decrease in LPL gene expression because of time restraints. However, the role o f two 
targets, GSK3 and forkhead transcription factor, was investigated in more detail 
because, similar to LPL, they have been implicated to play a pivotal role in diabetes, 
obesity and cardiovascular disease (Haq et al., 2000; Furuyama et al., 2003).
Activate PKB
Caspase-9 mTOR eNOSBad GSK3 FOX Raf
Figure 5.14: Some o f  the targets o f  PKB phosphorylation
Abbreviations; Bad, Bcl-associated death promoter; GSK3, glycogen 
synthase kinase 3; FOX, Forkhead transcription factors; mTOR, 
mammalian target o f rapamycin; Raf, a Mitogen-activated protein 
kinase kinase; e NOS, endothelial nitric oxide synthase (from 
Vanhaesebroeck and Alessi, 2000).
5.2.3.1 Effect o f IFN-y on the phosphorylation o f GSK3 in J774.2 macrophages 
GSK3 was one of the first identified substrates of PKB (Burering and Coffer, 1995). It 
was originally identified as the kinase responsible for the phosphorylation of glycogen 
synthase 3, a key enzyme in the regulation of glycogen metabolism and blood glucose 
levels. Since, a growing number of GSK3 substrates have been identified a more 
general role for this kinase has been delineated in the regulation of gene expression 
during cellular metabolism and differentiation (van Weeren et al., 1998).
Two mammalian isoforms of GSK3 have been identified; GSK3-a and GSK3- 
|3 that are encoded by two different genes (Woodgett, 1990). GSK3 is constitutively 
active in unstimulated cells; phosphorylation of GSK3-a at Ser21 and GSK3-p at Ser9
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by PKB renders the enzyme inactive (Stambolic and Woodgett, 1994). As a result 
pathways which are normally repressed by GSK3 become active (Stambolic and 
Woodgett, 1994).
Abnormal activity of GSK3 is associated with various diseases (Alsonso and 
Martinez, 2004). For example, it is clear that insulin suppresses the activity of GSK3, 
in diabetes (van Weeren et al., 1998). In addition, GSK3-P has been shown to 
negatively regulate hypertrophy, which leads to heart failure (Haq et al., 2000). 
GSK3-P is therefore a potential candidate that may be involved in the IFN-y-mediated 
regulation of LPL, and this might contribute to atherosclerosis. It was therefore 
decided to investigate the phosphorylation status of GSK3-p. For this J774.2 cells 
were treated with IFN-y for different periods of time. Untreated cells at the start and 
the end of the experiment were included for comparison. Whole cell extracts were 
prepared using phosphatase- and protease-free buffers (Section 2.6.1) and extracts 
were subjected to western blot analysis using an antibody specific for GSK3-P 
phosphorylated at Ser9, the residue that is phosphorylated by PKB. The membrane 
was then re-probed with anti-P-actin to assess the loading of the gels. Figure 5.15 
shows that the level of GSK3-p-Ser9 is not affected by exposure of the cells to IFN-y.
To confirm that GSK3 was not involved in the IFN-y-mediated regulation of 
LPL gene expression, the effect of its inhibitor, SB415286 (which is ATP- 
competitive), on the binding of Spl and Sp3 to the LPL promoter was assessed. The 
concentration of the inhibitor used was based on previously published studies (e.g. 
Roberts et al., 2004). J774.2 macrophages were treated with IFN-y for 20 hours in the 
absence or the presence of the indicated concentration of SB415286. The control 
sample was treated with an equal volume of DMSO present in the maximal dose of 
the inhibitor. Whole cell extracts were prepared (Section 2.6.1) and subjected to 
EMSA (Section 2.6.2). Figure 5.16 shows that the inhibitor did not substantially 
prevent the IFN-y mediated reduction of binding of Spl/Sp3 to the LPL promoter 
region, thereby suggesting that GSK was not involved in the response.
To confirm that GSK3 was not involved in the IFN-y-mediated decrease in 
LPL gene expression, the action of the inhibitor SB415286 on endogenous LPL gene 
expression was analysed. For this, THP-1 monocytes were differentiated into 
macrophages by treatment with PMA (Section 2.2.7). THP-1 macrophages were pre-
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treated for 1 hour with SB415286 prior to incubation alone or with IFN-y for 20 
hours. The concentration of inhibitor used was based on the previous experiment 
(Figure 5.16). RT-PCR was performed with primers against LPL or GAPDH and the 
products were analysed by agarose gel electrophoresis (Section 2.5.2.3). Figure 5.17 
shows that SB415286, which inhibits GSK3, did not affect the IFN-y-mediated 
reduction of LPL expression.
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Figure 5.15: Effect o f  IFN-y on the levels o f  phosho-GSK3-p-Ser9 in J774.2
macrophages.
The experimental approach was identical to that described in Figure 5.8 except that 
phospho-GSK3-p-Set* primary antibody was used. The mean 1SD was calculated 
form three independent experiments.
Cont
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5nM 25nM 50^iM5nM 25nM 50^iMSB415286
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+9Z+49 +46/+90
Figure 5.16: The effect o f  SB415286 on the IFN-y-mediated changes in the binding 
o f Spl/Sp3 to the LPL promoter
J774.2 macrophages were either left untreated or incubated with IFN-y (lOOOU/ml) in 
the absence or the presence o f the indicated concentrations o f SB415286for 20 hours. 
Whole cell extracts (5/ug) were subjected to EMSA using radiolabelled 
oligonucleotides which recognise +9Z+49 (A) or +46/+90 (B) regions o f the LPL 
promoter. These results are representative o f two independent experiments.
159
Chapter 5- Role o f PI3K in the IFN-y-mediated reduction o f LPL gene expression
SB415 (25|xM)
Cont IFN-y IFN-y
LPL
B
GAPDH
C
120 i
2+-coo 80 -
* 4 -o
5? 60 -
xQa.
<
0
-I
CL-I
40 -
20 -
Cont IFN SB415 SB415 + IFN
Figure 5.17: Effect o f  SB415286 on IFN- y-redu ced expression o f  LPL mRNA in 
THP-1 derived macrophages
The experimental approach was identical to that described in Figure 5.13 except that 
SB415286 (SB415) was used. Results are representative o f two independent 
experiments.
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5.2.3.2 Effect o f  IFN-y on the level o f  activated FRKHS in J774.2 macrophages 
Another key downstream target of PKB is the family of Forkhead transcription factors 
(FOX). FOX represents a large family consisting of FRHD, FKHRLI and AFX 
(Brunet et al., 1999; Rena et al., 1999; Guo et al., 1999). FOX factors bind as a 
monomer to the consensus sequence TTGTTTAC, and initiate the transcription of 
target genes (Furuyama et al., 2000). FOX are phosphorylated in vivo on multiple Thr 
and Ser residues. Three of these residues lie within a consensus sequence for 
phosphorylation by PKB and these residues have been found to be phosphorylated by 
the enzyme in vitro (Burnet et al, 1999; Rena et al., 1999). It seems that 
phosphorylation by PKB inhibits gene transcription by the factors. One proposed 
mechanism is that phosphorylation induces their translocation from the nucleus to the 
cytoplasm, and therefore away from their target genes (Guo et al., 1999).
One member, FRHD, has been shown to play an important role in the 
regulation of energy metabolism in response to pathological conditions (Furuyama et 
al., 2003). Given the critical role of LPL in metabolism, it was possible that FRHD 
could be involved in the regulation of LPL gene expression. In addition, Braun and 
Suske (1998), have shown that the FOX family members, HNF3-a and -p, strongly 
enhance Spl mediated promoter activation of uterglobin (a protein induced by 
progesterone that binds phospholipase A2). The phosphorylation of FRHD-Ser256 has 
been shown to alter the binding activity of FRHD (Zhang et al., 2002). It was 
therefore decided to determine whether IFN-y had any effect on the levels of phoshpo- 
FRHD-Ser , which has also been shown to be a good indicator of the activated form 
of this protein (Guo et al., 1999; Zhang et al., 2002).
J774.2 macrophages were treated with IFN-y for the indicated periods of time, 
whole cell extracts were prepared (using buffers containing phosphatase- and 
protease-inhibitors) (Section 2.6.1), and subjected to western blot analysis using an 
antibody specific for phosphorylated FRHD-Ser256 (Section 2.6.3). Extracts from 
untreated cells at the start and the end of the experiment were included for 
comparison. The membrane was re-probed using anti-P-actin as a loading control. 
Figure 5.18 shows that IFN-y has no significant effect on the level of phospho- 
FRHD256, thereby suggesting that it does not play a role in the IFN-y-mediated 
regulation of LPL gene expression.
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Figure 5.18: Effect o f  IFN-y on the level o f  phospho-FRHD-Ser256 in J774.2 
macrophages
The experimental approach was identical to that described in Figure 5.8 except that 
phospho-FRHD-Ser56 primary antibody was used. The mean \SD was calculated 
form three independent experiments.
162
Chapter 5- Role o f  PI3K in the IFN-y-mediated reduction o f  LPL gene expression
5.3 D is c u s s io n
It has been shown that PI3K is involved in the IFN-y-mediated reduction of LPL gene 
expression (Chapter 3) and so a further analysis of the pathway was required. The aim 
of this chapter was to investigate the role of the PI3K pathway and its different 
components in more detail.
It is well known that PKB is a downstream effector of the PI3K pathway. The 
kinase has been shown to mediate the effects of a number of cytokines such as the 
TGF-p induction of fibronectin expression (Ghosh Choudhury and Abbound, 2004) 
and interleukin-i-g- (IL-1P) mediated secretion of a matrix metalloproteinase (Ruhul 
Amin et al., 2003). To establish whether it was involved in the regulation of LPL 
expression by IFN-y, it was decided to study the effect of a DNPKB construct on the 
IFN-y-mediated changes in the activity of the LPL promoter. It was shown that when 
the LPL promoter-luciferase gene DNA construct containing the IFN-y-REs was 
transfected with the DNPKB construct, the consistently noted reduction in LPL 
promoter activity normally seen with IFN-y treatment was abolished (Figure 5.2). 
This confirmed that PKB was one of the downstream PI3K effectors involved in the 
IFN-y-mediated response. It was therefore decided to study the activation of this 
kinase in more detail.
Many studies have used phospho-specific antibodies to determine the 
phosphorylation state of key residues of PKB which are necessary for the activation of 
the enzyme (e.g. Ma et al, 2004, Wang et al., 1999; Qiu et al., 2004), and this 
provides a good indication of PKB activity. It was found that IFN-y treatment caused 
an increase in the phosphorylation of PKB at Ser473; this increased shortly after 
treatment and was highest at about 12-20 hours (Figures 5.3). On the other hand, the 
phosphorylation of the Thr308 peaked at about 3 hours after IFN-y treatment before 
gradually declining (Figure 5.4). Since the phosphorylation status of the two residues 
was different, it was decided to analyse the PKB activity directly. This was achieved 
using an in vitro kinase assay where its ability to phosphorylate GSK3-a-Ser21 and 
GSK3-p-Ser9 was assessed. Increased PKB activity was observed in response to IFN- 
y with the activity gradually increasing until it peaked at 20 hours (Figure 5.5). The 
activity followed a similar pattern as that of Ser473 phosphorylation but not Thr308
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phosphorylation. An explanation may be that phosphorylation of both of these 
residues is necessary to achieve maximal activity of the kinase; indeed this has been 
shown in several previous studies (e.g. Filippa et al., 2000). As described earlier, it is 
now known that the phosphorylation of PKB-Thr is dependent upon PDK1, which 
has a number of other substrates (Anderson et al., 1998; Alessi et al., 1997; Stokoe et 
al., 1997), whilst the kinase responsible for the phosphorylation of the Ser473 residue 
remains to be determined. Therefore, an additional explanation for the differences in 
the phosphorylation between Ser473 and Thr308 of PKB may be that PDK1 initially 
increases the phosphorylation of Thr and then acquires higher affinity for another 
substrate.
PKB can regulate gene expression via several transcription factors. For 
example, PKB can regulate the forkhead family of transcription factors by 
phosphorylation. This results in the translocation of forkhead members from the 
nucleus to the cytoplasm resulting in decreased transcriptional activity (Rena et al., 
1999; Biggs et al., 1999; Wolfrum et al., 1999). In addition, cyclic AMP-response 
element binding protein (CREB) is phosphorylated by PKB (at Ser133) and this causes 
an increase in the activity of the transcription factor (Du and Montminy, 1998). Infact, 
IFN-y has been shown to induce the phosphorylation of CREB at this residue; 
however, this was shown to result from CK2 stimulation (Mead, 2002) and so was not 
directly relevant to studies presented in this chapter. An important finding was that 
incubation of whole cell extracts with the PKB enzyme resulted in a decrease in the 
binding of Spl/Sp3 in the extracts to the LPL promoter (Figure 5.6). However when 
the enzyme was incubated with recombinant Spl protein (and ATP), there was no 
effect on binding (Figure 5.7). This suggests that PKB does not directly affect Spl 
binding but rather contributes to its regulation through another (or several other) 
protein(s) within cell extracts. Indeed residues in the middle of the glutamine 
activation domains of Spl have been shown to interact with other proteins such as 
TFII110 (Gill et al., 1994; Hoey et al., 1993). However the nature of the proteins in 
the regulation of LPL expression remains unidentified.
Although it is well established that PDK1 is responsible for the 
phosphorylation of PKB-Thr308, it has other substrates. For example it is necessary for
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the phosphorylation and activation of p70S6K (Alessi et al, 1998). As with many 
kinases, p70S6K is known to be phosphorylated at a number of sites (Pullen and 
Thomas, 1997; Weng et al, 1998) and this can be indicative of its activation 
(Romanelli et al, 1999). It was shown here that phosphorylation of p70S6K in 
response to IFN-y followed a similar pattern as that of PDK1, that is, the 
phosphorylation of both kinases gradually increased in response to IFN-y and 
maximal phosphorylation was achieved after 20 hours of IFN-y treatment (Figures 5.8 
and 5.11). It was therefore concluded that, in response to IFN-y, PDK1 not only 
phosphorylates (and hence contributes to the activation of) PKB but also 
phosphorylates p70S6K. The kinetics of PDK1 phosphorylation was more similar to 
p70S6K-Thr389 than PKB-Thr308 phosphorylation. It is therefore possible that PDK1 
initially targets PKB-Thr308 and then acquires a greater affinity to p70S6K389. This 
needs to be investigated further. As mentioned previously, co-localisation of PDK1 to 
the plasma membrane is necessary for the phosphorylation of PKB-Thr308 whereas 
PDK1 phosphorylates p70S6K in the cytosol (Biondi et al, 2001; Collins et al, 
2003). To gain a clearer insight into the activity of PDK1, the location/co-localisation 
of PDK1 in response to IFN-y needs to be studied by immunofluorescence analysis 
using PDK1 fluorescent antibodies.
From the studies presented in this chapter, it can be concluded that IFN-y 
signalling involves p70S6K, this is supported by a recent study by Lekmine et al, 
(2004). This group also showed IFN-y-dependent activation of p70S6K. They found 
that p70S6K was regulated by its interaction with mTOR (a common downstream 
effector of PI3K). Since p70S6K is commonly regulated by mTOR (Schmelzle and 
Hall, 2000), it was decided to determine whether this protein was also involved in the 
IFN-y-regulated LPL expression. Indeed the mTOR has been shown to regulate the 
expression of several genes including STAT-1 (Kristolff et al., 2003) and LPL itself 
(Kreamer et al, 1998). It was shown that the mTOR/p70S6K inhibitor rapamycin 
could prevent the IFN-y-mediated reduction of Spl/Sp3 binding to the LPL promoter 
(Figure 5.12) and the reduction of LPL mRNA expression (Figure 5.13). From this, it 
was concluded that the mTOR/p70S6K signalling pathway, along with the PKB 
pathway, is involved in the IFN-y-mediated reduction of LPL gene expression. Indeed
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several studies have shown an interaction between these two pathways in the 
regulation of gene expression (Kawauchi et al, 2005; Leuchuga et al, 2004).
It should also be noted that another group of factors which are commonly 
regulated by mTOR exist. These are the translational initiation factors 4E-BP1 and 
eIF-4E (Raught et al, 2001; Figure 5.10). These factors affect the translation of 
proteins and so it may be that they are involved in the decreased translation of Sp3 in 
response to IFN-y (Figure 4.7). However, to our knowledge a previous link between 
mTOR and Sp3 has not been identified. In addition, since the IFN-y-mediated 
regulation of LPL gene expression results from reduced mRNA levels, these 
translational factors are not likely to be directly involved in the regulation of the 
enzyme.
Active PTEN acts antagonistically to PI3K by converting PtdIns-(3,4,5)-P3 to 
PtdIns-(4,5)-P2. Therefore, the activation of PI3K leads to an increase in the levels of 
the PTEN substrate; this could lead to the activation of PTEN. PTEN can be regulated 
through phosphorylation-dependent modulation of protein stability (Leslie and 
Downes, 2002; Vazquez et al, 2000; Torres and Pulido, 2001). PTEN stability is 
inhibited by its phosphorylation. Since PTEN phosphorylated at Ser has previously 
been investigated in detail (Birle et al, 2002), this site was chosen to investigate the 
activation of PTEN in this project. Examination of the phosphorylation status of 
PTEN showed that soon after exposure to IFN-y the phosphorylation of PTEN-Ser380 
was decreased and this returned to normal levels by 20 hours (Figure 5.9). The results, 
therefore, indicate that the activity of the enzyme is turned on shortly after IFN-y 
treatment and returns to normal levels after prolonged treatment and support the 
theory that IFN-y induces PI3K activity. However, it has been proposed that PTEN is 
also phosphorylated at a number of other sites; these are Thr382, Thr383, and Ser385 
(Vazquez et al, 2000). Therefore, the phosphorylation status of these residues needs 
to be explored before any firm conclusions can be made.
A clear understanding of how cells regulate the activity of PTEN is yet to 
emerge. CK2 has been shown to catalyse the phosphorylation of PTEN (Torres and 
Pulido, 2001). CK2 could, therefore, be responsible for controlling the 
phosphorylation and activation of PTEN in J774.2 cells. This possibility needs to be
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investigated further and may be achieved by studying the effect of the CK2 inhibitor, 
apigenin or the dominant negative form of CK2 on the phosphorylation of PTEN.
A number of downstream effectors of PKB exist (Figure 5.14). Two of the 
most common include GSK3 and FRHD, which were investigated in more detail 
because, similar to LPL, they have been implicated to play a pivotal role in diabetes, 
obesity and cardiovascular disease (Haq et al., 2000; Furuyama et al., 2003). It was 
shown that the phosphorylation status of these proteins was not affected by IFN-y 
(Figure 5.15 and 5.18) suggesting that these pathways are not involved in IFN-y- 
mediated regulation of LPL expression. Furthermore, it was shown that the inhibitor 
of the GSK3 pathway did not affect the IFN-y-mediated decrease in binding of 
Spl/Sp3 to the LPL promoter (Figure 5.16) or the IFN-y-mediated decrease in LPL 
mRNA expression (Figure 5.17), thereby confirming that this pathway was not 
involved in the IFN-y-mediated regulation of LPL. It is therefore likely that PI3K 
mediates its effects on LPL through mTOR/p70S6K and other downstream 
components of PKB. This needs to be investigated further in detail.
From the results gathered in this chapter, a potential mechanism for the 
involvement of the PI3K pathway in the IFN-y-mediated regulation of LPL gene 
transcription can be drawn and is illustrated in Figure 5.19.
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Figure 5.19: Schematic representation of mechanisms involved in the regulation of 
LPL gene transcription by IFN-y based on results from this chapter
IFN-y stimulates PI3K and PDK1 activity. This leads to an increase in the 
phosphorylation and activity o f PKB. Active PKB contributes to the decreased 
binding o f Spl/Sp3 to the LPL promoter. It has also been shown that p70S6K and 
mTOR are involved in the IFN-y-mediated suppression o f LPL whilst FRKHD and 
GSK3 kinase are not. IFN-y has also been shown to increase the activity o f PTEN.
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6.1 O verview  o f  results presented in this thesis
LPL plays an important role in the control of lipid metabolism and transport but has 
also been implicated in the initiation and progression of atherosclerosis. The enzyme 
is expressed at high levels within the atherosclerotic plaque, where it is mainly 
associated with monocyte-derived macrophages. The LPL expressed by macrophages 
contributes to the initiation and the progression of foam cells, which represent a 
critical stage in the onset of the disease. Macrophage LPL therefore represents an 
excellent target against atherosclerosis and it is crucial that the processes which 
regulate its expression are understood. It is hoped that such studies will not only 
enhance our understanding of foam cell formation and atherosclerosis but, in the long 
term, may also lead to the identification of potentially novel targets for therapeutic 
intervention of the disease.
Macrophage LPL can be regulated by many factors; for example glucose, 
hydrogen peroxide (a source of oxidant stress/reactive oxygen intermediates), 
Platelet-Derived Growth Factor (PDGF) and Macrophage Colony-Stimulating Factor 
(M-CSF) all increase its expression (Sartippour et at., 1998; Sartippour and Reiner, 
2000 [a]; Reiner et al., 1996; Michaud and Reiner 2001; Beuchamp and Reiner, 2000; 
Inaba et al., 1995; Mori et al, 1991). In contrast, several factors suppress its 
expression or activity; for example, bacterial lipopolysaccharide (LPS), 
prostaglandins, oxidised LDL metabolites and some cytokines (Mead and Ramji, 
1999). Since inhibition of macrophage LPL expression represents a potential therapy 
against atherosclerosis, it is essential that a thorough understanding of the 
mechanisms by which this is achieved are understood in detail.
An understanding of the regulation of macrophage LPL by TNF-a and IFN-y 
has already been established. It has been shown that these cytokines decrease the 
expression of macrophage LPL at the transcriptional level (Tengku-Muhammad et al., 
1998 [d]). For example, IFN-y has been shown to substantially decrease macrophage 
LPL mRNA expression, activity and protein levels in several cell lines and primary 
isolates (Tengku-Muhammad et al., 1996; 1998 [a]; Jonasson et al., 1990; Table 3.1). 
Given the presence of IFN-y in the atherosclerotic lesion, its effect on macrophage 
LPL is likely to contribute to the onset of the disease. It is therefore necessary to
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investigate the mechanisms underlying the IFN-y-mediated reduction of macrophage 
LPL expression in more detail, and this formed the focus of my thesis.
It had already been established that IFN-y causes a decrease in the binding of 
the Spl and Sp3 transcription factors to the IFN-y-RE in the LPL promoter and that 
this leads to a decrease in the activity of the promoter and a corresponding reduction 
in the transcription of the LPL gene (Hughes et al., 2002).
Since TNF-a had also been shown to decrease LPL mRNA expression and to 
act in synergy with IFN-y (Tengku-Muhammad et al., 1998 [a] [b]), it was decided to 
determine whether this cytokine could also affect the binding of Spl and Sp3 to the 
LPL promoter. This objective was investigated by EMSA, a technique that studies 
DNA-protein interactions. It was found that TNF-a had no effect on the binding of 
Spl/Sp3 to the regulatory regions examined, suggesting that the action of TNF-a was 
not mediated through Spl/Sp3. TNF-a also had no effect on the IFN-y-mediated 
reduction in binding of these transcription factors suggesting that the previously noted 
synergism between the two cytokines is unlikely to be mediated through Spl/Sp3. It 
was decided therefore to focus further studies on the effect of IFN-y on the binding of 
Spl/Sp3 to their recognition sequence in the LPL promoter.
Since cytokines, as with many extra-cellular mediators, exert their effects 
through intra-cellular signal transduction pathways, the identification of these 
pathways is important to gain an understanding of how the mediators function and to 
assist in the development of new therapeutic strategies. Therefore, the main objective 
of the project was to investigate the signal transduction pathways that were 
responsible for the IFN-y-mediated regulation of LPL expression. This was achieved 
initially through the use of several pharmacological inhibitors that can block specific 
signalling pathways. It was found that inhibitors specific for several pathways (CK2, 
PI3K and JAK2) could prevent the IFN-y-mediated decrease in Spl/Sp3 binding to 
the LPL promoter region. It was also shown that these signalling pathways were 
involved in the IFN-y-mediated suppression of LPL mRNA expression.
Since studies were carried out in more than one type of macrophage source the 
results obtained are not a peculiar property of a specific cell line. The results therefore
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implicated a key role for CK2, PI3K and JAK2 in the action of IFN-y on LPL gene 
expression and provided a basis for further investigation of these pathways.
In vitro activity assays revealed that IFN-y could increase the activity of both 
the catalytic subunits of CK2. The use of inhibitors showed that this IFN-y-mediated 
increase in CK2 activity was independent of JAK2 and PI3K.
It was also shown that when the action of CK2 was inhibited using a dominant 
negative construct, the IFN-y-mediated decrease of LPL promoter activity was 
abolished. The promoter region analysed contained Spl and Sp3 binding sites, thereby 
suggesting that the action of CK2 was mediated through these two transcription 
factors. Consistent with this finding, co-immunoprecipitation experiments showed 
that IFN-y was able to induce the association of CK2 catalytic subunits with Spl and 
Sp3.
It was also shown that when whole cell extracts were incubated with the 
recombinant CK2 holoenzyme and then subjected to EMSA, the changes in binding of 
Spl/Sp3 to the LPL promoter could mimic those seen when cells were exposed to 
IFN-y. In addition, studies using recombinant Spl protein in EMSA showed that 
incubation with CK2 results in a decrease in binding to its recognition sequences 
present in the LPL promoter. These results therefore confirm that Spl acts as a 
substrate for CK2. Furthermore in vitro kinase assays revealed that Spl is 
phosphorylated directly by CK2.
These results provide a potential mechanism for the regulation of Spl binding 
by CK2. That is, stimulation of the cells with IFN-y causes an increase in the activity 
of the CK2 enzyme which leads to its increased association with Spl. Contact 
between the two proteins leads to increased phosphorylation of Spl which in turn 
leads to decreased binding to the LPL promoter. Since the Spl binding sites are 
conserved in human, mouse and the rat LPL promoter (Figure 3.17) this represents a 
potentially evolutionary conserved mechanism.
Inhibitor studies also revealed that PI3K is involved in the IFN-y-mediated 
decrease in Spl/Sp3 binding to the LPL promoter and that this leads to a decrease in 
the expression of LPL mRNA. Therefore, another objective of this project was to
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characterise the role of the PI3K signalling pathway in such an action of IFN-y, and to 
identify potential downstream target(s) which were involved in this response.
PKB is one of the most common downstream PI3K effectors; the results 
demonstrated that IFN-y induced the phosphorylation of PKB and that the 
phosphorylation of one of the PKB residues corresponded to its increased activity. 
Furthermore it was shown that if the action of the enzyme was inhibited (using a 
dominant negative construct), the IFN-y-mediated decrease of LPL promoter activity 
was abolished. PKB is therefore an important factor in the IFN-y-mediated 
suppression of LPL gene expression. It was also shown that PKB could significantly 
decrease the binding of whole cell extracts to the Spl/Sp3 recognition sequence in the 
LPL promoter to levels seen in IFN-y treated cells. However, this enzyme was not 
sufficient to inhibit the binding of recombinant Spl to the region. It is therefore 
proposed that the action of PKB on Spl/Sp3 is mediated through downstream 
component(s).
The effect of IFN-y on the phosphorylation of several other downstream PI3K 
effectors was also analysed. The results showed that two of these, one, a member of 
the forkhead family of transcription factors and the other, GSK3, were not involved in 
this action of IFN-y. On the other hand the phosphorylation of p70S6K was increased 
by IFN-y. An inhibitor of mTOR, which is often associated with p70S6K, was used to 
confirm that this pathway was involved in the IFN-y-mediated decrease in Spl/Sp3 
binding to the LPL promoter.
The combination of results gathered in this thesis and other studies have 
identified at least four signal transduction pathways that are involved in the IFN-y- 
mediated suppression of LPL gene expression, and have eliminated the involvement 
of others (Table 6.1).
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Table 6.I: Signalling pathways involved in the IFN-y-mediated 
reduction o f macrophage LPL expression__________________
Pa th w a y In v o lv ed? Source
CK2 Yes Chapter 4; Hughes et al, 2002
PI3K/PKB Yes Chapter 5
JAK2 Yes Chapter 1
mTOR/p70S6K Yes Chapter 5
GSK-3 No Chapter 5
FRHD No Chapter 5
PKA No Tengku-Muhammad et al., 1999 (b)
PKC No Tengku-Muhammad et al., 1999 (b)
Nuclear Dep1 PK No Tengku-Muhammad etal., 1999 (b)
Abbreviations: CK2, Casein kinase 2; PI3K,
phosphoatidylinositol-3-kinase; PKB, protein kinase B; JAK2,
Janus Kinase 2; mTOR, mammalian target o f rapamycin; p70S6K, 
phospho- 70S-kinae; GSK3, glycogen synthase kinase; FRHD, 
forkhead transcription factor family member ; PKA, protein kinase 
A; PKC, protein kinase C; Dep PK, Dependent Protein Kinase
In summary the following conclusions can be made from the work presented 
in this thesis (also see Figure 6.1)
• CK2, JAK2 and PI3K are involved in the IFN-y-mediated reduction in 
binding of Spl/Sp3 to the LPL promoter and this regulation leads to decreased 
LPL gene expression
• CK2 binds to and phosphorylates Spl and this is involved in the IFN-y- 
mediated reduction in binding of the transcription factor
• PKB and mTOR/p70S6K are involved in the IFN-y-mediated reduction of 
Spl/Sp3 binding to the LPL promoter
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Figure 6.1: Schematic representation o f  the likely mechanisms involved in the 
regulation o f  LPL gene transcription by IFN-y as determined by studies in this 
thesis. Binding o f IFN-y to its receptor leads to the activation o f JAK2, this is likely to 
result in the phosphorylation and activation o f PI3K. Signalling cascades are set in 
motion which leads to the activation o f PI3K effectors including PKB and 
mTOR/p70S6K. IFN-y stimulation also leads to the activation o f CK2, via an unknown 
mechanism (?). The downstream effectors o f PKB and CK2 enter the nucleus where 
they interfere with Spl/Sp3 binding to the LPL promoter resulting in the reduced 
transcription o f the protein T). The alteration o f Sp3 binding could result from  
degradation o f the protein, possibly via the ubiquitination pathway (A). Decreased 
Spl binding has been shown to result from the phosphorylation o f the transcription 
factor (B) by CK2 and an unidentified PKB effector.
6.2 Future Studies
As a result of the work presented in this thesis, several avenues for further 
investigation have become apparent. Initially it was shown that TNF-a did not act 
through Spl and Sp3 to regulate LPL promoter activity. It would be interesting to find 
the transcription factors through which the action of this cytokine is mediated and to 
determine whether IFN-y acts in synergy to affect those transcription factors. This 
may be achieved in a similar manner to the identification of the IFN-y-RE, initially by 
using an extensive region of the LPL promoter and dissecting it to identify the 
minimal region necessary for the TNF-a-mediated response (Hughes et al, 2002).
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The identification of important sites could then be confirmed by mutagenesis studies 
(Hughes et al., 2002). DNA-protein interactions could also be studied using EMSA, 
DNase 1-footprinting, and choromatin immunoprecipitation (CHIP) assays. CHIP 
assays investigate DNA-protein interactions in vivo and use formaldehyde to cross­
link transcription factors to DNA. Cell nuclei are then lysed and the chromatin 
fragmented (by sonication). Fragmented chromatin is subjected to
immunoprecipitation using antibodies against the transcription factors. Cross-links are 
then reversed and the precipitated DNA is purified and subjected to PCR using 
specific primers against the promoter region of interest. The amount of promoter 
region amplified is indicative of the degree of DNA-protein binding. In conjunction 
with such approaches, the signalling pathways controlling the TNF-a regulation of 
LPL could be determined; for example by the use of pharmacological inhibitors, DN 
constructs or RNA interference.
In addition, the effect of the cytokine on identified transcription factors could 
be investigated. For example, TNF-a has been shown to decrease the binding of Oct-1 
to the octamer binding site (within positions -59 to +44) and NF-Y to the CCA AT box 
(within positions -180 to 160) of the LPL promoter (Morin et al., 1995). However, no 
studies have yet investigated the impact of these findings in TNF-a-mediated 
inhibition of LPL gene transcription. Therefore, it will be necessary to perform 
mutagenesis studies of these sites and to determine whether they confer the response 
to the heterologous promoter.
Of course, IFN-y and TNF-a are not the only cytokines which are involved in 
the regulation of LPL gene expression and it is expected that such studies will become 
necessary for numerous regulators of the enzyme.
Although the interaction of Spl and Sp3 to the LPL promoter has been shown 
by in vitro approaches such as EMSA, it will be important to confirm these 
interactions in vivo, for example by the use of CHIP assays (described above). In 
addition whilst it has been shown that Spl and Sp3 interact with CK2 it will be 
necessary to confirm this; for example by co-immunoprecipitation assays using 
immunoprecipitated CK2. It will also be necessary to expand these findings by 
identifying the region(s) in the transcription factors that bind to the two subunits of 
the enzyme. There are five important domains in the Spl protein, from the amino to
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the carboxyl terminus: two glutamine-rich activation domains (A and B); a 
modulating domain (C); the zinc-finger domain; and another activation domain (D) 
(Lee et al., 2005). DNA constructs specifying GST fusion proteins containing full- 
length Spl or domain A, domains A and B, the zinc finger and domain D in the 
pGex2TKMSC expression vector are available and could be used to map the site of 
interaction with CK2. This could be achieved using GST pull-down assays. For this, 
in v/Yro-translated [35S]-labelled CK2 -a  or -a ’ is incubated with full length or mutant 
GST-Spl proteins immobilised on the glutathione-sepharose beads, and the associated 
CK2 subunits are then analysed by SDS-PAGE followed by fluorography.
The consensus CK2 site in Spl (Thr579) has been shown to be phosphorylated 
by the enzyme (Armstrong et al, 1997; Leggett et al, 1995) and this phosphorylation 
has been shown to correlate with decreased activity of Spl-DNA binding. Phospho- 
peptide mapping or mass spectrometry could be used to determine the precise site of 
phosphorylation in response to IFN-y. Phospho-peptide mapping involves the 
labelling of proteins with radioactive [ P]. The labelled proteins are then digested by 
enzymes such as trypsin, and the phospho-peptides are analysed by electrophoresis in 
the first dimension and chromatography in the second dimension followed by 
autoradiography (Boyle et al., 1991). The phospho-peptides can be sequenced. Mass 
spectrometry can identify the increase in mass of the protein caused by 
phosphorylation and the phospho-peptides can also be sequenced. Once the precise 
phosphorylation site is determined, its importance could then be studied by 
mutagenesis.
It will also be necessary to investigate in more detail how IFN-y regulates CK2 
activity. In most cases IFN-y signalling is mediated through JAK-STAT pathways 
(Kotenko et al., 1999). However, it has been shown here that inhibition of JAK2 (by 
AG490) has no effect on the activation of CK2 by IFN-y, suggesting that JAK2 is not 
involved in this response. Since AG490 only inhibits JAK2, it is possible that JAK1 
or JAK3 can substitute for its loss (Zhang et al., 2000) and so the involvement of 
these kinases needs to be assessed. This could be achieved using a global tyrosine 
inhibitor that blocks the activation of all JAKs, or more specifically by RNA 
interference. If JAK1 or JAK3 are found to be involved in the activation of CK2 then 
it will be necessary to investigate this further; for example by investigating the
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interactions of JAK1 and JAK3 with CK2. Alternatively, if JAK1 and JAK3 are not 
found to be involved then it will be necessary to study the direct interaction between 
CK2 and the IFN-y receptor, for example by co-immunoprecipitation assays.
Localisation studies have shown that the CK2 subunits are not exclusively co­
localised (Stigare et al, 1993). Instead, it has been shown that the activation of CK2 
can result in the relocation of the enzyme. For example, the infection of cells with the 
HSV-1 virus causes redistribution of the CK2-a and -p  subunits from the nucleus to 
the cytoplasm (Koffa et al., 2003). It would be interesting to determine the location of 
CK2 subunits in un-stimulated cells and whether it undergoes relocation in response 
to IFN-y. For example, if the enzyme translocates to the nucleus this would 
substantiate the results shown in this thesis because Spl and Sp3 reside there. It would 
also be necessary to follow the localisation of the CK2 subunits and Spl/Sp3 at the 
same time. This could confirm their interaction. These studies could be achieved 
through the use of immunofluorescence, using commercially available fluorescent 
antibodies against the proteins of interest.
In contrast to Spl, information regarding the regulation of Sp3 by IFN-y is 
lacking. It has been shown that the steady state levels of the Sp3 protein in 
macrophages decrease by treatment of the cells with IFN-y, and that this does not 
result from a decrease in Sp3 mRNA expression. Mechanisms which may cause this 
suppression need to be considered, these include the degradation of the protein. 
Indeed it has been shown that Spl can be degraded by the proteosomal pathway 
(Mortensen et al., 1997) and therefore it is possible that this mechanism is responsible 
for the suppression of Sp3. Numerous inhibitors of the proteosomal pathway exist; for 
example, lactacystin, TPCK, TLCK and E64D. It will be necessary to use these 
inhibitors to determine whether they prevent the IFN-y-mediated decrease in Sp3 
polypeptide levels.
Since most proteins are ubiquitinated prior to degradation this possibility may 
also need to be investigated. IFN-y has been shown to induce the expression of at least 
two ubiquitination conjugating enzymes, UbcH5 and UbcH8, in several cell types 
(Nyman et al., 2000). It has been suggested that these enzymes constitute a novel 
intra-cellular signalling pathway that regulates the post-transcriptional control of gene
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expression in response to IFN-y (Kalvakolanu, 2003). It is possible therefore, that 
IFN-y causes the ubiquitination and subsequent degradation of Sp3. This could be 
investigated using western blot analysis of immunoprecipitates obtained using Sp3 
antiserum (from untreated and IFN-y-treated cells) with anti-ubiquitin immune sera.
If ubiquitination is found to be involved in Sp3 degradation, the 
phosphorylation of the protein should also be investigated, as phosphorylation often 
acts as a signal for ubiquitination. Since it is known that CK2 interacts with Sp3, it 
may be that CK2 is responsible for this phosphorylation. In vitro kinase assays using 
recombinant Sp3 and CK2 could be used to analyse this. These studies could be 
confirmed by monitoring the steady state levels of Sp3 in untreated and IFN-y- 
stimulated cells where the expression of CK2 has been ‘knocked down’ using RNA 
interference. If these results do show that CK2 phosphorylates Sp3 then it will be 
necessary to map the precise site of phosphorylation for example by phospho-peptide 
mapping or mass spectrometry (described previously).
Due to time restraints not all of the potential downstream effectors of PI3K 
have been investigated. The components involved in relaying the information of PKB 
to LPL promoter binding will need to be investigated in more detail. This should 
involve the analysis of the stress-activated protein kinase/c-jun N-terminal kinase 
(SAPK/JNK) or non-classical forms of PKC. In addition, it will be necessary to 
identify downstream targets of the p70S6K/mTOR pathway (such as the initiation 
factors, eIF2a and eIF-4E) that are involved in the IFN-y-mediated regulation of LPL 
expression. Identification of such pathways could be achieved through the use of 
specific pharmacological inhibitors, dominant negative constructs and phospho- 
specific antibodies.
In addition to LPL, analysis of promoter regions of several other genes that are 
expressed in monocyte/macrophages has revealed a potential role for Spl/Sp3. For 
example, Spl/Sp3 binding sites have been identified in regions that are crucial for the 
regulation of the scavenger receptor CD 163 and the ATP-binding cassette A 
transporter (ABCA1), both of which are involved in modulating cholesterol levels in 
macrophages (Ritter et al., 1999; Santamarina-Fojo et al., 2000). Interestingly, the 
expression of these genes is also inhibited by IFN-y (Buechler et al., 2000; Alfaro
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Loen et al., 2005). The role of Spl/Sp3 in such regulation clearly needs to be 
addressed and this may be achieved through the use of antisense technology or RNA 
interference to inhibit their expression. Indeed this has been achieved in several 
instances. For example, Verrecchia et al, (2001) defined the targets of Spl regulated 
genes on fibroblasts by the application of gene array technology on cells that had been 
stably transfected with an antisense Spl expression vector.
Finally whilst human cell lines have been analysed, the majority of studies in 
this thesis pertain to the murine cell line J774.2. Ultimately a drug for atherosclerosis 
prevention will be used in humans and so for our results to be fully relevant, they 
must all be reproduced in primary cultures of human macrophages.
6.3 W ider perspectives o f  this thesis
A novel mechanism for IFN-y signalling has been confirmed here, that is, the cytokine 
acts through Spl/Sp3 to exert its effects on LPL gene expression. As mentioned 
above, this mechanism may be responsible for the regulation of several other genes 
implicated in the pathogenesis of atherosclerosis. In fact Spl/Sp3 recognition 
sequences are present in the promoter regions of several genes expressed by 
macrophages; for example, carboxylesterase, which plays an important role in the 
defence mechanisms of the monocyte/macrophage system (Langmann et al., 1997) 
and the intergrins beta, C D llb  and CD lid , which play key roles in cell signalling 
along with the immune and inflammatory responses (Boring et al., 1998; Chen et al., 
1993; Noti, 1997). Additionally, an induction of the Spl/Sp3 binding activity has 
been reported during monocytic differentiation (e.g. Langmann et al., 1999; Ries et 
al., 1998). It is therefore likely that such a crucial role of Spl and Sp3, and the novel 
pathway of IFN-y action may extend to the constitutive and regulated expression of 
numerous genes in macrophages that are involved in cardiovascular disorders.
Although it has been shown that PI3K/PKB is involved in the decreased 
expression of macrophage LPL through IFN-y and that this is undoubtedly an anti­
atherogenic effect, other studies regarding this pathway have shown that PI3K is 
involved in the expression of pro-atherogenic genes. For example, PI3K has been 
shown to be involved in the induction of monocyte chemoattractant protein (MCP-1)
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expression in response to IFN-y (E Harvey, personal communication). In fact, studies 
in mice have shown that inhibition of the PI3K pathway leads to a decreased 
incidence of atherosclerosis (Pinderski et al, 2005). This is, however, consistent with 
the complex nature of the disease. Indeed, there are a number of genes implicated in 
atherosclerosis whose precise action depends on the stage of the disease (Fan and 
Watanabe, 2003). It may, therefore, be necessary to develop stage-specific strategies 
for therapeutic intervention of atherosclerosis (for example, potentiating the action of 
PI3K/PKB during foam cell formation).
In contrast to atherosclerosis, PI3K is considered necessary for insulin- 
mediated metabolic effects and is blunted in tissues of type 2 diabetes patients (Jiang 
and Zhang, 2002). There is also evidence to suggest that IFN-y is involved in the 
development of diabetes (Tsiavou et al., 2005). For example, IFN-y has been shown 
to up-regulate the expression of major histocompatibility complex antigens and 
adhesion molecules on pancreatic p-cells that contribute to their destruction 
(Campbell et al., 1985; Sarvetnick et al., 1988). It is therefore possible that IFN-y 
signalling via the PI3K pathway may play a role in diabetes and should be considered 
in greater detail.
IFN-y has been described to enhance cellular susceptibility to apoptosis in a 
number of tumor cells (Ruiz de Almodovar, 2004). For example, treatment of human 
breast tumor cells with IFN-y elevates caspase-8 expression and this sensitizes cells to 
death receptor-mediated apoptosis (Ruiz-Ruiz et al., 2004). The caspase-8 gene 
promoter contains a consensus Spl binding site (Ruiz-Ruiz et al., 2004) and so the 
novel mechanism described in this thesis, whereby IFN-y regulates Spl/Sp3 binding, 
might be more widespread and also apply to genes involved in cancer. In fact, Spl 
and Sp3 have been found to be associated with multiple onogenes and tumour 
suppressor genes (Black et al., 2001). For example, Spl has been shown to be 
involved in the inhibition of growth promoting genes by p53, including IGF-1 
(Webster et al., 1996), and is involved in the up-regulation of growth inhibitory genes, 
such as caveolin (Bist et al., 2000) by p53. Since p53 has been found to interact with 
CK2, a potential mechanism similar to the one described in this thesis might exist in 
relation to cancer whereby CK2 regulates the activity of Spl/Sp3.
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6.4 C onclud ing rem arks
Macrophage LPL plays a crucial role in the pathogenesis of atherosclerosis by 
contributing to foam cell formation. The regulation of LPL expression in 
macrophages by factors that are present in atherosclerotic lesions will make a major 
contribution to the initiation and the development of the disease. The studies 
presented in this thesis provide novel insights into the mechanisms underlying the 
regulation of macrophage LPL gene transcription by the cytokine IFN-y. The studies 
not only improve our current understanding of the regulation of this enzyme by 
identify new avenues for further research and therapeutic approaches against the 
disease.
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Appendices
Maps of DNA molecular weight markers
Base Pairs DNA Mass
-1,517
(ng)
45
-1.200 35
-1 ,0 0 0 95
- 900 27
- 800 24
- 700 21
- 600 18
- 500/517 97
- 400 38
- 300 29
- 200 25
- 100 48
Kilobases
10.0
s . o
6.0
5 .0
4 .0
3 .0
2.0 
1.5
1.0
0 .5
1OOBP DNA marker (NEB) 
Maps of protein Rainbow markers
I KB DNA marker (GlBCO)
Mr (X 10*)
« -  250
* -  160 
« -  105 
« -  75
50
30
25
15
lO
Map of the rainbow protein size marker (Amersham-Pharmacia)
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Maps for plasmid vectors used in this study
MCS
ppgal-Control
7 .9  kb
5 V 4 0
*nh*rx*r
''V SV40
ntron ;
poly(A) signal
(for background reduction)
Sma I 
Kpn I 
Sac I 
Mb I 
Nhe I 
Xho I
rori
2744
2738
Sa/I 
BamH I pGL2-Basic
Vector
(5S97bp)
28
33
37
47poiy(A) signal - 1 
(tor be reporter)
SV40
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Sal I
pSG5
vector
4.1 kb
Bglll
Pvul
E£^
pcDNA3
5.4 kb
Sm al
T th H 1 l
T h e r e  i s  a n  A T G  u p s t r e a m  
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